Cycloalkylurea derivative

ABSTRACT

The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin type 2 receptor, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.

TECHNICAL FIELD

The present invention relates to a medicament for treating or preventinga disease related to orexin receptor, especially orexin type 2 receptor,comprising a new compound having a urea structure or a pharmaceuticallyacceptable salt thereof as an active ingredient. In more detail, thepresent invention relates to a medicament for treating or preventingnarcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome,etc.

BACKGROUND ART

Orexin is a neuropeptide which is specifically produced in a specificneuron spreading across lateral hypothalamus and its adjacent region.Orexin is an endogenous ligand of orexin receptor that is aG-protein-coupled receptor existing mainly in brain, which binds toorexin receptor. It is known that orexin receptor has two subtypes, type1 and type 2 (Non-patent Reference 1).

It was reported that a narcolepsy-like symptom in a transgenic mousewhose orexin neuron was denatured could be improved by intraventricularinjection of an orexin peptide (Non-patent Reference 2), and anarcolepsy-like symptom could be initiated by knocking out prepro-orexinwhich is a precursor protein of orexin (Non-patent Reference 3),furthermore the orexin concentration in cerebrospinal fluid ofnarcolepsy patients was markedly lowered (Non-patent Reference 4). Thus,it is suggested that narcolepsy can be initiated due to lack of orexin.

In addition, it was reported that there was a mutation of orexin 2receptor in a dog suffering from hereditary narcolepsy (Non-patentReference 5), which suggests that orexin 2 receptor is involved insleep-wake function. Furthermore, it was revealed that narcolepsy-likesymptom was initiated in a KO mouse of orexin 2 receptor (Non-patentReference 6), which strongly suggests that the stimulation on orexin 2receptor is involved in sleep-wake function. Thus, an orexin 2 receptoragonist is expected to be a hopeful therapy for a patient presentingwith hypersomnia-like symptom such as narcolepsy.

Recently, a compound having orexin 2 receptor agonistic action has beenreported (Patent Reference 1).

PRIOR ART Patent Reference

-   [Patent Literature 1] WO 2017/135306

Non-Patent Reference

-   [Non-patent Literature 1] Cell, Vol. 92, 573-585, 1998-   [Non-patent Literature 2] Proc. Natl. Acad. Sci. USA, Vol. 101,    4649-4654, 2004-   [Non-patent Literature 3] Cell, Vol. 98, 437-451, 1999-   [Non-patent Literature 4] THE LANCET, Vol. 355, 39-40, 2000-   [Non-patent Literature 5] Cell, Vol. 98, 365-376, 1999-   [Non-patent Literature 6] Neuron, Vol. 38, 715-730, 2003-   [Non-patent Literature 7] Brain, Vol. 130, 1577-1585, 2007-   [Non-patent Literature 8] Neuroscience Letters, Vol. 569, 68-73,    2014

SUMMARY OF INVENTION Technical Problem

The purpose of the present invention may be to provide a medicament fortreating or preventing a disease related to orexin type 2 receptor, forexample, narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apneasyndrome, etc.

Solution to Problem

The present inventors have extensively studied to reach the abovepurpose, and then have found that a compound of the following formula(1) or a pharmaceutically acceptable salt thereof (hereinafter, it maybe referred to as “the present compound”) has therapeutic and preventiveeffect for a disease related to orexin type 2 receptor, for example,narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome,etc. Based upon the new findings, the present invention has beencompleted.

The present invention can show as follows.

(Item A1)

A compound of formula (1):

or a pharmaceutically acceptable salt thereofwherein

R¹ is optionally-substituted C₆₋₁₀ aromatic carbocyclyl group,optionally-substituted 5- to 10-membered aromatic heterocyclyl group,optionally-substituted C₃₋₆ saturated carbocyclyl group,optionally-substituted 4- to 10-membered saturated heterocyclyl group,or cyano;

L¹ and L² are each independently single bond, —CH₂—, or oxygen atom;

R² is hydrogen atom, hydroxy group, halogen atom, cyano, oroptionally-substituted C₁₋₄ alkyl; or

when L¹ is single bond, R¹ and R² may be combined together as a Spiroring to form optionally-substituted O₃₋₆ saturated carbocyclic ring oroptionally-substituted 4- to 10-membered saturated heteroring;

R³ and R⁴ are each independently hydrogen atom, halogen atom, cyano,—(C═O)NR⁵R⁶, carboxy group, —(C═O)O—R⁷, optionally-substituted C₁₋₄alkyl, or optionally-substituted C₁₋₄ alkoxy, wherein R³ and R⁴ may bindto the same carbon atom if chemically possible; or

when R³ and R⁴ bind to different ring carbon atoms, R³ and R⁴ may betaken together via C₁₋₆ alkylene to form a fused ring or a bridged ring;

R⁵ to R⁷ are each independently hydrogen atom, halogen atom, oroptionally-substituted C₁₋₄ alkyl;

n is an integer of 1 or 2;

Ring G is optionally-substituted C₆₋₁₀ aromatic carbocyclyl group,optionally-substituted 5- to 10-membered aromatic heterocyclyl group,optionally-substituted C₃₋₆ saturated carbocyclyl group, oroptionally-substituted 4- to 10-membered saturated heterocyclyl group;

A¹ is oxygen atom or sulfur atom;

A² is oxygen atom or —NH—;

A³ is —CH—, nitrogen atom, or carbon atom; and the bond accompanied withbroken line is each independently single bond or double bond.

(Item A2)

The compound of Item A1 or a pharmaceutically acceptable salt thereof,wherein

in R²-R⁷, the optional substituent of “optionally-substituted C₁₋₄alkyl” is the same or different one or more substituents selected fromthe group consisting of halogen atom, hydroxy group, C₁₋₄ alkoxy, andC₃₋₇ cycloalkyl; and the optional substituent of “optionally-substitutedC₁₋₄ alkoxy” is the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,and C₃₋₇ cycloalkyl;

in R¹, the optional substituent of “optionally-substituted C₆₋₁₀aromatic carbocyclyl group”, “optionally-substituted 5- to 10-memberedaromatic heterocyclyl group”, “optionally-substituted C₃₋₆ saturatedcarbocyclyl group”, and “optionally-substituted 4- to 10-memberedsaturated heterocyclyl group” is each independently at least onesubstituent selected from the group consisting of hydrogen atom, halogenatom, hydroxy group, C₆₋₁₀ aromatic carbocyclyl group (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₁₋₄ alkyl (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₃₋₇ cycloalkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₃₋₇ cycloalkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), cyano,C₁₋₄ alkoxy (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl optionally-substituted with thesame or different one or more halogen atoms, and C₃₋₇ cycloalkyl), and5- to 10-membered aromatic heterocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl); and

in Ring G, the optional substituent of “optionally-substituted C₆₋₁₀aromatic carbocyclyl group”, “optionally-substituted 5- to 10-memberedaromatic heterocyclyl group”, “optionally-substituted C₃₋₆ saturatedcarbocyclyl group”, and “optionally-substituted 4- to 10-memberedsaturated heterocyclyl group” is each independently at least onesubstituent selected from the group consisting of halogen atom, C₁₋₆alkyl (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₆₋₁₀ aromaticcarbocyclyl group (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇cycloalkyl), C₁₋₄ alkoxy (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and C₃₋₇cycloalkyl), C₃₋₇ cycloalkyl (which may be optionally substituted withthe same or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, C₁₋₄ alkoxy, andC₃₋₇ cycloalkyl), and C₃₋₇ cycloalkoxy (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl); or when there are plural optionalsubstituents, two of them may be taken together via C₁₋₆ alkylene toform a chemically-possible bicyclic structure selected from a fusedring, a spiro ring, and bridged ring.

(Item A3)

The compound of Item A1 or A2 or a pharmaceutically acceptable saltthereof, wherein

in R²-R⁷, the optional substituent of “optionally-substituted C₁₋₄alkyl” is the same or different one or more substituents selected fromthe group consisting of halogen atom and C₁₋₄ alkoxy; and the optionalsubstituent of “optionally-substituted C₁₋₄ alkoxy” is the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkyl;

in R¹, the optional substituent of “optionally-substituted C₆₋₁₀aromatic carbocyclyl group”, “optionally-substituted 5- to 10-memberedaromatic heterocyclyl group”, “optionally-substituted C₃₋₆ saturatedcarbocyclyl group”, and “optionally-substituted 4- to 10-memberedsaturated heterocyclyl group” is each independently at least onesubstituent selected from the group consisting of hydrogen atom, halogenatom, hydroxy group, C₆₋₁₀ aromatic carbocyclyl group (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₁₋₄ alkyl (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₃₋₇ cycloalkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), cyano, C₁₋₄ alkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl optionally-substituted with the same ordifferent one or more halogen atoms, and C₃₋₇ cycloalkyl), and 5- to10-membered aromatic heterocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl); and

in Ring G, the optional substituent of “optionally-substituted C₆₋₁₀aromatic carbocyclyl group”, “optionally-substituted 5- to 10-memberedaromatic heterocyclyl group”, “optionally-substituted C₃₋₆ saturatedcarbocyclyl group”, and “optionally-substituted 4- to 10-memberedsaturated heterocyclyl group” is each independently at least onesubstituent selected from the group consisting of halogen atom, C₁₋₆alkyl (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom and C₁₋₄ alkoxy), C₆₋₁₀ aromatic carbocyclyl group (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy), C₁₋₄ alkoxy (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkyl), C₃₋₇cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy), and C₃₋₇ cycloalkoxy (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy); or when there are plural optional substituents,two of them may be taken together via C₁₋₆ alkylene to form achemically-possible bicyclic structure selected from a fused ring, aSpiro ring, and bridged ring.

(Item A4)

The compound of any one of Items A1 to A3 or a pharmaceuticallyacceptable salt thereof, wherein

R¹ is selected from the following formulae (1a-1) to (1a-4):

wherein

X¹-X⁷ are each independently nitrogen atom or CR^(a6);

Q¹ and Q² are oxygen atom, —NR^(a7)—, or sulfur atom;

R^(a1)-R^(a7) are each independently (if there are plural CR^(a6), eachR^(a6) is also independently), hydrogen atom, halogen atom, C₆₋₁₀aromatic carbocyclyl group (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy),C₁₋₄ alkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, and alkoxy), C₃₋₇ cycloalkyl(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), cyano, C₁₋₄ alkoxy (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₇ cycloalkoxy (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or 5- to 10-membered aromaticheterocyclyl group; wherein R^(a4) and R^(a5) may bind to the samecarbon atom if chemically possible; and when X¹ and X³ are both CR^(a6),the two R^(a6) may be taken together with the carbon atoms to which theyare each attached to form 6-membered carbon ring that is fused with the5-membered ring comprising X¹, X², and X³; and

q¹ is an integer of 1 or 2.

(Item A5)

The compound of any one of Items A1 to A4 or a pharmaceuticallyacceptable salt thereof, wherein

Ring G is selected from the following (1b-1) to (1b-4):

wherein

W¹, W³, W⁵, W⁶, and W⁷ are each independently nitrogen atom or CR^(b4);

W², W⁴ and W⁸ are NR^(b5), oxygen atom, or CR^(b6)R^(b7);

R^(b1)-R^(b7) are each independently (if there are plural CR^(b4), eachR^(b4) is also independently), hydrogen atom, C₁₋₆ alkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom and C₁₋₄alkoxy), C₆₋₁₀ aromatic carbocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),C₁₋₄ alkoxy (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkyl), C₃₋₇ cycloalkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),or C₃₋₇ cycloalkoxy (which may be optionally substituted with the sameor different one or more substituents selected from the group consistingof halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy); wherein R^(b1) and R^(b2)may bind to the same carbon atom if chemically possible; or R^(b1) andR^(b2) may be taken together via C₁₋₆ alkylene to form achemically-possible bicyclic structure selected from a fused ring, aspiro ring, and bridged ring.

(Item A6)

The compound of any one of Items A1 to A5 of formula (2):

or a pharmaceutically acceptable salt thereof, wherein

R¹ is selected from the following formulae (1a-1) to (1a-4):

wherein

X¹-X⁷ are each independently nitrogen atom or CR^(a6);

Q¹ and Q² are oxygen atom, —NR^(a7)—, or sulfur atom;

R^(a1)-R^(a7) are each independently (if there are plural CR^(a6), eachR^(a6) is also independently), hydrogen atom, halogen atom, C₆₋₁₀aromatic carbocyclyl group (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, alkyl, and C₁₋₄ alkoxy), C₁₋₄alkyl (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₆ cycloalkyl(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), cyano, C₁₋₄ alkoxy (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₇ cycloalkoxy (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or 5- to 10-membered aromaticheterocyclyl group; wherein R^(a4) and R^(a5) may bind to the samecarbon atom if chemically possible; and when X¹ and X³ are both CR^(a6),the two R^(a6) may be taken together with the carbon atoms to which theyare each attached to form 6-membered carbon ring that is fused with the5-membered ring comprising X¹, X², and X³; and

g¹ is an integer of 1 or 2;

L¹ and L² are each independently single bond, —CH₂—, or oxygen atom;

R² is hydrogen atom, hydroxy group, halogen atom, cyano, oroptionally-substituted C₁₋₄ alkyl;

R³ and R⁴ are each independently hydrogen atom, halogen atom, C₁₋₄ alkyl(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), or C₁₋₄ alkoxy (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₃₋₇ cycloalkyl); wherein R³ and R⁴ may bind tothe same carbon atom if chemically possible; and when R³ and R⁴ bind todifferent carbon atoms on the ring, R³ and R⁴ may be taken together viaC₁₋₆ alkylene to form a fused ring or bridged ring;

Ring G is selected from the following (1b-1) to (1b-4):

wherein

W¹, W³, W⁵, W⁶, and W⁷ are each independently nitrogen atom orCR^(b6)R^(b7);

W², W⁴, and W⁸ are NR^(b5), oxygen atom or CR^(b6)R^(b7);

R^(b1)-R^(b7) are each independently (if there are plural CR^(b4), eachR^(b4) is also independently), hydrogen atom, C₁₋₆ alkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom and C₁₋₄alkoxy), C₆₋₁₀ aromatic carbocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),C₁₋₄ alkoxy (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkyl), C₃₋₇ cycloalkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),or C₃₋₇ cycloalkoxy (which may be optionally substituted with the sameor different one or more substituents selected from the group consistingof halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy); wherein R^(b1) and R^(b2)may bind to the same carbon atom if chemically possible; or R^(b1) andR^(b2) may be taken together via C₁₋₆ alkylene to form achemically-possible bicyclic structure selected from a fused ring, aSpiro ring, and bridged ring;

A¹ is oxygen atom or sulfur atom;

A² is oxygen atom or —NH—; and

A³ is —CH—, nitrogen atom, or carbon atom.

(Item A7)

The compound of Item A6 or a pharmaceutically acceptable salt thereof,wherein

R¹ is selected from the following formulae (1a-1), (1a-2), and (1a-3-1):

wherein

X¹-X⁶ are each independently nitrogen atom or CR^(a6);

Q¹ and Q² are oxygen atom, —NR^(a7)—, or sulfur atom; and

R^(a1)-R^(a3), R^(a6), and R^(a7) are each independently (if there areplural CR^(a6), each R^(a6) is also independently), hydrogen atom,halogen atom, C₆₋₁₀ aromatic carbocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,and C₁₋₄ alkoxy), C₁₋₄ alkyl (which may be optionally substituted withthe same or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy),C₃₋₇ cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), cyano, C₁₋₄alkoxy (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₇ cycloalkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or 5- to 10-memberedaromatic heterocyclyl group; wherein when X¹ and X³ are both CR^(a6),the two R^(a6) may be taken together with the carbon atoms to which theyare each attached to form 6-membered carbon ring that is fused with the5-membered ring comprising X¹, X², and X³.

(Item A8)

The compound of Items A6 or A7 or a pharmaceutically acceptable saltthereof, wherein

Ring G is selected from the following (1b-1), (1b-2), and (1b-4):

wherein

W¹, W³, W⁵, W⁶, and W⁷ are each independently nitrogen atom or CR^(b4);

W² and W⁴ are NR^(b5) or CR^(b6)R^(b7); and

R^(b1), R^(b2), and R^(b4)-R^(b7) are each independently (if there areplural CR^(b4), each R^(b4) is also independently), hydrogen atom, C₁₋₆alkyl (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom and C₁₋₄ alkoxy), C₆₋₁₀ aromatic carbocyclyl group (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy), C₁₋₄ alkoxy (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkyl), C₃₋₇cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or C₃₋₇ cycloalkoxy (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy); wherein R^(b1) and R^(b2) may bind to the samecarbon atom if chemically possible; or R^(b1) and R^(b2) may be takentogether via C₁₋₆ alkylene to form a bridged bicyclic structure.

(Item A9)

The compound of any one of Items A6 to A8 or a pharmaceuticallyacceptable salt thereof, wherein

Ring G is selected from the following (1b-1) and (1b-2):

wherein

W¹ and W³ are nitrogen atom or CR^(b4);

W² and W⁴ are NR^(b5) or CR^(b6)R^(b7); and

R^(b1), R^(b2), and R^(b4)-R^(b7) are each independently hydrogen atom,C₁₋₆ alkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkoxy), C₆₋₁₀ aromatic carbocyclyl group (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy), alkoxy (which may be optionally substitutedwith the same or different one or more substituents selected from thegroup consisting of halogen atom and C₁₋₄ alkyl), C₃₋₇ cycloalkyl (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy), or C₃₋₇ cycloalkoxy (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy);wherein R^(b1) and R^(b2) may bind to the same carbon atom if chemicallypossible; or R^(b1) and R^(b2) may be taken together via C₁₋₆ alkyleneto form a bridged bicyclic structure.

(Item A10)

The compound of any one of Items A1 to A9 of formula (3):

or a pharmaceutically acceptable salt thereof, wherein

R¹ is the following formula (1a-1), (1a-2), or (1a-3-1):

wherein

X¹-X⁶ are each independently nitrogen atom or CR^(a6);

Q¹ and Q² are oxygen atom or sulfur atom;

R^(a1)-R^(a3) and R^(a6) are each independently (if there are pluralCR^(a6), each R^(a6) is also independently), hydrogen atom, halogenatom, C₁₋₄ alkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, and C₁₋₄ alkoxy), C₃₋₇ cycloalkyl (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), cyano, or C₁₋₄ alkoxy (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy); wherein when X¹ and X³ are bothCR^(a6), the two R^(a6) may be taken together with the carbon atoms towhich they are each attached to form 6-membered carbon ring that isfused with the 5-membered ring comprising X¹, X², and X³;

L¹ and L² are each independently single bond or oxygen atom;

R² is hydrogen atom, halogen atom, or C₁₋₄ alkyl which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and hydroxy group;

R³ and R⁴ are each independently halogen atom;

Ring G is the following (1b-1), (1b-2-1), (1b-2-2), or (1b-2-3):

wherein

R^(b5) is hydrogen atom, or C₁₋₆ alkyl which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkoxy; and

A¹ is oxygen atom or sulfur atom.

(Item A11)

The compound of any one of Items A4 to A10 or a pharmaceuticallyacceptable salt thereof, wherein

R¹ is formula (1a-2), and

R^(a1) is hydrogen atom, halogen atom, C₁₋₄ alkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom and C₁₋₄alkoxy), C₃₋₇ cycloalkyl (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy),or C₁₋₄ alkoxy (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkyl).

(Item A12)

The compound of Item A10 or A11 or a pharmaceutically acceptable saltthereof, wherein

R¹ is formula (1a-2), and

X⁴ and X⁵ are both nitrogen atom.

(Item A13)

The compound of any one of Items A10 to A12 or a pharmaceuticallyacceptable salt thereof, wherein

Ring G is formula (1b-1-1), and

R^(b5) is alkyl which may be optionally substituted with the same ordifferent one or more halogen atoms.

(Item A14)

The compound of any one of Items A10 to A12 or a pharmaceuticallyacceptable salt thereof, wherein

Ring G is formula (1b-2-1), and

R^(b5) is hydrogen atom, or C₁₋₄ alkyl which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkoxy.

(Item A15)

The compound of any one of Items A1 to A12 of formula (4):

or a pharmaceutically acceptable salt thereof, wherein

R¹ is the following (1a-2-1):

wherein

Q² is oxygen atom or sulfur atom;

R^(a2) is C₃₋₇ cycloalkyl group (which may be optionally substitutedwith the same or different one or more substituents selected from thegroup consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy) orcycloalkoxy group (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy);

R² is C₁₋₄ alkyl;

Ring G is the following (1b-1-1) or (1b-2-1):

wherein

R^(b5) is C₁₋₄ alkyl which may be optionally substituted with the sameor different one or more substituents selected from the group consistingof halogen atom and C₁₋₄ alkyl; and

L² is single bond or oxygen atom.

(Item A16)

The compound of Item A15 or a pharmaceutically acceptable salt thereof,wherein

R^(a2) is C₃₋₇ cycloalkyl group which may be optionally substituted withthe same or different one or more substituents selected from halogenatoms, and

R² is methyl group.

(Item A17)

The compound of Item A15 or A16 or a pharmaceutically acceptable saltthereof, wherein

R^(a2) is cyclopropyl group which may be optionally substituted with thesame or different one or more substituents selected from halogen atoms,and

R² is methyl group.

(Item A18)

The compound of any one of Items A15 to A17 or a pharmaceuticallyacceptable salt thereof, wherein

Ring G is formula (1b-2-1), and

R^(b8) is isopropyl group.

(Item A19)

The compound of any one of Items A15 to A17 or a pharmaceuticallyacceptable salt thereof, wherein

Ring G is formula (1b-1-1),

R^(b5) is isopropyl group, and

L² is oxygen atom.

(Item A20)

The compound of any one of Items A15 to A19 or a pharmaceuticallyacceptable salt thereof, wherein Q² is oxygen atom.

(Item A21)

The compound of Item A1 or a pharmaceutically acceptable salt thereof,which is selected from the following compound names or structures:

Example 22:4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 23:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 24:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 25:4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 62:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 63:N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamide

Example 65:4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 66:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 68:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-{5-[(1S,2R)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamide

Example 69:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-{5-[(1R,2S)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamide

Example 79:rac-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carbothioamide

Example 80:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carbothioamide

(Item A22)

The compound of Item A1 or a pharmaceutically acceptable salt thereof,which is selected from the following compound names or structures:

Example 64:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

Example 67:N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamide

Example 71:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

Example 72:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 73:N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 74:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methyl-4-(5-[(1R,2S)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl)piperidine-1-carboxamide

Example 75:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S,4S)-4-fluoro-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

Example 76:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-6-{[(3R)-4,4-difluoro-1-(propan-2-yl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-methylpiperidine-1-carboxamide

(Item A23)

A medicament for treating a disease related to orexin receptor,comprising the compound of any one of Items A1 to A22 or apharmaceutically acceptable salt thereof.

(Item A24)

A medicament for treating narcolepsy, idiopathic hypersomnia,hypersomnia, sleep apnea syndrome, narcolepsy syndrome involvingnarcolepsy-like symptom, hypersomnia associated with Parkinson'sdisease, hypersomnia associated with dementia with Lewy body,hypersomnia syndrome involving daytime hypersomnia (e.g. Kleine-Levinsyndrome, major depression accompanied by hypersomnia, dementia withLewy body, Parkinson's disease, progressive supranuclear palsy,Prader-Willi syndrome, Moebius syndrome, hypoventilation syndrome,Niemann-Pick disease type C, brain contusion, cerebral infarction, braintumor, muscular dystrophy, multiple sclerosis, acute disseminatedencephalomyelitis, Guillain-Barre syndrome, Rasmussen's encephalitis,Wernicke's encephalopathy, limbic encephalitis, Hashimotoencephalopathy), coma, loss of consciousness, obesity (e.g. malignantmast cell, extrinsic obesity, hyperinsulinar obesity, hyperplasmicobesity, hypophysial obesity, hypoplasmic obesity, hypothyroid obesity,hypothalamic obesity, symptomatic obesity, childhood obesity, upper bodyobesity, alimentary obesity, gonadal obesity, systemic mastocytosis,primary obesity, central obesity), insulin resistance syndrome,Alzheimer, impaired consciousness such as coma, side effect orcomplication caused by anesthesia, sleep disturbance, sleep problem,insomnia, intermittent sleep, night myoclonus, REM sleep interruption,jet lag, jet lag syndrome, sleep disorder of shift workers, dyssomnia,sleep terror, depression, major depression, sleepwalking, enuresis,sleep disorder, Alzheimer's sundown syndrome, disease associated withcircadian rhythm, fibromyalgia, condition resulting from decrease insleeping quality, bulimia, obsessive eating disorder, obesity-relateddiseases, hypertension, diabetes, elevated plasma insulin level/insulinresistance, hyperlipemia, hyperlipidaemia, endometrial cancer, breastcancer, prostate cancer, colon cancer, cancer, osteoarthritis,obstructive sleep apnea, cholelithiasis, gallstone, heart disease,abnormal heartbeat, arrhythmia, myocardial infarction, congestive heartfailure, heart failure, coronary heart disease, cardiovascular disease,sudden death, polycystic ovary, craniopharyngioma, Prader-Willisyndrome, Froehlich syndrome, growth hormone deficiency, normal variantshort stature, Turner syndrome, children suffering from acutelymphoblastic leukemia, syndrome X, reproductive hormone abnormality,decrease of fecundability, infertility, hypogonadism in men,sexual/reproductive-function dysfunction such as hirsutism in women,fetal defect associated with maternity obesity, gastrointestinalmotility disorder such as obesity-related gastroesophageal reflux,obesity hypoventilation syndrome (Pickwickian syndrome), respiratorydisease such as respiratory distress, inflammation such as vascularsystemic inflammation, arteriosclerosis, hypercholesterolemia,hyperuricemia, low back pain, gallbladder disease, gout, renal cancer,secondary risk of obesity such as risk of left ventricle hypertrophy,migraine, headache, neuropathic pain, Parkinson's disease, psychosis,schizophrenia, facial flushing, night sweat, disease ingenitalium/urinary system, disease associated with sexual function orfecundability, dysthymic disorder, bipolar disorder, bipolar I disorder,bipolar II disorder, cyclothymic disorder, acute stress disorder,agoraphobia, generalized anxiety disorder, obsessive-compulsivedisorder, panic attack, panic disorder, posttraumatic stress disorder,separation anxiety disorder, social phobia, anxiety disorder, acuteneurological and psychiatric disorder such as cerebral deficiencydeveloped after heart bypass surgery or heart transplant, stroke,ischemic stroke, cerebral ischemia, spinal cord trauma, head injury,periparturient hypoxia, cardiac arrest, hypoglycemic nerve injury,Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis,eye damage, retinopathy, cognitive impairment, muscle spasm, tremor,epilepsy, disorder associated with muscle spasm, delirium, amnesticdisorder, age-associated cognitive decline, schizoaffective disorder,paranoia, drug addiction, movement disorder, chronic fatigue syndrome,fatigue, medication-induced parkinsonian syndrome, Gilles de la Tourettesyndrome, chorea, myoclonus, tic, restless legs syndrome, dystonia,dyskinesia, attention deficit hyperactivity disorder (ADHD), conductdisorder, urinary incontinence, withdrawal symptom, trigeminalneuralgia, hearing loss, tinnitus, nerve injury, retinopathy, maculardegeneration, vomiting, cerebral edema, pain, bone pain, arthralgia,toothache, cataplexy, or traumatic brain injury, comprising the compoundof any one of Items A1 to A22 or a pharmaceutically acceptable saltthereof.

(Item A25)

A medicament for treating narcolepsy, idiopathic hypersomnia,hypersomnia, sleep apnea syndrome, narcolepsy syndrome involvingnarcolepsy-like symptom, hypersomnia associated with Parkinson'sdisease, or hypersomnia associated with dementia with Lewy body,comprising the compound of any one of Items A1 to A22 or apharmaceutically acceptable salt thereof.

(Item A26)

A method for treating narcolepsy, idiopathic hypersomnia, hypersomnia,sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-likesymptom, hypersomnia associated with Parkinson's disease, or hypersomniaassociated with dementia with Lewy body, comprising administering atherapeutically effective amount of the compound of any one of Items A1to A22 or a pharmaceutically acceptable salt thereof to a patient inneed thereof.

(Item A27)

Use of the compound of any one of Items A1 to A22 or a pharmaceuticallyacceptable salt thereof, in the manufacture of a medicament for treatingnarcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome,narcolepsy syndrome involving narcolepsy-like symptom, hypersomniaassociated with Parkinson's disease, or hypersomnia associated withdementia with Lewy body.The present invention can also show as follows.

(Item 1)

A compound of formula (1):

or a pharmaceutically acceptable salt thereof

wherein R¹ is optionally-substituted C₆₋₁₀ aromatic carbocyclyl group,optionally-substituted 5- to 10-membered aromatic heterocyclyl group,optionally-substituted C₃₋₆ saturated carbocyclyl group,optionally-substituted 4- to 10-membered saturated heterocyclyl group,or cyano;

L¹ and L² are each independently single bond, methylene (which may beoptionally substituted with the same or different one or more C₁₋₄alky), —NR⁸—, —C(═O)—, —OC(═O)—, —SO—, —SO₂—, —S—, or oxygen atom;

R² is hydrogen atom, hydroxy group, halogen atom, cyano, oroptionally-substituted C₁₋₄ alkyl; or

when L¹ is single bond, R¹ and R² may be combined together as a spiroring to form optionally-substituted C₃₋₄ saturated carbocyclic ring oroptionally-substituted 4- to 10-membered saturated heteroring;

R³ and R⁴ are each independently hydrogen atom, halogen atom, cyano,—(C═O)NR⁵R⁶, carboxy group, —(C═O)O—R⁷, optionally-substituted C₁₋₄alkyl, or optionally-substituted C₁₋₄ alkoxy, wherein R³ and R⁴ may bindto the same carbon atom if chemically possible; or

when R³ and R⁴ bind to different ring carbon atoms, R³ and R⁴ may betaken together via C₁₋₆ alkylene to form a fused ring or a bridged ring;

R⁵ to R⁷ are each independently hydrogen atom, halogen atom, oroptionally-substituted C₁₋₄ alkyl;

R⁸ is each independently hydrogen atom or optionally-substituted C₁₋₄alkyl;

n is an integer of 1, 2, 3, or 4;

Ring G is optionally-substituted C₆₋₁₀ aromatic carbocyclyl group,optionally-substituted 5- to 10-membered aromatic heterocyclyl group,optionally-substituted C₃₋₆ saturated carbocyclyl group, oroptionally-substituted 4- to 10-membered saturated heterocyclyl group;

A¹ is oxygen atom or sulfur atom;

A² is oxygen atom or —NR⁸—;

A³ is —CH—, nitrogen atom, or carbon atom; and

the bond accompanied with broken line is each independently single bondor double bond.

(Item 2)

The compound of Item 1 or a pharmaceutically acceptable salt thereof,wherein

in R²-R⁸, the optional substituent of “optionally-substituted C₁₋₄alkyl” is the same or different one or more substituents selected fromthe group consisting of halogen atom, hydroxy group, C₁₋₄ alkoxy, C₆₋₁₀aromatic carbocyclyl group, and C₃₋₇ cycloalkyl; and the optionalsubstituent of “optionally-substituted C₁₋₄ alkoxy” is the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, and C₃₋₇ cycloalkyl;

in R¹, the optional substituent of “optionally-substituted C₆₋₁₀aromatic carbocyclyl group”, “optionally-substituted 5- to 10-memberedaromatic heterocyclyl group”, “optionally-substituted C₃₋₆ saturatedcarbocyclyl group”, and “optionally-substituted 4- to 10-memberedsaturated heterocyclyl group” is each independently at least onesubstituent selected from the group consisting of hydrogen atom, halogenatom, hydroxy group, C₆₋₁₀ aromatic carbocyclyl group (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₁₋₄ alkyl (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₃₋₇ cycloalkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, alkoxy, and C₃₋₇ cycloalkyl), C₁₋₆ alkylamino (thealkyl group of which may be optionally substituted with halogen atom,hydroxy group, or C₃₋₇ cycloalkyl), C₃₋₇ cycloalkoxy (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), cyano, C₁₋₄ alkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl optionally-substituted with the same ordifferent one or more halogen atoms, and C₃₋₇ cycloalkyl), and 5- to10-membered aromatic heterocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl); and

in Ring G, the optional substituent of “optionally-substituted C₆₋₁₀aromatic carbocyclyl group”, “optionally-substituted 5- to 10-memberedaromatic heterocyclyl group”, “optionally-substituted C₃₋₆ saturatedcarbocyclyl group”, and “optionally-substituted 4- to 10-memberedsaturated heterocyclyl group” is each independently at least onesubstituent selected from the group consisting of halogen atom, C₁₋₆alkyl (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₆₋₁₀ aromaticcarbocyclyl group (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇cycloalkyl), C₁₋₄ alkoxy (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and C₃₋₇cycloalkyl), C₁₋₆ alkylamino (the alkyl group of which may be optionallysubstituted with halogen atom, hydroxy group, or C₃₋₇ cycloalkyl), C₃₋₇cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇cycloalkyl), and C₃₋₇ cycloalkoxy (which may be optionally substitutedwith the same or different one or more substituents selected from thegroup consisting of halogen atom, hydroxy group, C₁₋₄ alkyl, C₁₋₄alkoxy, and C₃₋₇ cycloalkyl); or when there are plural optionalsubstituents, two of them may be taken together via C₁₋₆ alkylene toform a chemically-possible bicyclic structure selected from a fusedring, a spiro ring, and bridged ring.

(Item 3)

The compound of Item 1 or 2 or a pharmaceutically acceptable saltthereof, wherein

in R²-R⁷, the optional substituent of “optionally-substituted C₁₋₄alkyl” is the same or different one or more substituents selected fromthe group consisting of halogen atom and C₁₋₄ alkoxy; and the optionalsubstituent of “optionally-substituted C₁₋₄ alkoxy” is the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkyl;

in R¹, the optional substituent of “optionally-substituted C₆₋₁₀aromatic carbocyclyl group”, “optionally-substituted 5- to 10-memberedaromatic heterocyclyl group”, “optionally-substituted C₃₋₆ saturatedcarbocyclyl group”, and “optionally-substituted 4- to 10-memberedsaturated heterocyclyl group” is each independently at least onesubstituent selected from the group consisting of hydrogen atom, halogenatom, hydroxy group, C₆₋₁₀ aromatic carbocyclyl group (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₁₋₄ alkyl (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₃₋₇ cycloalkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), cyano, C₁₋₄ alkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl optionally-substituted with the same ordifferent one or more halogen atoms, and C₃₋₇ cycloalkyl), and 5- to10-membered aromatic heterocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl); and

in Ring G, the optional substituent of “optionally-substituted C₆₋₁₀aromatic carbocyclyl group”, “optionally-substituted 5- to 10-memberedaromatic heterocyclyl group”, “optionally-substituted C₃₋₆ saturatedcarbocyclyl group”, and “optionally-substituted 4- to 10-memberedsaturated heterocyclyl group” is each independently at least onesubstituent selected from the group consisting of halogen atom, C₁₋₆alkyl (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom and alkoxy), C₆₋₁₀ aromatic carbocyclyl group (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy), C₁₋₄ alkoxy (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkyl), C₃₋₇cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₁₋₆ alkylamino (the alkylgroup of which may be optionally substituted with halogen atom, hydroxygroup, or C₃₋₇ cycloalkyl), and C₃₋₇ cycloalkoxy (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy); or when there are plural optional substituents,two of them may be taken together via C₁₋₆ alkylene to form achemically-possible bicyclic structure selected from a fused ring, aspiro ring, and bridged ring.

(Item 4)

The compound of any one of Items 1 to 3 or a pharmaceutically acceptablesalt thereof, wherein

R¹ is selected from the following formulae (1a-1) to (1a-4):

wherein

X¹-X⁷ are each independently nitrogen atom or CR^(a6);

Q¹ and Q² are oxygen atom, —NR^(a7)—, or sulfur atom;

R^(a1)-R^(a7) are each independently (if there are plural CR^(a6), eachR^(a6) is also independently), hydrogen atom, halogen optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,and C₁₋₄ alkoxy), C₁₋₄ alkyl (which may be optionally substituted withthe same or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy),C₃₋₇ cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), cyano, C₁₋₄alkoxy (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₇ cycloalkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or 5- to 10-memberedaromatic heterocyclyl group; wherein R^(a4) and R^(a5) may bind to thesame carbon atom if chemically possible; and when X¹ and X³ are bothCR^(a6), the two R^(a6) may be taken together with the carbon atoms towhich they are each attached to form 6-membered carbon ring that isfused with the 5-membered ring comprising X¹, X², and X³; and

q¹ is an integer of 1 or 2.

(Item 5)

The compound of any one of Items 1 to 4 or a pharmaceutically acceptablesalt thereof, wherein

Ring G is selected from the following (1b-1) to (1b-14):

wherein

W¹, W³, W⁵, W⁶, W⁷, W¹¹, W¹², W¹³, W¹⁵, W¹⁶, W¹⁷, W¹⁹, and W²⁵ are eachindependently nitrogen atom or CR^(b4);

W², W⁴, W⁸, W⁹, W¹⁰, W¹⁴, W¹⁸, W²⁰, W²¹, W²², W²³, and W²⁴ are NR^(b5),oxygen atom, or CR^(b6)R^(b7);

R^(b1)-R^(b7) are each independently (if there are plural CR^(b4), eachR^(b4) is also independently), hydrogen atom, N(R^(b8))R^(b9), C₁₋₆alkyl (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, C₃₋₇ cycloalkyl which may be optionally substituted with the sameor different one or more substituents selected from the group consistingof halogen atom and C₁₋₄ alkyl (said C₁₋₄ alkyl may be substituted withhalogen atom), and C₁₋₄ alkoxy), C₆₋₁₀ aromatic carbocyclyl group (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy), 5- to 10-membered aromatic heterocyclyl group(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₁₋₄ alkoxy (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkyl), C₃₋₇cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or C₃₋₇ cycloalkoxy (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy); wherein R^(b1) and R^(b2) may bind to the samecarbon atom if chemically possible; or R^(b1) and R^(b2) may be takentogether via C₁₋₆ alkylene to form a chemically-possible bicyclicstructure selected from a fused ring, a Spiro ring, and bridged ring;and

R^(b8) and R^(b9) are each independently hydrogen atom, C₁₋₆ alkyl(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,alkoxy, C₃₋₇ cycloalkyl which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom and C₁₋₄ alkyl (said C₁₋₄ alkyl may besubstituted with halogen atom), and 5- to 10-membered aromaticheterocyclyl group), C₁₋₄ alkoxy (which may be optionally substitutedwith the same or different one or more substituents selected from thegroup consisting of halogen atom and C₁₋₄ alkyl), 5- to 10-memberedaromatic heterocyclyl group (which may be optionally substituted withthe same or different one or more substituents selected from the groupconsisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or C₃₋₇cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy); or R^(b8) andR^(b9) may be taken together with the nitrogen atom to which they areattached to form 3- to 7-membered nitrogen-containing saturatedheterocycle.

(Item 6)

The compound of any one of Items 1 to 5 of formula (2):

or a pharmaceutically acceptable salt thereof, wherein

R¹ is selected from the following formulae (1a-1) to (1a-4):

wherein

X¹-X⁷ are each independently nitrogen atom or CR^(a6);

Q¹ and Q² are oxygen atom, —NR^(a7)—, or sulfur atom;

R^(a1)-R^(a7) are each independently (if there are plural CR^(a6), eachR^(a6) is also independently), hydrogen atom, halogen atom, C₆₋₁₀aromatic carbocyclyl group (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy),C₁₋₄ alkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₆cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), cyano, C₁₋₄alkoxy (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₇ cycloalkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or 5- to 10-memberedaromatic heterocyclyl group; wherein R^(a4) and R^(a5) may bind to thesame carbon atom if chemically possible; and when X¹ and X³ are bothCR^(a6), the two R^(a6) may be taken together with the carbon atoms towhich they are each attached to form 6-membered carbon ring that isfused with the 5-membered ring comprising X¹, X², and X³; and

q¹ is an integer of 1 or 2;

L¹ and L² are each independently single bond, —CH₂—, or oxygen atom;

R² is hydrogen atom, hydroxy group, halogen atom, cyano, oroptionally-substituted C₁₋₄ alkyl;

R³ and R⁴ are each independently hydrogen atom, halogen atom, C₁₋₄ alkyl(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), or C₁₋₄ alkoxy (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₃₋₇ cycloalkyl); wherein R³ and R⁴ may bind tothe same carbon atom if chemically possible; and when R³ and R⁴ bind todifferent carbon atoms on the ring, R³ and R⁴ may be taken together viaC₁₋₆ alkylene to form a fused ring or bridged ring;

Ring G is selected from the following (1b-1) to (1b-4):

wherein

W¹, W³, W⁵, W⁶, and W⁷ are each independently nitrogen atom or CR^(b4);

W², W⁴, and W⁸ are NR^(b5), oxygen atom or CR^(b6)R^(b7);

R^(b1)-R^(b7) are each independently (if there are plural CR^(b4), eachR^(b4) is also independently), hydrogen atom, C₁₋₆ alkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom and C₁₋₄alkoxy), C₆₋₁₀ aromatic carbocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),C₁₋₄ alkoxy (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkyl), C₃₋₇ cycloalkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),or C₃₋₇ cycloalkoxy (which may be optionally substituted with the sameor different one or more substituents selected from the group consistingof halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy); wherein R^(b1) and R^(b2)may bind to the same carbon atom if chemically possible; or R^(b1) andR^(b2) may be taken together via C₁₋₆ alkylene to form achemically-possible bicyclic structure selected from a fused ring, aspiro ring, and bridged ring;

A¹ is oxygen atom or sulfur atom;

A² is oxygen atom or —NH—; and

A³ is —CH—, nitrogen atom, or carbon atom.

(Item 7)

The compound of Item 6 or a pharmaceutically acceptable salt thereof,wherein

R¹ is selected from the following formulae (1a-1), (1a-2), and (1a-3-1):

wherein

X¹-X⁶ are each independently nitrogen atom or CR^(a6);

Q¹ and Q² are oxygen atom, —NR^(a7)—, or sulfur atom; and

R^(a1)-R^(a3), R^(a6) and R^(a7) are each independently (if there areplural CR^(a6), each R^(a6) is also independently), hydrogen atom,halogen atom, C₆₋₁₀ aromatic carbocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,and C₁₋₄ alkoxy), C₁₋₄ alkyl (which may be optionally substituted withthe same or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and alkoxy), C₃₋₇cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), cyano, C₁₋₄alkoxy (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₇ cycloalkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or 5- to 10-memberedaromatic heterocyclyl group; wherein when X¹ and X³ are both CR^(a6),the two R^(a6) may be taken together with the carbon atoms to which theyare each attached to form 6-membered carbon ring that is fused with the5-membered ring comprising X¹, X², and X³.

(Item 8)

The compound of Items 6 or 7 or a pharmaceutically acceptable saltthereof, wherein

Ring G is selected from the following (1b-1), (1b-2), and (1b-4):

wherein

W¹, W³, W⁵, W⁶ and W⁷ are each independently nitrogen atom or CR^(b4);

W² and W⁴ are NR^(b5) or CR^(b6)R^(b7); and

R^(b1), R^(b2), and R^(b4)-R^(b7) are each independently (if there areplural CR^(b4), each R^(b4) is also independently), hydrogen atom, C₁₋₆alkyl (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom and C₁₋₄ alkoxy), C₆₋₁₀ aromatic carbocyclyl group (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy), alkoxy (which may be optionally substitutedwith the same or different one or more substituents selected from thegroup consisting of halogen atom and C₁₋₄ alkyl), C₃₋₇ cycloalkyl (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy), or C₃₋₇ cycloalkoxy (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy);wherein R^(b1) and R^(b2) may bind to the same carbon atom if chemicallypossible; or R^(b1) and R^(b2) may be taken together via C₁₋₆ alkyleneto form a bridged bicyclic structure.

(Item 9)

The compound of any one of Items 6 to 8 or a pharmaceutically acceptablesalt thereof, wherein

Ring G is selected from the following (1b-1) and (1b-2):

wherein

W¹ and W³ are nitrogen atom or CR^(b4);

W² and W⁴ are NR^(b5) or CR^(b6)R^(b7); and

R^(b1), R^(b2), and R^(b4)-R^(b7) are each independently hydrogen atom,C₁₋₆ alkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkoxy), C₆₋₁₀ aromatic carbocyclyl group (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy), C₁₋₄ alkoxy (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkyl), C₃₋₇cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or C₃₋₇ cycloalkoxy (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy); wherein R^(b1) and R^(b2) may bind to the samecarbon atom if chemically possible; or R^(b1) and R^(b2) may be takentogether via C₁₋₆ alkylene to form a bridged bicyclic structure.

(Item 10)

The compound of any one of Items 1 to 9 of formula (3):

or a pharmaceutically acceptable salt thereof, wherein

R¹ is the following formula (1a-1), (1a-2), or (1a-3-1):

wherein

X¹-X⁶ are each independently nitrogen atom or CR^(a6);

Q¹ and Q² are oxygen atom or sulfur atom;

R^(a1)-R^(a3) and R^(a6) are each independently (if there are pluralCR^(a6), each R^(a6) is also independently), hydrogen atom, halogenatom, C₁₋₄ alkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, and C₁₋₄ alkoxy), C₃₋₇ cycloalkyl (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), cyano, or C₁₋₄ alkoxy (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and alkoxy); wherein when X¹ and X³ are both CR^(a6),the two R^(a6) may be taken together with the carbon atoms to which theyare each attached to form 6-membered carbon ring that is fused with the5-membered ring comprising X¹, X², and X³;

L¹ and L² are each independently single bond or oxygen atom;

R² is hydrogen atom, halogen atom, or C₁₋₄ alkyl which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and hydroxy group;

R³ and R⁴ are each independently halogen atom;

Ring G is the following (1b-1), (1b-2-1), (1b-2-2), or (1b-2-3):

wherein

R^(b5) is hydrogen atom, or C₁₋₆ alkyl which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkoxy; and

A¹ is oxygen atom or sulfur atom.

(Item 11)

The compound of any one of Items 4 to 10 or a pharmaceuticallyacceptable salt thereof, wherein

R¹ is formula (1a-2), and

R^(a1) is hydrogen atom, halogen atom, C₁₋₄ alkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom and C₁₋₄alkoxy), C₃₋₇ cycloalkyl (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy),or C₁₋₄ alkoxy (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkyl).

(Item 12)

The compound of Item 10 to 11 or a pharmaceutically acceptable saltthereof, wherein

R¹ is formula (1a-2), and

X⁴ and X⁵ are both nitrogen atom.

(Item 13)

The compound of any one of Items 10 to 12 or a pharmaceuticallyacceptable salt thereof, wherein

Ring G is formula (1b-1-1), and

R^(b5) is C₁₋₄ alkyl which may be optionally substituted with the sameor different one or more substituents selected from halogen atoms.

(Item 14)

The compound of any one of Items 10 to 12 or a pharmaceuticallyacceptable salt thereof, wherein

Ring G is formula (1b-2-1), and

R^(b5) is hydrogen atom, or C₁₋₄ alkyl which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkoxy.

(Item 15)

The compound of any one of Items 1 to 12 of formula (4):

or a pharmaceutically acceptable salt thereof, wherein

R¹ is the following (1a-2-1):

wherein

Q² is oxygen atom or sulfur atom;

R^(a2) is C₃₋₇ cycloalkyl group (which may be optionally substitutedwith the same or different one or more substituents selected from thegroup consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy) orcycloalkoxy group (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy);

R² is C₁₋₄ alkyl;

Ring G is the following (1b-1-1) or (1b-2-1):

wherein

R^(b5) is C₁₋₄ alkyl which may be optionally substituted with the sameor different one or more substituents selected from the group consistingof halogen atom and C₁₋₄ alkoxy; and

L² is single bond or oxygen atom.

(Item 16)

The compound of Item 15 or a pharmaceutically acceptable salt thereof,wherein

R^(a2) is C₃₋₇ cycloalkyl group which may be optionally substituted withthe same or different one or more substituents selected from halogenatoms, and

R² is methyl group.

(Item 17)

The compound of Item 15 or 16 or a pharmaceutically acceptable saltthereof, wherein

R^(a2) is cyclopropyl group which may be optionally substituted with thesame or different one or more substituents selected from halogen atoms,and

R² is methyl group.

(Item 18)

The compound of any one of Items 15 to 17 or a pharmaceuticallyacceptable salt thereof, wherein

Ring G is formula (1b-2-1), and

R^(b5) is isopropyl group.

(Item 19)

The compound of any one of Items 15 to 17 or a pharmaceuticallyacceptable salt thereof, wherein

Ring G is formula (1b-1-1), and

R^(b5) is isobutyl group.

(Item 20)

The compound of any one of Items 15 to 17 or a pharmaceuticallyacceptable salt thereof, wherein

Ring G is formula (1b-1-1),

R^(b5) is isopropyl group, and

L² is oxygen atom.

(Item 21)

The compound of any one of Items 15 to 20 or a pharmaceuticallyacceptable salt thereof, wherein Q² is oxygen atom.

(Item 22)

The compound of Item 1 or a pharmaceutically acceptable salt thereof,which is selected from the following compound names or structures:

Example 22:4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 23:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 24:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 25:4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 62:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 63:N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamide

Example 65:4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 66:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 68:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-{5-[(1S,2R)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamide

Example 69:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-{5-[(1R,2S)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamide

Example 79:rac-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carbothioamide

Example 80:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carbothioamide

(Item 23)

The compound of Item 1 or a pharmaceutically acceptable salt thereof,which is selected from the following compound names or structures:

Example 64:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

Example 67:N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamide

Example 71:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

Example 72:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 73:N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 74:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methyl-4-{5-[(1R,2S)-2-methylcyclopropyl]-1,2,1-oxadiazol-3-yl}piperidine-1-carboxamide

Example 75:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S,4S)-4-fluoro-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

Example 76:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-6-{[(3R)-4,4-difluoro-1-(propan-2-yl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-methylpiperidine-1-carboxamide

(Item 24)

The compound of Item 1 or a pharmaceutically acceptable salt thereof,which is selected from the following compound names or structures:

Example 82:N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1R,2R)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 95:N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 96:N-[(1R,6S)-2,2-difluoro-6-{(3S)-3-[methyl(propan-2-yl)amino]pyrrolidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 97:4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 99:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{(3S)-3-[methyl(propan-2-yl)amino]pyrrolidin-1-yl}cyclohexyl]-4-methylpiperidine-1-carboxamide

Example 110:N-{(1R,6S)-2,2-difluoro-6-[(2S)-2-methyl-4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 111:N-{(1R,6S)-2,2-difluoro-6-[(2R)-2-methyl-4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 112:N-[(1R,6S)-2,2-difluoro-6-{(3R)-3-[methyl(propan-2-yl)amino]pyrrolidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 114:N-[(1R,6S)-2,2-difluoro-6-{4-[methyl(propan-2-yl)amino]piperidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 115:N-[(1R,6S)-6-{(3S)-3-[cyclopropyl(methyl)amino]pyrrolidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 128:N-[(1R,6S)-2,2-difluoro-6-{(3S)-3-[methyl(2-methylpropyl)amino]pyrrolidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 134:N-[(1R,6S)-2,2-difluoro-6-(4-{methyl[(1-methylcyclopropyl)methyl]amino}piperidin-1-yl)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 136:N-[(1R,6S)-2,2-difluoro-6-(4-{[(1-fluorocyclopropyl)methyl](methyl)amino}piperidin-1-yl)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 137:N-[(1R,6S)-6-{(3S)-3-[(cyclopropylmethyl)(methyl)amino]pyrrolidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 138:N-[(1R,6S)-6-{(3S)-3-[(cyclopropylmethyl)(methyl)amino]pyrrolidin-1-yl}-2,2-difluorocyclohexyl]-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide

Example 139:rac-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,2R,6S)-2-fluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 152:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)-1,4-diazepan-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 156-A:4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-{(1R,2S,6S)-2-fluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 156-B:4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-{(1S,2R,6R)-2-fluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

Example 157:N-[(1R,6S)-2,2-difluoro-6-{4-[methyl(2-methylpropyl)amino]piperidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 158:N-[(1R,6S)-6-{4-[(cyclopropylmethyl)(methyl)amino]piperidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 159:N-[(1R,6S)-6-{4-[cyclobutyl(methyl)amino]piperidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 161:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

(Item 25)

The compound of Item 1 or a pharmaceutically acceptable salt thereof,which is selected from the following compound names or structures:

Example 83:N-[(1R,6S)-2,2-difluoro-6-{[1-(propan-2-yl)piperidin-4-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 84:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[1-(propan-2-yl)piperidin-4-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

Example 102:4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

Example 103:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-ethyl-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamide

Example 107:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(2-methylpropyl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 116:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(2-methylpropyl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

Example 118:N-[(1R,6S)-6-{[(3S)-1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 119:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-6-{[(3S)-1-(2,2-dimethylpropyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-methylpiperidine-1-carboxamide

Example 120:N-[(1R,6S)-6-{[(3S)-1-(2,2-dimethylpropyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 121:N-[(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-methylcyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 122:N-[(1R,6S)-6-{[(3S)-1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide

Example 126:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-methylcyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-methylpiperidine-1-carboxamide

Example 133:N-[(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-fluorocyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 134:N-[(1R,6S)-2,2-difluoro-6-(4-{methyl[(1-methylcyclopropyl)methyl]amino}piperidin-1-yl)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Example 143:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(2-fluoro-2-methylpropyl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

(Item 26)

A medicament for treating a disease related to orexin receptor,comprising the compound of any one of Items 1 to 25 or apharmaceutically acceptable salt thereof.

(Item 27)

A medicament for treating narcolepsy, idiopathic hypersomnia,hypersomnia, sleep apnea syndrome, narcolepsy syndrome involvingnarcolepsy-like symptom, hypersomnia associated with Parkinson'sdisease, hypersomnia associated with dementia with Lewy body,hypersomnia syndrome involving daytime hypersomnia (e.g. Kleine-Levinsyndrome, major depression accompanied by hypersomnia, dementia withLewy body, Parkinson's disease, progressive supranuclear palsy,Prader-Willi syndrome, Moebius syndrome, hypoventilation syndrome,Niemann-Pick disease type C, brain contusion, cerebral infarction, braintumor, muscular dystrophy, multiple sclerosis, acute disseminatedencephalomyelitis, Guillain-Barre syndrome, Rasmussen's encephalitis,Wernicke's encephalopathy, limbic encephalitis, Hashimotoencephalopathy), coma, loss of consciousness, obesity (e.g. malignantmast cell, extrinsic obesity, hyperinsulinar obesity, hyperplasmicobesity, hypophysial obesity, hypoplasmic obesity, hypothyroid obesity,hypothalamic obesity, symptomatic obesity, childhood obesity, upper bodyobesity, alimentary obesity, gonadal obesity, systemic mastocytosis,primary obesity, central obesity), insulin resistance syndrome,Alzheimer, impaired consciousness such as coma, side effect orcomplication caused by anesthesia, sleep disturbance, sleep problem,insomnia, intermittent sleep, night myoclonus, REM sleep interruption,jet lag, jet lag syndrome, sleep disorder of shift workers, dyssomnia,sleep terror, depression, major depression, sleepwalking, enuresis,sleep disorder, Alzheimer's sundown syndrome, disease associated withcircadian rhythm, fibromyalgia, condition resulting from decrease insleeping quality, bulimia, obsessive eating disorder, obesity-relateddiseases, hypertension, diabetes, elevated plasma insulin level/insulinresistance, hyperlipemia, hyperlipidaemia, endometrial cancer, breastcancer, prostate cancer, colon cancer, cancer, osteoarthritis,obstructive sleep apnea, cholelithiasis, gallstone, heart disease,abnormal heartbeat, arrhythmia, myocardial infarction, congestive heartfailure, heart failure, coronary heart disease, cardiovascular disease,sudden death, polycystic ovary, craniopharyngioma, Prader-Willisyndrome, Froehlich syndrome, growth hormone deficiency, normal variantshort stature, Turner syndrome, children suffering from acutelymphoblastic leukemia, syndrome X, reproductive hormone abnormality,decrease of fecundability, infertility, hypogonadism in men,sexual/reproductive-function dysfunction such as hirsutism in women,fetal defect associated with maternity obesity, gastrointestinalmotility disorder such as obesity-related gastroesophageal reflux,obesity hypoventilation syndrome (Pickwickian syndrome), respiratorydisease such as respiratory distress, inflammation such as vascularsystemic inflammation, arteriosclerosis, hypercholesterolemia,hyperuricemia, low back pain, gallbladder disease, gout, renal cancer,secondary risk of obesity such as risk of left ventricle hypertrophy,migraine, headache, neuropathic pain, Parkinson's disease, psychosis,schizophrenia, facial flushing, night sweat, disease ingenitalium/urinary system, disease associated with sexual function orfecundability, dysthymic disorder, bipolar disorder, bipolar I disorder,bipolar II disorder, cyclothymic disorder, acute stress disorder,agoraphobia, generalized anxiety disorder, obsessive-compulsivedisorder, panic attack, panic disorder, posttraumatic stress disorder,separation anxiety disorder, social phobia, anxiety disorder, acuteneurological and psychiatric disorder such as cerebral deficiencydeveloped after heart bypass surgery or heart transplant, stroke,ischemic stroke, cerebral ischemia, spinal cord trauma, head injury,periparturient hypoxia, cardiac arrest, hypoglycemic nerve injury,Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis,eye damage, retinopathy, cognitive impairment, muscle spasm, tremor,epilepsy, disorder associated with muscle spasm, delirium, amnesticdisorder, age-associated cognitive decline, schizoaffective disorder,paranoia, drug addiction, movement disorder, chronic fatigue syndrome,fatigue, medication-induced parkinsonian syndrome, Gilles de la Tourettesyndrome, chorea, myoclonus, tic, restless legs syndrome, dystonia,dyskinesia, attention deficit hyperactivity disorder (ADHD), conductdisorder, urinary incontinence, withdrawal symptom, trigeminalneuralgia, hearing loss, tinnitus, nerve injury, retinopathy, maculardegeneration, vomiting, cerebral edema, pain, bone pain, arthralgia,toothache, cataplexy, or traumatic brain injury, comprising the compoundof any one of Items 1 to 25 or a pharmaceutically acceptable saltthereof.

(Item 28)

A medicament for treating narcolepsy, idiopathic hypersomnia,hypersomnia, sleep apnea syndrome, narcolepsy syndrome involvingnarcolepsy-like symptom, hypersomnia associated with Parkinson'sdisease, or hypersomnia associated with dementia with Lewy body,comprising the compound of any one of Items 1 to 25 or apharmaceutically acceptable salt thereof.

(Item 29)

A method for treating narcolepsy, idiopathic hypersomnia, hypersomnia,sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-likesymptom, hypersomnia associated with Parkinson's disease, or hypersomniaassociated with dementia with Lewy body, comprising administering atherapeutically effective amount of the compound of any one of Items 1to 25 or a pharmaceutically acceptable salt thereof to a patient in needthereof.

(Item 30)

Use of the compound of any one of Items 1 to 25 or a pharmaceuticallyacceptable salt thereof, in the manufacture of a medicament for treatingnarcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome,narcolepsy syndrome involving narcolepsy-like symptom, hypersomniaassociated with Parkinson's disease, or hypersomnia associated withdementia with Lewy body.

DESCRIPTION OF EMBODIMENTS

Hereinafter, the present invention is explained in more detail. In thedescription, the number of carbon atoms in the definition of“substituents” can indicates, for example, “C₁₋₆”. The specificdefinition “C₁₋₆ alkyl” means an alkyl group having 1 to 6 carbon atoms.In the present description, a substituent group which is not accompaniedwith “optionally-substituted” or “substituted” means an “unsubstituted”substituent group. For example, “C₁₋₆ alkyl” means “unsubstituted C₁₋₆alkyl”.

The substituent groups in the present description may be sometimesexpressed without the term “group”. In case that“optionally-substituted” is used in the definition of substituentgroups, the number of the substituting groups is not limited as long asthe substitutions are available, i.e., it is one or more. It means thatthe possible number of substituting groups is the substitution-availablenumber on carbon atoms or carbon/nitrogen atoms in a substituent groupwhich are acceptable for substitution. Unless otherwise specified, thedefinition of each substituent group also extends over the case that thesubstituent group is partially included in another substituent group orthe case that the substituent group is attached to another substituentgroup.

Unless otherwise specified, the binding site of substituent groups isnot limited as long as the site is available to be bound.

The “halogen” includes, for example, fluorine, chlorine, bromine,iodine, and the like. It is preferably fluorine or chlorine.

The “C₁₋₄ alkyl” means straight or branched chain saturated hydrocarbongroup having 1 to 4 carbon atoms, and the “C₁₋₆ alkyl” means straight orbranched chain saturated hydrocarbon group having 1 to 6 carbon atoms.The “C₁₋₄ alkyl” includes, for example, methyl, ethyl, propyl,isopropyl, butyl, isobutyl, sec-butyl, and Cert-butyl, and the “C₁₋₆alkyl” includes, for example, pentyl, isopentyl, neopentyl,1-ethylpropyl, hexyl, and a structural isomer thereof, besides the aboveC₁₋₄ alkyl. Preferred examples of the “C₁₋₆ alkyl” or “C₁₋₄ alkyl”include methyl, ethyl, propyl, and isopropyl; more preferably methyl andisopropyl.

The “C₁₋₆ alkylene” means divalent straight or branched chain saturatedhydrocarbon group having 1 to 6 carbon atoms. The “C₁₋₆ alkylene”includes preferably “C₁₋₄ alkylene”, more preferably “C₁₋₃ alkylene”.The “C₁₋₃ alkylene” includes, for example, methylene, ethylene,propylene, trimethylene, and the like. The “C₁₋₄ alkylene” includes, forexample, butylene, 1,1-dimethylethylene, 1,2-dimethylethylene,1-methyltrimethylene, 2-methyltrimethylene, and the like, besides theexamples listed in the said “C₁₋₃ alkylene”. The “C₁₋₆ alkylene”includes, for example, pentylene, 1,1-dimethyltrimethylene,1,2-dimethyltrimethylene, 1-methylbutylene, 2-methylbutylene,1-methylpentylene, 2-methylpentylene, 3-methylpentylene, hexylene, andthe like, besides the examples listed in the said “C₁₋₄ alkylene”.

The “C₃₋₇ cycloalkyl” means a non-aromatic cyclic hydrocarbon group(i.e., saturated hydrocarbon group and partially-unsaturated hydrocarbongroup) having 3 to 7 carbon atoms, which includes preferably “C₃₋₆cycloalkyl”. The “C₃₋₇ cycloalkyl” also includes a bridged one. The“C₃₋₁₀ cycloalkyl” includes, for example, cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, and cycloheptyl.

The “C₃₋₇ cycloalkyl” also includes a bi-cyclic condensed ring in whichthe “C₃₋₇ cycloalkyl” is fused with benzene or a 5- or 6-membered ringhaving one heteroatom selected from nitrogen, sulfur, or oxygen atom, orthe same or different and two or more (for example, 2 to 4) heteroatomsthereof (for example, “5- or 6-membered monocyclic heteroaryl” mentionedbelow, and 5- or 6-membered ring in “4- to 10-membered saturatedheterocyclyl” mentioned below).

The “C₁₋₄ alkoxy” means oxy group substituted with the above “C₁₋₄alkyl”, and the “C₁₋₆ alkoxy” means oxy group substituted with the above“C₁₋₆ alkyl”. The “C₁₋₄ alkoxy” includes, for example, methoxy, ethoxy,propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and Cert-butoxy.Preferably, the “C₁₋₄ alkoxy” includes methoxy, ethoxy, and isopropoxy.

The “C₃₋₇ cycloalkoxy” means oxy group substituted with the above “C₃₋₇cycloalkyl”, which includes preferably “C₃₋₆ cycloalkoxy”. The “C₃₋₇cycloalkoxy” includes, for example, cyclopropyloxy, cyclobutyloxy,cyclopentyloxy, and cyclohexyloxy, and preferably cyclohexyloxy.

The “C₆₋₁₀ aromatic carbocyclyl group” means an aromatic hydrocarbongroup having 6 to 10 carbon atoms, which is also referred to as “C₆₋₁₀aryl”. More preferably, it is phenyl. The “C₆₋₁₀ aromatic carbocyclylgroup” includes, for example, phenyl, 1-naphthyl, and 2-naphthyl.

The “C₆₋₁₀ aromatic carbocyclyl group” also includes a condensed ring inwhich “phenyl” is fused with a 5- or 6-membered ring having oneheteroatom selected from nitrogen, sulfur, or oxygen atom, or the sameor different and two or more (for example, 2 to 4) heteroatoms thereof(for example, “5- or 6-membered monocyclic aromatic heterocyclyl group”mentioned below, and 5- or 6-membered ring in “4- to 10-memberedsaturated heterocyclyl” mentioned below), or a 5- to 7-memberedcycloalkyl ring (for example, cyclopentane, cyclohexane andcycloheptane).

The “5- to 10-membered aromatic heterocyclyl group” means a 5- to10-membered mono- or multiple-cyclic aromatic group having oneheteroatom selected from nitrogen, sulfur, or oxygen atom, or the sameor different and two or more (for example, 2 to 4) heteroatoms thereof,besides carbon atoms as the ring atoms, preferably, “5- or 6-memberedmonocyclic aromatic heterocyclyl group”. The “5- or 6-memberedmonocyclic aromatic heterocyclyl group” means a 5- or 6-memberedmonocyclic aromatic group within the “5- to 10-membered aromaticheterocyclyl group”.

The multiple-cyclic aromatic heterocyclyl group in the “5- to10-membered aromatic heterocyclyl group” includes, for example, acondensed ring in which the same or different two monocyclic aromaticheterorings are fused, or a monocyclic aromatic heteroring and anaromatic ring (for example, benzene) or a non-aromatic ring (forexample, cyclohexane) are fused.

The “5- to 10-membered aromatic heterocyclyl group” includes, forexample, pyrazolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, andpyridazinyl. Another embodiment includes, preferably, benzofuranyl inwhich the binding site is on the heteroaryl (furan) ring, pyridyl,pyrimidinyl, pyrazinyl, and pyridazinyl.

The “C₃₋₆ saturated carbocyclic ring” means a monocyclic saturated orpartially-unsaturated hydrocarbon ring having 3 to 6 carbon atoms. The“C₃₋₆ saturated carbocyclic ring” includes, for example, cyclopropane,cyclobutane, cyclopentane, cyclohexane, cyclopropene, cyclobutane,cyclopentene, cyclohexene, and cyclohexadiene, and preferablycyclopropane and cyclobutane.

The “4- to 10-membered saturated heteroring” means a monocyclic orbicyclic saturated heteroring composed of 4 to 10 atoms, which has thesame or different and one or more (for example, 2 to 4, preferably 2 to3, more preferably 2) heteroatoms selected from oxygen atom, nitrogenatom, and sulfur atom, besides carbon atoms as the ring atoms. Theheteroring may include a partially-unsaturated one, a partially-bridgedone, and a partially-spiro one. Preferred one thereof is a 5- or6-membered saturated heteroring. The bicyclic saturated heteroring alsoincludes a condensed ring of a monocyclic saturated heteroring, andbenzene or a 5- or 6-membered monocyclic aromatic heteroring. And, thesaturated heteroring may further comprise one or two carbonyl,thiocarbonyl, sulfinyl, or sulfonyl, that is, the saturated heteroringincludes, for example, a cyclic group such as lactam, thiolactam,lactone, thiolactone, cyclic imide, cyclic carbamate, and cyclicthiocarbamate, wherein the number of atoms composing 4- to 10-memberedring (i.e., ring size) or the number of heteroatoms composing heteroring does not count the oxygen atom in carbonyl, sulfinyl, and sulfonyl,and the sulfur atom in thiocarbonyl. The “4-to 10-membered saturatedheteroring” includes preferably monocyclic or bicyclic “4- to 8-memberedsaturated heteroring”, more preferably monocyclic “4- to 6-memberedsaturated heteroring”, and even more preferably monocyclic “5- or6-membered saturated heteroring”. The “4- to 10-membered saturatedheteroring” includes, for example, piperazine, oxetanyl, azetidinyl,pyranyl, tetrahydrofuryl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl,piperidinyl, morpholinyl, homopiperidinyl, oxetanyl, thiomorpholinyl,dioxothiomorpholinyl, hexamethyleneiminyl, oxazolidinyl, thiazolidinyl,imidazolidinyl, oxoimidazolidinyl, dioxoimidazolidinyl, oxooxazolidinyl,dioxooxazolidinyl, dioxothiazolidinyl, tetrahydrofuranyl,tetrahydropyranyl, and tetrahydropyridinyl, and preferably pyranyl,tetrahydrofuryl, pyrrolidinyl, piperidinyl, piperazinyl, andmorpholinyl. The “bicyclic saturated heteroring” includes, for example,dihydroindolyl, dihydroisoindolyl, dihydropurinyl,dihydrothiazolopyrimidinyl, dihydrobenzodioxanyl, isoindolinyl,indazolyl, pyrrolopyridinyl, tetrahydroquinolinyl, decahydroquinolinyl,tetrahydroisoquinolinyl, decahydroisoquinolinyl,tetrahydronaphthyridinyl, and tetrahydropyrido-azepinyl.

The “4- to 6-membered saturated heterocyclyl group” means a monovalentsubstituent derived from “4- to 6-membered saturated heteroring” whichbelongs to the above “4- to 10-membered saturated heteroring”. Itincludes preferably azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl,morpholinyl, oxetanyl, tetrahydrofuranyl, and tetrahydropyranyl.

The “3- to 7-membered nitrogen-containing saturated heterocycle” whichis formed by taking together R^(b8) and R^(b9) with the nitrogen atom towhich they are attached corresponds to the above “4- to 10-memberedsaturated heteroring” wherein the number of atoms composing the ring is3 to 7, and one nitrogen atom is included as an atom composing the ringbesides carbon atoms.

The compound of the present invention includes various hydrate, solvate,and crystal polymorph thereof.

The compound of the present invention may include one or more isotopeatoms such as D, ³H, ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ³⁵S, ¹⁸F, and ¹²⁵I bysubstitution, and such isotope-substituted compound is also included inthe compound of the present invention.

The “pharmaceutically acceptable salt” used herein means apharmaceutically usable acid addition salt and a pharmaceutically usablebase addition salt. The “pharmaceutically acceptable salt” includes, butnot limited thereto, for example, an acid addition salt such as acetate,propionate, butyrate, formate, trifluoroacetate, maleate, fumarate,tartrate, citrate, stearate, succinate, ethylsuccinate, malonate,lactobionate, gluconate, glucoheptonate, benzoate, methanesulfonate,benzenesulfonate, p-toluenesulfonate (tosylate), laurylsulfate, malate,ascorbate, mandelate, saccharin, xinafoate, pamoate, cinnamate, adipate,cysteine, N-acetylcysteine, hydrochloride, hydrobromide, phosphate,sulfate, hydroiodide, nicotinate, oxalate, picrate, thiocyanate,undecanoate, polyacrylate, and carboxy vinyl polymer; an inorganic baseaddition salt such as lithium salt, sodium salt, potassium salt, andcalcium salt; an organic base addition salt such as morpholine andpiperidine; and amino acid addition salt such as aspartate andglutamate.

The present compounds can be orally or parenterally administereddirectly or as a suitable formulation such as drug product, medicament,and pharmaceutical composition. The formulation thereof may include, forexample, tablet, capsule, powder, granule, liquid, suspension,injection, patch, gel patch, and the like, but not limited thereto. Theformulation can be prepared with pharmaceutically acceptable additiveagents in known means.

The additive agents can be chosen for any purpose, including anexcipient, a disintegrant, a binder, a fluidizer, a lubricant, a coatingagent, a solubilizer, a solubilizing agent, a thickener, dispersant, astabilizing agent, a sweetening agent, a flavor, and the like.Specifically, they include, for example, lactose, mannitol,microcrystalline cellulose, low-substituted hydroxypropylcellulose,cornstarch, partially-pregelatinized starch, carmellose calcium,croscarmellose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, magnesium stearate, sodium stearylfumarate, polyethylene glycol, propylene glycol, titanium oxide, talc,and the like.

The dose of the present compound should be suitably determined dependingon subject animal for administration, administration route, targetdisease, and age, body weight, and condition of patients. For example,in the case of oral administration, about 0.01 mg as minimum to 10000 mgas maximum may be administered a day for an adult in one to severalportions.

The compound of the present invention has agonist activity for orexinreceptor. Thereby, the compound can be a medicament for preventing ortreating a disease related to orexin receptor. The disease includes, forexample, narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apneasyndrome, narcolepsy syndrome involving narcolepsy-like symptom,hypersomnia associated with Parkinson's disease, hypersomnia associatedwith dementia with Lewy body, hypersomnia syndrome involving daytimehypersomnia (e.g. Kleine-Levin syndrome, major depression accompanied byhypersomnia, dementia with Lewy body, Parkinson's disease, progressivesupranuclear palsy, Prader-Willi syndrome, Moebius syndrome,hypoventilation syndrome, Niemann-Pick disease type C, brain contusion,cerebral infarction, brain tumor, muscular dystrophy, multiplesclerosis, acute disseminated encephalomyelitis, Guillain-Barresyndrome, Rasmussen's encephalitis, Wernicke's encephalopathy, limbicencephalitis, Hashimoto encephalopathy), coma, loss of consciousness,obesity (e.g. malignant mast cell, extrinsic obesity, hyperinsulinarobesity, hyperplasmic obesity, hypophysial obesity, hypoplasmic obesity,hypothyroid obesity, hypothalamic obesity, symptomatic obesity,childhood obesity, upper body obesity, alimentary obesity, gonadalobesity, systemic mastocytosis, primary obesity, central obesity),insulin resistance syndrome, Alzheimer, impaired consciousness such ascoma, side effect or complication caused by anesthesia, sleepdisturbance, sleep problem, insomnia, intermittent sleep, nightmyoclonus, REM sleep interruption, jet lag, jet lag syndrome, sleepdisorder of shift workers, dyssomnia, sleep terror, depression, majordepression, sleepwalking, enuresis, sleep disorder, Alzheimer's sundownsyndrome, disease associated with circadian rhythm, fibromyalgia,condition resulting from decrease in sleeping quality, bulimia,obsessive eating disorder, obesity-related diseases, hypertension,diabetes, elevated plasma insulin level/insulin resistance,hyperlipemia, hyperlipidaemia, endometrial cancer, breast cancer,prostate cancer, colon cancer, cancer, osteoarthritis, obstructive sleepapnea, cholelithiasis, gallstone, heart disease, abnormal heartbeat,arrhythmia, myocardial infarction, congestive heart failure, heartfailure, coronary heart disease, cardiovascular disease, sudden death,polycystic ovary, craniopharyngioma, Prader-Willi syndrome, Froehlichsyndrome, growth hormone deficiency, normal variant short stature,Turner syndrome, children suffering from acute lymphoblastic leukemia,syndrome X, reproductive hormone abnormality, decrease of fecundability,infertility, hypogonadism in men, sexual/reproductive-functiondysfunction such as hirsutism in women, fetal defect associated withmaternity obesity, gastrointestinal motility disorder such asobesity-related gastroesophageal reflux, obesity hypoventilationsyndrome (Pickwickian syndrome), respiratory disease such as respiratorydistress, inflammation such as vascular systemic inflammation,arteriosclerosis, hypercholesterolemia, hyperuricemia, low back pain,gallbladder disease, gout, renal cancer, secondary risk of obesity suchas risk of left ventricle hypertrophy, migraine, headache, neuropathicpain, Parkinson's disease, psychosis, schizophrenia, facial flushing,night sweat, disease in genitalium/urinary system, disease associatedwith sexual function or fecundability, dysthymic disorder, bipolardisorder, bipolar I disorder, bipolar II disorder, cyclothymic disorder,acute stress disorder, agoraphobia, generalized anxiety disorder,obsessive-compulsive disorder, panic attack, panic disorder,posttraumatic stress disorder, separation anxiety disorder, socialphobia, anxiety disorder, acute neurological and psychiatric disordersuch as cerebral deficiency developed after heart bypass surgery orheart transplant, stroke, ischemic stroke, cerebral ischemia, spinalcord trauma, head injury, periparturient hypoxia, cardiac arrest,hypoglycemic nerve injury, Huntington's disease, amyotrophic lateralsclerosis, multiple sclerosis, eye damage, retinopathy, cognitiveimpairment, muscle spasm, tremor, epilepsy, disorder associated withmuscle spasm, delirium, amnestic disorder, age-associated cognitivedecline, schizoaffective disorder, paranoia, drug addiction, movementdisorder, chronic fatigue syndrome, fatigue, medication-inducedparkinsonian syndrome, Gilles de la Tourette syndrome, chorea,myoclonus, tic, restless legs syndrome, dystonia, dyskinesia, attentiondeficit hyperactivity disorder (ADHD), conduct disorder, urinaryincontinence, withdrawal symptom, trigeminal neuralgia, hearing loss,tinnitus, nerve injury, retinopathy, macular degeneration, vomiting,cerebral edema, pain, bone pain, arthralgia, toothache, cataplexy, andtraumatic brain injury; and preferably narcolepsy, idiopathichypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndromeinvolving narcolepsy-like symptom, hypersomnia associated withParkinson's disease, and hypersomnia associated with dementia with Lewybody.

Hereinafter, the processes to prepare the compound of the presentinvention of formula (1) are exemplified along with examples, but theprocesses of the present invention should not be limited to theexamples.

Preparation Process

The compound of the present invention may be synthesized according toeach Preparation Process shown below or its combination with a knownsynthetic process.

Each compound in the following schemes may exist as a salt thereof,wherein the salt includes, for example, the “pharmaceutically acceptablesalt” mentioned above. The following schemes are disclosed as justexamples, thus it is also possible to optionally prepare the presentcompound by a different process based on the knowledge of a skilledperson in synthetic organic chemistry field.

In each Preparation Process described below, protecting groups can beused as necessary, even if the use of protecting groups is notexplicitly stated. And, the protecting groups can be deprotected after areaction is completed or a series of reactions have been carried out toobtain the desired compound.

As such protecting groups, for example, general protecting groupsdescribed in T. W. Greene, and P. G. M. Wuts, “Protective Groups inOrganic Synthesis”, 3rd Ed., John Wiley & Sons, Inc., New York (1999),and the like may be used. Examples of amino-protecting groups include,for toluenesulfonyl, o-nitrobenzenesulfonyl, tetrahydropyranyl, and thelike; examples of hydroxy-protecting groups include, for example,trialkylsilyl, acetyl, benzyl, tetrahydropyranyl, methoxymethyl, and thelike; examples of aldehyde-protecting groups include, for example,dialkylacetal, cyclic alkylacetal, and the like; and examples ofcarboxyl-protecting groups include, for example, tert-butyl ester,orthoester, amide, and the like.

The introduction and elimination of protecting groups can be carried outby a method commonly-used in synthetic organic chemistry (for example,see T. W. Greene, and P. G. M. Wuts, “Protective Groups in OrganicSynthesis”, 3rd Ed., John Wiley & Sons, Inc., New York (1999)), or asimilar method.

Preparation Process 1:

In compounds according to formula (1) or a pharmaceutically acceptablesalt thereof, the compound of formula (s-1-1) or a pharmaceuticallyacceptable salt thereof which is a compound of formula (1) wherein A³ isnitrogen atom can be prepared, for example, by the following process.

wherein R¹-R⁴, L¹, L², n, Ring G, A¹, and the bond accompanied withbroken line are as defined in Item 1.

Step (1-1):

Compound (s-1-1) can be prepared by reacting compound (s-1-2) andcompound (s-1-3) in a suitable inert solvent under a reaction conditionof urea-binding formulation. The present reaction condition includes,for example, using triphosgene, 4-nitrophenyl chloroformate,1,1′-carbonyldiimidazole, or thiophosgene. A base is used in the presentreaction, and the base used herein includes triethylamine anddiisopropylethylamine. The inert solvent includes a halogenated carbonsolvent such as chloroform and dichloromethane; a ether solvent such asdiethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solventsuch as benzene, toluene, and xylene; and an ester solvent such as ethylacetate and methyl acetate. The reaction time is generally about 1 hourto 24 hours, and the reaction temperature is −20° C. to boiling point ofa solvent used herein.

In Step (1-1), the intermediate such as an isocyanate may isolated,followed by transforming the intermediate.

Preparation Process 2:

In compounds according to formula (s-1-3), the compound of formula(s-2-1) which is a compound of formula (s-1-3) having no unsaturatedbond in the ring can be prepared, for example, by the following process,provided that L² is oxygen atom or —NR¹⁰—, or L² is single bond and RingG is connected to the cycloalkyl via a nitrogen atom therein, whereinR¹⁰ is H or C₁₋₄ alkyl, said definition is used below unless otherwiseindicated.

wherein R³, R⁴, L², n, and Ring G are as defined in Item 1; P¹ is asuitable protecting group; and LG is a suitable leaving group, saiddefinitions are used below unless otherwise indicated.

Compound (s-2-1) can be prepared from compound (s-2-2) via Step (2-1)and Step (2-2).

Step (2-1):

Compound (s-2-4) can be prepared by reacting compound (s-2-2) andcompound (s-2-3) in a suitable inert solvent without additives or in thepresence of a acid or a base. The acid used herein includes, forexample, a protonic acid such as hydrochloric acid, sulfuric acid,phosphoric acid, methanesulfonic acid, benzenesulfonic acid, andp-toluenesulfonic; and a Lewis acid such as zinc(II) chloride,scandium(III) triflate, copper(I) chloride, boron trifluoride, boronicacid, and boronate ester. The base used herein includes, for example, anorganic base such as triethylamine, diisopropylethylamine, and DBU; aninorganic base such as sodium hydrogen carbonate, sodium carbonate, andpotassium carbonate; a metal alkoxide such as potassium tert-butoxide;an organometallic reagent such as n-butyl lithium and isopropylmagnesiumchloride; and a metal amide reagent such as LDA and LHMDS. The inertsolvent includes a halogenated carbon solvent such as chloroform anddichloromethane; a ether solvent such as diethyl ether, THF, and1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene,and xylene; and an ester solvent such as ethyl acetate and methylacetate. The reaction time is generally about 1 hour to 24 hours, andthe reaction temperature is −20° C. to boiling point of a solvent usedherein.

Step (2-2):

Compound (s-2-1) can be prepared by reacting compound (s-2-4) in asuitable inert solvent or under hydrogen atmosphere as necessary, undera conventional condition of nitro-reduction. The present reactioncondition includes, for example, using ferrum, zinc, tin(II) chloride,Raney nickel, palladium carbon, or palladium(II) hydroxide. The inertsolvent includes a halogenated carbon solvent such as chloroform anddichloromethane; a ether solvent such as diethyl ether, THF, and1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene,and xylene; an ester solvent such as ethyl acetate and methyl acetate;and an alcohol solvent such as methanol and ethanol. The reaction timeis generally about 1 hour to 24 hours, and the reaction temperature is−20° C. to boiling point of a solvent used herein.

Compound (s-2-1) can be also prepared from compound (s-2-5) via Step(2-3) and Step (2-4).

Step (2-3):

Compound (s-2-6) can be prepared by reacting compound (s-2-5) andcompound (s-2-3) in a suitable inert solvent without additives or in thepresence of an acid or a base under a conventional condition ofaziridine-ring-opening reaction. The acid used herein includes, forexample, a protonic acid such as hydrochloric acid, sulfuric acid,phosphoric acid, methanesulfonic acid, benzenesulfonic acid, andp-toluenesulfonic; and a Lewis acid such as zinc(II) chloride,scandium(III) triflate, copper(I) chloride, boron trifluoride, boronicacid, and boronate ester. The base used herein includes, for example, anorganic base such as triethylamine, diisopropylethylamine, and DBU; aninorganic base such as sodium hydrogen carbonate, sodium carbonate, andpotassium carbonate; a metal alkoxide such as potassium tert-butoxide;an organometallic reagent such as n-butyl lithium and isopropylmagnesiumchloride; and a metal amide reagent such as LDA and LHMDS. The inertsolvent includes a halogenated carbon solvent such as chloroform anddichloromethane; a ether solvent such as diethyl ether, THF, and1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene,and xylene; and an ester solvent such as ethyl acetate and methylacetate. The reaction time is generally about 1 hour to 24 hours, andthe reaction temperature is −20° C. to boiling point of a solvent usedherein.

Step (2-4):

Compound (s-2-1) can be prepared by deprotecting compound (s-2-6) in aknown manner (for example, a manner described in Protective Groups inOrganic Synthesis 3^(rd) Edition (John Wiley & Sons, Inc.),Comprehensive Organic Transformation, edited by R. C. Larock, VCHpublisher Inc., 1989, etc.) or a similar manner thereto.

Compound (s-2-1) can be also prepared from compound (s-2-7) via Step(2-5)-Step (2-7), and Step (2-4).

Step (2-5):

Compound (s-2-8) can be prepared by reacting compound (s-2-7) andcompound (s-2-3) in a suitable inert solvent without additives or in thepresence of a acid or a base under a conventional condition ofepoxide-ring-opening reaction. The acid used herein includes, forexample, a protonic acid such as hydrochloric acid, sulfuric acid,phosphoric acid, methanesulfonic acid, benzenesulfonic acid, andp-toluenesulfonic; and a Lewis acid such as boron trifluoride, zinc(II)chloride, scandium(III) triflate, copper(I) chloride, boronic acid, andboronate ester. The base used herein includes, for example, an organicbase such as triethylamine, diisopropylethylamine, and DBU; an inorganicbase such as sodium hydrogen carbonate, sodium carbonate, and potassiumcarbonate; a metal alkoxide such as potassium tert-butoxide; anorganometallic reagent such as n-butyl lithium and isopropylmagnesiumchloride; and a metal amide reagent such as LDA and LHMDS. The inertsolvent includes a halogenated carbon solvent such as chloroform anddichloromethane; a ether solvent such as diethyl ether, THF, and1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene,and xylene; and an ester solvent such as ethyl acetate and methylacetate. The reaction time is generally about 1 hour to 24 hours, andthe reaction temperature is −20° C. to boiling point of a solvent usedherein.

Step (2-6):

Compound (s-2-9) can be prepared by reacting compound (s-2-8) in asuitable inert solvent under a conventional condition of transformationreaction from hydroxy group to a leaving group. The present reactioncondition includes, for example, using methanesulfonyl chloride,p-toluenesulfonyl chloride, or trifluoromethanesulfonyl chloride. A baseis used in the present reaction, and the base used herein includes, forexample, an organic base such as triethylamine, diisopropylethylamine,and DBU; an inorganic base such as sodium hydrogen carbonate, sodiumcarbonate, and potassium carbonate; a metal alkoxide such as potassiumCert-butoxide; an organometallic reagent such as n-butyl lithium andisopropylmagnesium chloride; and a metal amide reagent such as LDA andLHMDS. The inert solvent includes a halogenated carbon solvent such aschloroform and dichloromethane; a ether solvent such as diethyl ether,THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene,toluene, and xylene; and an ester solvent such as ethyl acetate andmethyl acetate. The reaction time is generally about 1 hour to 24 hours,and the reaction temperature is −20° C. to boiling point of a solventused herein.

Step (2-7):

Compound (s-2-6) can be prepared in a general nucleophilic substitutionreaction with compound (s-2-9), P¹NH₂, and a base. The base used hereinincludes, for example, an organic base such as triethylamine,diisopropylethylamine, and DBU; an inorganic base such as sodiumhydrogen carbonate, sodium carbonate, and potassium carbonate; a metalalkoxide such as potassium tert-butoxide; an organometallic reagent suchas n-butyl lithium and isopropylmagnesium chloride; and a metal amidereagent such as LDA and LHMDS. The solvent used herein includes ahalogenated carbon solvent such as chloroform and dichloromethane; aether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatichydrocarbon solvent such as benzene, toluene, and xylene; and an estersolvent such as ethyl acetate and methyl acetate. The reaction time isgenerally about 1 hour to 24 hours, and the reaction temperature is −20°C. to boiling point of a solvent used herein.

Step (2-6) and Step (2-7) may be carried out as one step withoutisolating the intermediate. And, Step (2-6) and Step (2-7) may be alsocarried out as one step under Mitsunobu reaction condition.

Preparation Process 3-1:

In compounds according to formula (s-2-1), the compound of formula(s-3-1) which is a compound of formula (s-2-1) wherein L² is single bondand Ring G binds to cycloalkyl via nitrogen atom therein can be alsoprepared, for example, by the following process.

wherein R³, R⁴, n, and Ring G are as defined in Item 1.

Compound (s-3-1) can be prepared from compound (s-2-2) via Step(3-1)-Step (3-3).

Step (3-1):

Compound (s-3-2) can be prepared in a similar manner to Step (2-1) withcompound (s-2-2) and ammonia or a reagent equal to ammonia that includesa protected-amine reagent which is deprotected after the amination andan azide-inducer which is reduced after the azidation.

Step (3-2):

Compound (s-3-3) can be prepared in a nitrogen-containingheteroring-formulation with compound (s-3-2). For example, compound(s-3-3) wherein Ring G is piperazine can be prepared by reactingcompound (s-3-2) with N-benzyl-bis(2-chloroethyl)amine, followed bydeprotection and alkylation.

Step (3-3):

Compound (s-3-1) can be prepared in a similar manner to Step (2-2) withcompound (s-3-3).

Compound (s-3-1) can be also prepared from compound (s-2-5) via Step(3-4)-Step (3-6).

Step (3-4):

Compound (s-3-4) can be prepared in a similar manner to Step (2-3) withcompound (s-2-5) and ammonia or a reagent equal to ammonia that includesa protected-amine reagent which is deprotected after the amination andan azide-inducer which is reduced after the azidation.

Step (3-5):

Compound (s-3-5) can be prepared in a similar manner to Step (3-2) withcompound (s-3-4).

Step (3-6):

Compound (s-3-1) can be prepared in a similar deprotection to Step (2-4)with compound (s-3-5).

Preparation Process 3-2:

The compound according to formula (s-3-1) can be also prepared, forexample, by the following process.

wherein R³, R⁴, n, and Ring G are as defined in Item 1.

Compound (s-3-1) can be prepared from compound (s-3-6) via Step (3-7)and Step (3-8).

Step (3-7):

Compound (s-3-6) is compound (s-2-9) in Preparation Process 2, whereinL² is single bond and Ring G is connected to the cycloalkyl via anitrogen atom therein. Compound (s-3-7) can be prepared in a generalnucleophilic substitution reaction like Step (2-7) with compound (s-3-6)and a conventional base as intramolecular reaction. Compound (s-3-7) maybe used in the next step without isolation.

Step (3-8):

Compound (s-3-1) can be prepared in a general ring-opening reaction withcompound (s-3-7) and ammonia or a reagent equal to ammonia that includesa protected-amine reagent which is deprotected after the amination andan azide-inducer which is reduced after the azidation.

Preparation Process 4:

In compounds according to formula (s-2-1), the compound of formula(s-4-1) which is a compound of formula (s-2-1) wherein L² is O or NR¹⁰can be also prepared, for example, by the following process.

wherein R³, R⁴, n, and Ring G are as defined in Item 1; and Y is O orNR¹⁰, said definitions are used below unless otherwise indicated.

Compound (s-4-1) can be prepared from compound (s-2-2) via Step(4-1)-Step (4-3).

Step (4-1):

Compound (s-4-2) can be prepared by reacting compound (s-2-2) in asimilar manner to Step (2-1) with YH₂ or a reagent equal to YH₂ thatincludes a protected reagent P²YH which is deprotected after theaddition reaction, wherein P² is a suitable protecting group, saiddefinition is used below unless otherwise indicated.

Step (4-2):

Compound (s-4-3) can be prepared in a general nucleophilic substitutionreaction or aromatic nucleophilic substitution reaction with compound(s-4-2), Ring G accompanied with a leaving group, and a base. The baseused herein includes, for example, an organic base such astriethylamine, diisopropylethylamine, and DBU; an inorganic base such assodium hydrogen carbonate, sodium carbonate, and potassium carbonate; ametal alkoxide such as potassium tert-butoxide; an organometallicreagent such as n-butyl lithium and isopropylmagnesium chloride; and ametal amide reagent such as LDA and LHMDS. The solvent used hereinincludes a halogenated carbon solvent such as chloroform anddichloromethane; a ether solvent such as diethyl ether, THF, and1,4-dioxane; an aromatic hydrocarbon solvent such as benzene, toluene,and xylene; and an ester solvent such as ethyl acetate and methylacetate. The reaction time is generally about 1 hour to 24 hours, andthe reaction temperature is −20° C. to boiling point of a solvent usedherein.

Step (4-3):

Compound (s-4-1) can be prepared in a similar manner to Step (2-2) withcompound (s-4-3).

Compound (s-4-1) can be also prepared from compound (s-2-5) via Step(4-4)-Step (4-6).

Step (4-4):

Compound (s-4-4) can be prepared by reacting compound (s-2-5) in asimilar manner to Step (2-3) with YH₂ or a reagent equal to YH₂ thatincludes a protected reagent P²YH which is deprotected after theaddition reaction.

Step (4-5):

Compound (s-4-5) can be prepared in a similar manner to Step (4-2) withcompound (s-4-4).

Step (4-6):

Compound (s-4-1) can be prepared in a similar deprotection to Step (2-4)with compound (s-4-5).

Preparation Process 5:

The compound of formula (s-2-5) can be also prepared, for example, bythe following process.

wherein R³, R⁴, and n are as defined in Item 1.

Compound (s-2-5) can be prepared from compound (s-5-1) via Step(5-1)-Step (5-4).

Step (5-1):

Compound (s-2-7) can be prepared by reacting compound (s-5-1) in asuitable inert solvent under a conventional condition ofepoxide-formulation. The present reaction condition includes, forexample, using an oxidizing agent such as hydrogen peroxide solution,mCPBA, tert-butyl hydroperoxide, and Oxone. In the present reaction, ametal catalyst such as V, Mo, Al, Ti, Fe, Ta, Zr, Nb, W, and Re may beused, as appropriate. The inert solvent includes a halogenated carbonsolvent such as chloroform and dichloromethane; an aromatic hydrocarbonsolvent such as benzene, toluene, and xylene; and an ester solvent suchas ethyl acetate and methyl acetate. The reaction time is generallyabout 1 hour to 24 hours, and the reaction temperature is −20° C. toboiling point of a solvent used herein.

Step (5-2):

Compound (s-5-2) can be prepared in a similar manner to Step (2-5) withcompound (s-2-7) and P¹NH₂ in a suitable inert solvent.

Step (5-2) may be carried out in a process comprising reacting compound(s-2-7) and ammonia or a reagent equal to ammonia that includes aprotected-amine reagent which is deprotected after the amination and anazide-inducer which is reduced after the azidation, and then protectingthe product with a protecting group P¹.

Step (5-3):

Compound (s-5-3) can be prepared in a similar manner to Step (2-6) withcompound (s-5-2) in a suitable inert solvent.

Step (5-4):

Compound (s-2-5) can be prepared by reacting compound (s-5-3) in thepresence of a base in a suitable inert solvent under a conventionalcondition of intramolecular cyclization reaction. The base used hereinincludes, for example, an organic base such as triethylamine,diisopropylethylamine, and DBU; an inorganic base such as sodiumhydrogen carbonate, sodium carbonate, and potassium carbonate; a metalalkoxide such as potassium tert-butoxide; an organometallic reagent suchas n-butyl lithium and isopropylmagnesium chloride; and a metal amidereagent such as LDA and LHMDS. The inert solvent includes a halogenatedcarbon solvent such as chloroform and dichloromethane; a ether solventsuch as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbonsolvent such as benzene, toluene, and xylene; and an ester solvent suchas ethyl acetate and methyl acetate. The reaction time is generallyabout 1 hour to 24 hours, and the reaction temperature is −20° C. toboiling point of a solvent used herein.

Step (5-3) and Step (5-4) may be carried out as one step withoutisolating the intermediate. And, (5-3) and Step (5-4) may be alsocarried out as one step under Mitsunobu reaction condition.

Compound (s-2-5) can be also prepared from compound (s-5-1) via Step(5-5).

Step (5-5):

Compound (s-2-5) can be prepared by reacting compound (s-5-1) in asuitable inert solvent under a conventional condition ofaziridine-ring-formulation reaction. The present reaction conditionincludes, for example, using P¹NH₂ and an oxidizing agent such asiodosylbenzene in the presence of a metallic catalyst, and using ahydroxylamine derivative P¹N(H)O-LG and a metallica catalyst.

Preparation Process 6:

In compounds according to formula (s-1-1), the compound of formula(s-6-1) which has an unsaturated bond in the ring can be prepared, forexample, by the following process.

wherein R³, R⁴, L², n, and Ring G are as defined in Item 1; Z is boronicacid, boronate ester, BF₃K, BF₃Na, trialkyl tin, zinc halide, orhydrogen atom; and X is halogen.

Compound (s-6-1) can be prepared from compound (s-6-6) via Step (6-7).And, compound (s-6-6) can be prepared from compound (s-6-2) via Step(6-1)-Step (6-3), or via Step (6-4)-Step (6-6).

Step (6-1):

Compound (s-6-4) wherein L² is single bond or methylene which may beoptionally substituted with the same or different one or more C₁₋₄ alkylcan be prepared by reacting compound (s-6-2) with compound (s-6-3)wherein Z is boronic acid, boronate ester, BF₃K, BF₃Na, trialkyl tin, orzinc halide, in the presence of palladium catalyst and phosphine ligand,and optionally in the presence of a base, in a suitable inert solvent.Compound (s-6-3) is commercially available, or can be prepared accordingto a known method or a similar method thereto. The palladium catalystused herein includes, for example,tetrakis(triphenylphosphine)palladium(0),bis(dibenzylideneacetone)palladium(0),tris(dibenzylideneacetone)dipalladium(0),bis(tri-tort-butylphosphine)palladium(0), palladium(0) acetate,[1,1-bis(diphenylphosphino) ferrocene]palladium(II) dichloride, andbis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II).

The phosphine ligand used herein includes, for example,dimethoxybiphenyl (S-Phos),2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (X-Phos),1,1′-bis(diphenylphosphino)ferrocene (DPPF),1,2-bis(diphenylphosphino)ethane (DPPE),1,3-bis(diphenylphosphino)propane (DPPP),1,4-bis(diphenylphosphino)butane (DPPB),2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (BINAP),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (XANT-Phos), andbis((2-diphenylphosphino)phenyl) ether (DPE-Phos). The base used hereinincludes, for example, sodium carbonate, potassium carbonate, cesiumcarbonate, potassium phosphate, sodium hydroxide, and potassiumhydroxide. The inert solvent includes, for example, 1,4-dioxane, THF,1,2-dimethoxyethane, acetonitrile, water, and a mixture thereof. Thereaction time is generally about 1 hour to 24 hours, and the reactiontemperature is −20° C. to boiling point of a solvent used herein.

In addition, compound (s-6-4) wherein L² is O or NR¹⁰ can be alsoprepared by reacting compound (s-6-2) with compound (s-6-3) wherein Z ishydrogen atom in the presence of palladium catalyst, phosphine ligand,and a base in a suitable inert solvent.

Step (6-2):

Compound (s-6-5) can be prepared in a similar manner to Step (2-6) withcompound (s-6-4).

Step (6-3):

Compound (s-6-6) can be prepared in a similar manner to Step (2-7) withcompound (s-6-5) and P¹NH₂.

Step (6-3) may be carried out in a process comprising reacting compound(s-6-5) and ammonia or a reagent equal to ammonia that includes aprotected-amine reagent which is deprotected after the amination and anazide-inducer which is reduced after the azidation, and then protectingthe product with a protecting group P¹.

Step (6-2) and Step (6-3) may be carried out as one step withoutisolating the intermediate. And, Step (6-2) and Step (6-3) may be alsocarried out as one step under Mitsunobu reaction condition.

Step (6-4):

Compound (s-6-7) can be prepared in a similar manner to Step (6-2) withcompound (s-6-2).

Step (6-5):

Compound (s-6-8) can be prepared in a similar manner to Step (6-3) withcompound (s-6-7).

Step (6-5) may be carried out in a process comprising reacting compound(s-6-7) and ammonia or a reagent equal to ammonia that includes aprotected-amine reagent which is deprotected after the amination and anazide-inducer which is reduced after the azidation, and then protectingthe product with a protecting group P¹.

Step (6-4) and Step (6-5) may be carried out as one step withoutisolating the intermediate. And, Step (6-4) and Step (6-5) may be alsocarried out as one step under Mitsunobu reaction condition.

Step (6-6):

Compound (s-6-6) can be prepared in a similar manner to Step (6-1) withcompound (s-6-8).

Step (6-7):

Compound (s-6-1) can be prepared in a similar deprotection to Step (2-4)with compound (s-6-6).

Preparation Process 7:

In compounds according to formula (s-1-1), the compound of formula(s-7-1) which has no unsaturated bond in the ring can be prepared, forexample, by the following process.

wherein R¹-R⁴, L¹, L², n, Ring G, and A¹ are as defined in Item 1.

Compound (s-7-1) can be prepared from compound (s-7-4) via Step (7-6).And, compound (s-7-4) can be prepared from compound (s-5-3) via Step(7-1) Step (7-3), or from compound (s-2-5) via Step (7-4) and Step(7-5).

Step (7-1):

Compound (s-7-2) can be prepared in a similar deprotection to Step (2-4)with compound (s-5-3).

Step (7-2):

Compound (s-7-3) can be prepared in a similar ureation to Step (1-1)with compound (s-7-2) and compound (s-1-2). In this step, the hydroxygroup may be protected and deprotected, if necessary.

Step (7-3):

Compound (s-7-4) can be prepared in a similar manner to Step (5-3) andStep (5-4) with compound (s-7-3).

Step (7-4):

Compound (s-7-5) can be prepared in a similar deprotection to Step (2-4)with compound (s-2-5).

Step (7-5):

Compound (s-7-4) can be prepared in a similar urea formation to Step(1-1) with compound (s-7-5) and compound (s-1-2).

Step (7-6):

Compound (s-7-1) can be prepared in a similar aziridine-ring-openreaction to Step (2-3) with compound (s-7-4) and compound (s-2-3).

Preparation Process 8:

The compound of formula (s-1-1) can be also prepared from compound(s-8-1) via Step (8-1)-Step (8-3).

wherein R¹-R⁴, L¹, L², n, Ring G, A¹, and the bond accompanied withbroken line are as defined in Item 1.

Step (8-1):

Compound (s-8-2) can be prepared by reacting compound (s-8-1) in asuitable inert solvent under a conventional condition of acyl azideformulation. The present reaction condition includes, for example, usingdiphenylphosphoryl azide, or converting the carboxylic acid to its acidhalide and then azidating the acid halide with a metallic azide. Theinert solvent includes an ether solvent such as diethyl ether,diisopropyl ether, tetrahydrofuran, and 1,4-dioxane; an aromatichydrocarbon solvent such as benzene, toluene, and xylene, an estersolvent such as ethyl acetate and methyl acetate; an aprotic polarsolvent such as N,N-dimethylformamide, N,N-dimethylacetamide,N-methyl-2-pyrrolidinone, 1,3-dimethyl-2-imidazolidinone, and dimethylsulfoxide. The reaction time is generally about 1 hour to 24 hours, andthe reaction temperature is −20° C. to boiling point of a solvent usedherein.

Step (8-2):

Compound (s-8-3) can be prepared by reacting compound (s-8-2) in asuitable inert solvent under a condition of Curtius rearrangementreaction. Compound (s-8-2) used herein may be the un-isolated productfrom the prior step.

Step (8-3):

Compound (s-1-1) can be prepared by reacting compound (s-8-3) andcompound (s-1-2) in a suitable inert solvent under a conventionalcondition of addition reaction. Compound (s-8-3) used herein may be theun-isolated product from the prior step.

Preparation Process 9:

In compounds according to formula (s-8-1), the compound of formula(s-9-1) which has no unsaturated bond in the ring can be prepared, forexample, by the following process.

wherein R³, R⁴, L², n, and Ring G are as defined in Item 1; and P³ is asuitable protecting group or C₁₋₃ alkyl, said definitions are used belowunless otherwise indicated.

Compound (s-9-1) can be prepared from compound (s-9-2) via Step (9-1)and Step (9-2).

Step (9-1):

Compound (s-9-3) can be prepared in a similar manner to Step (2-1) withcompound (s-9-2) and compound (s-2-3).

Step (9-2):

Compound (s-9-1) can be prepared by subjecting compound (s-9-3) to ageneral condition of hydrolysis or deprotection.

Compound (s-9-1) can be prepared from compound (s-2-9) via Step (9-3)and Step (9-4).

Step (9-3):

Compound (s-9-4) can be prepared in a similar manner to Step (2-7) withcompound (s-2-9) and a metallic cyanide.

Step (9-4):

Compound (s-9-1) can be prepared by reacting compound (s-9-4) in asuitable inert solvent under a general condition of hydrolysis.

Preparation Process 10:

In compounds according to formula (s-8-1), the compound of formula(s-10-1) which has an unsaturated bond in the ring can be prepared, forexample, by the following process.

wherein R³, R⁴, L², n, and Ring G are as defined in Item 1; Z is boronicacid, boronate ester, BF₃K, BF₃Na, trialkyl tin, zinc halide, orhydrogen atom; and X is halogen.

Compound (s-10-1) can be prepared from compound (s-10-2) via Step(10-2). And, compound (s-10-2) can be prepared from compound (s-6-5) viaStep (10-1), or from compound (s-6-7) via Step (10-3) and Step (10-4).

Step (10-1):

Compound (s-10-2) can be prepared in a similar manner to Step (2-7) withcompound (s-6-5) and a metallic cyanide.

Step (10-2):

Compound (s-10-1) can be prepared by reacting compound (s-10-2) in asuitable inert solvent under a general condition of hydrolysis.

Step (10-3):

Compound (s-10-3) can be prepared in a similar manner to Step (10-1)with compound (s-6-7) and a metallic cyanide.

Step (10-4):

Compound (s-10-2) can be prepared in a similar manner to Step (6-1) withcompound (s-10-3) and compound (s-6-3).

Preparation Process 11:

In compounds according to formula (1) or a pharmaceutically acceptablesalt thereof, the compound of formula (s-11-1) which is a compound offormula (1) wherein A³ is carbon atom or a pharmaceutically acceptablesalt thereof can be prepared, for example, by the following process.

wherein R¹-R⁴, L¹, L², n, Ring G, and the bond accompanied with brokenline are as defined in Item 1.

Step (11-1):

Compound (s-11-1) can be prepared by reacting compound (s-11-2) andcompound (s-1-3) in a suitable inert solvent under a conventionalcondition of amide-bond formulation reaction. The present reactioncondition includes, for example, using a condensation agent and a base,and the condensation agent used herein includes, for example, acarbodiimide such as dicyclohexylcarbodiimide, 1,1′-carbonyldiimidazole,diphenylphosphoryl azide (DPPA), diethylphosphoryl cyanide (DEPC),dicyclohexylcarbodiimide (DCC), carbonyldiimidazole (CDI),1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDO.HCl),O-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium tetrahydroborate(TBTU), O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HBTU), andO-(7-azabenzotriazol-1-yl)-N,N,N′,N′,-tetramethyluroniumhexafluorophosphate (HATU). The base used herein includes an organicbase such as triethylamine, diisopropylethylamine, tributylamine, DBU,pyridine, and dimethylaminopyridine. The inert solvent includes ahalogenated hydrocarbon solvent such as dichloromethane and chloroform;an ether solvent such as diethyl ether, diisopropyl ether,tetrahydrofuran, and 1,4-dioxane; an aromatic hydrocarbon solvent suchas benzene, toluene, and xylene; an ester solvent such as ethyl acetateand methyl acetate; an aprotic polar solvent such asN,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone,1,3-dimethyl-2-imidazolidinone, and dimethyl sulfoxide. The reactiontime is generally about 1 hour to 24 hours, and the reaction temperatureis −20° C. to boiling point of a solvent used herein.

Compound (s-11-1) can be also prepared from compound (s-11-2) via Step(11-2) and Step (11-3).

Step (11-2):

Compound (s-11-3) can be prepared by reacting compound (s-11-2) in asuitable inert solvent under a conventional condition of acid halideformulation reaction. The present reaction condition includes, forexample, using a halogenating agent, and the halogenating agent usedherein includes, for example, thionyl chloride, oxalyl chloride,phosphoryl chloride, sulfuryl chloride, phosphorus trichloride,phosphorus tribromide, and phosphorus pentachloride. The inert solventincludes a halogenated hydrocarbon solvent such as dichloromethane andchloroform; an ether solvent such as diethyl ether, diisopropyl ether,tetrahydrofuran, and 1,4-dioxane; an aromatic hydrocarbon solvent suchas benzene, toluene, and xylene; and an ester solvent such as ethylacetate and methyl acetate. The reaction time is generally about 1 hourto 24 hours, and the reaction temperature is −20° C. to boiling point ofa solvent used herein.

Step (11-3):

Compound (s-11-1) can be prepared by reacting compound (s-11-3) andcompound (s-1-3) in a suitable inert solvent in the presence of a base.The base used herein includes an organic base such as triethylamine,diisopropylethylamine, tributylamine, DBU, pyridine, anddimethylaminopyridine; and an inorganic base such as sodium hydrogencarbonate, sodium carbonate, and potassium carbonate. The inert solventincludes a halogenated hydrocarbon solvent such as dichloromethane andchloroform; an ether solvent such as diethyl ether, diisopropyl ether,tetrahydrofuran, and 1,4-dioxane; an aromatic hydrocarbon solvent suchas benzene, toluene, and xylene; and an ester solvent such as ethylacetate and methyl acetate. The reaction time is generally about 1 hourto 24 hours, and the reaction temperature is −20° C. to boiling point ofa solvent used herein.

Preparation Process 12:

In compounds according to formula (1) or a pharmaceutically acceptablesalt thereof, the compound of formula (s-12-1) which is a compound offormula (1) wherein A² is oxygen atom or a pharmaceutically acceptablesalt thereof can be prepared, for example, by the following process.

wherein R¹-R⁴, L¹, L², n, Ring G, A¹, and the bond accompanied withbroken line are as defined in Item 1.

Step (12-1):

Compound (s-12-1) can be prepared by reacting compound (s-1-2) andcompound (s-12-2) in a suitable inert solvent under a conventionalcondition of carbamate formulation reaction. The present reactioncondition includes, for example, using triphosgene, 4-nitrophenylchloroformate, or thiophosgene. A base is used in the present reaction,and the base used herein includes triethylamine anddiisopropylethylamine. The inert solvent includes a halogenated carbonsolvent such as chloroform and dichloromethane; a ether solvent such asdiethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solventsuch as benzene, toluene, and xylene; and an ester solvent such as ethylacetate and methyl acetate. The reaction time is generally about 1 hourto 24 hours, and the reaction temperature is −20° C. to boiling point ofa solvent used herein.

Compound (s-12-2) which has no unsaturated bond in the ring is preparedin the Preparation Process of compound (s-2-8). And, compound (s-12-2)which has a unsaturated bond in the ring is prepared in the PreparationProcess of compound (s-6-4).

Preparation Process 13:

In compounds according to formula (s-1-2), the compound of formula(s-13-1) can be prepared, for example, by the following process.

wherein R² is as defined in Item 1, R^(a1) and Q² are as defined in Item4; and P⁴ is a suitable protecting group, said definitions are usedbelow unless otherwise indicated.

Step (13-1):

Compound (s-13-4) can be prepared by reacting compound (s-13-2) andcompound (s-13-3) in a suitable inert solvent under a conventionalcondition of addition reaction. The inert solvent includes a halogenatedcarbon solvent such as chloroform and dichloromethane; a ether solventsuch as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbonsolvent such as benzene, toluene, and xylene; an alcohol solvent such asmethanol and ethanol; and water. The reaction time is generally about 1hour to 24 hours, and the reaction temperature is −20° C. to boilingpoint of a solvent used herein.

Step (13-2):

Compound (s-13-6) can be prepared by reacting compound (s-13-4) andcompound (s-13-5) in a suitable inert solvent under a conventionalcondition of condensation reaction. The present reaction conditionincludes, for example, using HATU, DCC, or CDI. A base is used in thepresent reaction, and the base used herein includes triethylamine anddiisopropylethylamine. The inert solvent includes a halogenated carbonsolvent such as chloroform and dichloromethane; a ether solvent such asdiethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbon solventsuch as benzene, toluene, and xylene; and an ester solvent such as ethylacetate and methyl acetate. The reaction time is generally about 1 hourto 24 hours, and the reaction temperature is −20° C. to boiling point ofa solvent used herein.

Step (13-3):

Compound (s-13-7) can be prepared by reacting compound (s-13-6) in asuitable inert solvent under a conventional condition of dehydrationreaction. In the present reaction, a base such as triethylamine and DBUmay be used as appropriate. The inert solvent includes a halogenatedcarbon solvent such as chloroform and dichloromethane; a ether solventsuch as diethyl ether, THF, and 1,4-dioxane; an aromatic hydrocarbonsolvent such as benzene, toluene, and xylene; and an ester solvent suchas ethyl acetate and methyl acetate. The reaction time is generallyabout 1 hour to 24 hours, and the reaction temperature is −20° C. toboiling point of a solvent used herein.

Step (13-4):

Compound (s-13-1) can be prepared by deprotecting compound (s-13-7) in aknown manner (for example, a manner described in Protective Groups inOrganic Synthesis 3^(rd) Edition (John Wiley & Sons, Inc.),Comprehensive Organic Transformation, edited by R. C. Larock, VCHpublisher Inc., 1989, etc.) or a similar manner thereto.

Preparation Process 14:

In compounds according to formula (s-1-2), the compound of formula(s-14-1) which is a compound of formula (s-1-2) wherein L¹ is singlebond and R¹ is optionally-substituted 5-membered aromatic heterocyclylgroup can be also prepared, for example, by the following process.

wherein R² is as defined in Item 1, X⁴ and R^(a1) are as defined in Item4.

Compound (s-14-1) can be prepared from compound (s-14-2) via Step(14-1)-Step (14-3).

Step (14-1):

Compound (s-14-3) can be prepared by reacting compound (s-14-2) in asuitable inert solvent under a conventional condition of chlorinationreaction. The present reaction condition includes, for example, usingchlorine, N-succinimide, and trimethylbenzylammonium tetrachloroiodate.The inert solvent includes a halogenated carbon solvent such aschloroform and dichloromethane; a ether solvent such as diethyl ether,THF, and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene,toluene, and xylene; an aprotic polar solvent such asN,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone,1,3-dimethyl-2-imidazolidinone and dimethyl sulfoxide; water; and amixture thereof. The reaction time is generally about 1 hour to 24hours, and the reaction temperature is −20° C. to boiling point of asolvent used herein.

Step (14-2):

Compound (s-14-5) can be prepared by reacting compound (s-14-3) andcompound (s-14-4) in a suitable inert solvent under a conventionalcondition of 1,3-dipolar cycloaddition reaction. The present reactioncondition includes, for example, using a base, and the base used hereinincludes an inorganic base such as potassium carbonate, cesiumcarbonate, sodium carbonate, sodium hydrogen carbonate, sodiummethoxide, sodium t-butoxide, sodium hydroxide, potassium hydroxide, andpotassium fluoride; and an organic base such as triethylamine,diisopropylethylamine, tributylamine, DBN, DABCO, DBU, pyridine,dimethylaminopyridine, picoline, and NMM. The inert solvent includes ahalogenated carbon solvent such as chloroform and dichloromethane; aether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatichydrocarbon solvent such as benzene, toluene, and xylene; and an estersolvent such as ethyl acetate and methyl acetate. The reaction time isgenerally about 1 hour to 24 hours, and the reaction temperature is −20°C. to boiling point of a solvent used herein.

Step (14-3):

Compound (s-14-1) can be prepared in a similar manner to Step (13-4)with compound (s-14-5).

Preparation Process 15:

In compounds according to formula (s-1-2), the compound of formula(s-15-1) can be prepared, for example, by the following process.

wherein R² is as defined in Item 1, X¹-X³, Q¹ and R^(a6) are as definedin Item 4.

Step (15-1):

Compound (s-15-4) can be prepared by reacting compound (s-15-2) andcompound (s-15-3) in a suitable inert solvent under a condensationreaction like Step (13-2).

Step (15-2):

Compound (s-15-5) can be prepared by reacting compound (s-15-4) in asuitable inert solvent under a conventional condition of dehydrationreaction, or a cyclization condition after the treatment with Lawesson'sreagent or the like.

Step (15-3):

Compound (s-15-1) can be prepared in a similar manner to Step (13-4)with compound (s-15-5).

Preparation Process 16:

In compounds according to formula (s-1-2), the compound of formula(s-16-5) or the compound of formula (s-16-8) which is a compound offormula (s-1-2) wherein L¹ is single bond and R¹ isoptionally-substituted C₆₋₁₀ aromatic carbocyclyl group oroptionally-substituted 5- to 10-membered aromatic heterocyclyl group canbe prepared, for example, by the following process.

wherein R¹ and R² are as defined in Item 1; Z is exemplified in thefollowing Step (16-1); and X is halogen.

Compound (s-16-5) can be prepared from compound (s-16-1) via Step(16-1)-Step (16-3).

Step (16-1):

Compound (s-16-3) can be prepared by coupling compound (s-16-1) withorganic boron compound (for example, Z is B(OH)₂ and the like), organiczinc compound (for example, Z is ZnCl and the like), alkenyl compound,alkynyl compound, hydroxy compound (for example, Z is OH and the like),amine compound (for example, Z is NH₂ and the like), or metallic cyanide(for example, Z is CuCN and the like), in the presence of a base andmetallic catalyst. The base used herein includes an inorganic base suchas potassium carbonate, cesium carbonate, sodium carbonate, sodiumhydrogen carbonate, sodium methoxide, sodium t-butoxide, sodiumhydroxide, potassium hydroxide, and potassium fluoride; and an organicbase such as triethylamine, diisopropylethylamine, tributylamine, DBN,DABCO, DBU, pyridine, dimethylaminopyridine, picoline, and NMM.Sometimes, a base is not used depending on the coupling type. Themetallic catalyst used herein includes, for example,bis(tri-tert-butylphosphine)palladium,bis(tri-o-tolylphosphine)dichloropalladium,bis(tri-o-tolylphosphine)palladium,tetrakis(triphenylphosphine)palladium,dichlorobis(acetonitrile)palladium,bis(tri-o-tolylphosphine)dichloropalladium,[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium, andPEPPSI™.IPr((1,3-bis(2,6-diisopropylphenyl)imidazolidene)(3-chloropyridyl)palladium(II)dichloride). Palladium acetate orpalladium chloride may be used herein, and a ligand described inPalladium reagents and catalysts, John Wiley & Sons Inc. (2004) or asimilar ligand may be also used in place of the acetate in palladiumacetate or the chloride in palladium chloride. The solvent used hereinincludes, for example, an ether solvent such as diethyl ether,diisopropyl ether, tetrahydrofuran, methyl cyclopentyl ether, anisole,and 1,4-dioxane; an aromatic hydrocarbon solvent such as benzene,toluene, chlorobenzene, and xylene; an ester solvent such as ethylacetate and methyl acetate; an aprotic polar solvent such asN,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidinone,1,3-dimethyl-2-imidazolidinone, and dimethyl sulfoxide; water; and amixture thereof. The reaction temperature should be determined dependingon the starting compound to be used, which is generally about 0° C. toabout 250° C., preferably about 20° C. to about 200° C. The reactiontime is generally 30 minutes to 48 hours, preferably 1 to 24 hours.

Step (16-2):

Compound (s-16-4) can be prepared by reacting compound (s-16-3) in asuitable inert solvent under a conventional condition ofalkene-reduction reaction, and under hydrogen atmosphere if necessary.The present reaction condition includes, for example, using a reducingagent such as palladium carbon, palladium(II) hydroxide, platinum oncarbon, platinum(IV) oxide, Raney nickel, ruthenium carbon, andtris(triphenylphosphine)rhodium(I) chloride. The inert solvent includesa halogenated carbon solvent such as chloroform and dichloromethane; aether solvent such as diethyl ether, THF, and 1,4-dioxane; an aromatichydrocarbon solvent such as benzene, toluene, and xylene; an alcoholsolvent such as methanol and ethanol; and an ester solvent such as ethylacetate and methyl acetate. The reaction time is generally about 1 hourto 24 hours, and the reaction temperature is −20° C. to boiling point ofa solvent used herein.

Step (16-3):

Compound (s-16-5) can be prepared in a similar manner to Step (13-4)with compound (s-16-4).

Compound (s-16-8) can be prepared from compound (s-16-1) via Step(16-1), and Step (16-4)-Step (16-6).

Step (16-4):

Compound (s-16-6) can be prepared by reacting compound (s-16-3), analkylating agent R²—X, and a base in a suitable inert solvent under acondition of alkylation reaction. The base used herein includes LDA,LHMDS, and n-butyllithium. The inert solvent includes a ether solventsuch as diethyl ether, THF, and 1,4-dioxane; and an aromatic hydrocarbonsolvent such as benzene, toluene, and xylene. The reaction time isgenerally about 1 hour to 24 hours, and the reaction temperature is −20°C. to boiling point of a solvent used herein.

Step (16-5):

Compound (s-16-7) can be prepared by reacting compound (s-16-6) in asuitable inert solvent in a similar manner to Step (16-2) wherein thereducing agent may include sodium borohydride, sodium cyanoborohydride,and sodium triacetoxyborohydride.

Step (16-6):

Compound (s-16-8) can be prepared in a similar manner to Step (13-4)with compound (s-16-7).

Preparation Process 17:

In compounds according to formula (s-1-2), the compound of formula(s-17-1) can be prepared, for example, by the following process.

wherein R¹ is as defined in Item 1, and R⁸ is C₁₋₃ alkyl.

Step (17-1):

Compound (s-17-3) can be prepared by reacting compound (s-17-2) and analkylating agent R¹—X wherein X is halogen in a suitable inert solventunder a condition of alkylation reaction like Step (16-4).

Step (17-2):

Compound (s-17-4) can be prepared by reacting compound (s-17-3) in asuitable inert solvent under a conventional condition of reductionreaction. The present reaction condition includes, for example, usingLAH or DIBAL. The inert solvent includes a halogenated carbon solventsuch as chloroform and dichloromethane; a ether solvent such as diethylether, THF, and 1,4-dioxane; and an aromatic hydrocarbon solvent such asbenzene, toluene, and xylene. The reaction time is generally about 1hour to 24 hours, and the reaction temperature is −20° C. to boilingpoint of a solvent used herein.

Step (17-3):

Compound (s-17-5) can be prepared by reacting compound (s-17-4) in asuitable inert solvent under a condition of Barton-McCombiedeoxygenation.

Step (17-4):

Compound (s-17-1) can be prepared in a similar manner to Step (13-4)with compound (s-17-5).

EXAMPLES

The present invention is explained in more detail in the following byreferring to Reference examples, Examples, and Tests; however, thetechnical scope of the present invention should not be limited thereto.It should be understood that the names of compounds used in thefollowing Reference examples and Examples do not necessarily follow theIUPAC nomenclature.

In the present specification, the abbreviations shown below may be used.

CDCl₃: deuterochloroformDMSO-d₆: deuterodimethylsulfoxideRt: retention timemin: minuteHATU: O-(7-aza-1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphateDCC: N,N′-dicyclohexylcarbodiimideCDI: carbonyldiimidazoleTHF: tetrahydrofuranTFA: trifluoroacetic acid

DMF: N,N-dimethylformamide

DMSO: dimethyl sulfoxideCPME: cyclopentyl methyl etherBoc: tert-butoxycarbonylNs: 2-nitrobenzenesulfonylTf: trifluoromethanesulfonylDBU: diazabicycloundeceneDBN: 1,5-diazabicyclo[4.3.0]non-5-eneLDA: lithium diisopropylamideLHMDS: lithium bis(trimethylsilyl)amidemCPBA: meLa-chloroperbenzoic acidDABCO: 1,4-diazabicyclo[2.2.2]octane

NMM: N-methylmorpholine

LAH: lithium aluminium hydrideDIBAL: diisobutylaluminium hydrideAbs: Absolute Configuration; each chemical structure of compoundsdescribed along with Abs mark surrounded with a square flame is shown inabsolute configuration with a wedged bond. However, not all compoundswithout Abs mark are shown in non-absolute configuration, i.e., theconfiguration should be properly judged based on the disclosure aboutthe subject compound in the present description and its context, and askilled person's technical knowledge, with or without Abs mark.

In the column chromatography and amino chromatography used in Referenceexamples and Examples, silica gel column and amino column made byYAMAZEN CORPORATION were used. The TLC (silica gel plate) used in theTLC purification was Silica gel 60F254 (Merck), and the TLC (NH silicagel plate) used therein was TLC plate NH (FujiSilysia).

In Reference examples and Examples, the reactors shown below were used.The physicochemical data described in Reference examples and Exampleswere obtained with the apparatuses below.

Microwave reactor: Biotage AB Initiator

¹H-NMR: JEOL JNM-AL400; JEOL JNM-ECS400; Brucker AVANCE 400 Spectrometer

The symbols used in NMR are defined as follows, s: singlet, d: doublet,dd: doublet of doublet, ddd: doublet of doublet of doublet, dddd:doublet of doublet of doublet of doublet, t: triplet, td: triplet ofdoublet, q: quartet, m: multiplet, br: broad singlet or multiplet, andJ: coupling constant.

The LC/MS data of each compound in Examples and Reference examples wereobtained with any one of the apparatuses below.

Method A

Detection apparatus: ACQUITY™ SQ detector (Waters Corporation)

HPLC: ACQUITY™ UPLC SYSTEM

Column: Waters ACQUITY™ UPLC BEH C18 (1.7 μm, 2.1 mm×30 mm)

Method B

Detection apparatus: Shimadzu LCMS-2020Column: Phenomenex Kinetex (C18, 1.7 μm, 2.1 mm×50 mm)

Method C

Detection apparatus: ACQUITY™ SQ detector (Waters Corporation)

HPLC: ACQUITY™ UPLC SYSTEM

Column: Waters ACQUITY™ UPLC BEH C18 (1.7 μm, 2.1 mm×30 mm)

High-performance liquid chromatograph mass spectrometer; the measurementconditions of LC/MS are as follows, wherein the observed [MS (m/z)] isdenoted by [M+H]⁺ and the retention time is denoted by Rt (min). Eachmeasured MS value shown in the working examples is accompanied by anyone of A-D which were measurement methods used in the actualmeasurements.

Method A

Solvent: A; 0.06% formic acid/H₂O, B; 0.06% formic acid/acetonitrileGradient condition: 0.0-1.3 min (linear gradient from B 2% to B 96%)Flow rate: 0.8 mL/min; Detective UV: 220 nm and 254 nm; Temperature: 40°C.

Hereinafter, the LC-MS data shown below were measured by Method A,unless otherwise indicated.

Method B

Solvent: A; 0.05% TFA/H₂O, B; acetonitrileGradient condition: 0.0-1.7 min (linear gradient from B 10% to B 99%)Flow rate: 0.5 mL/min; Detective UV: 220 nm; Temperature: 40° C.

Method C

Solvent: A; 0.05% formic acid/H₂O, B; acetonitrileGradient condition: 0.0-1.3 min (linear gradient from B 10% to B 95%)1.3-1.5 min (B 10%)Flow rate: 0.8 mL/min; Detective UV: 220 nm and 254 nm; Temperature: 40°C.

Example 1rac-4-(4-Methylphenyl)-N-{(1S,2S)-2-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}piperidine-1-carboxamide

To a mixture of Reference example 1 (211 mg) (Material A), triethylamine(0.391 mL), and chloroform (3 mL) was added 4-nitrophenyl chloroformate(208 mg) at 0° C., and the mixture was stirred at the same temperaturefor 40 minutes. To the reaction mixture was added4-(4-methylphenyl)piperidine hydrochloride (238 mg) (Material B) at 0°C., and the mixture was stirred at room temperature for one hour. Waterwas added to the reaction mixture, and the mixture was extracted withchloroform. The organic layer was dried over anhydrous sodium sulfate,concentrated in vacuo, and then the obtained residue was purified byamino silica gel column chromatography (eluate: hexane/ethyl acetate) togive the title compound (346 mg).

¹H-NMR (CDCl₃) δ: 1.02 (6H, d, J=6.7 Hz), 1.04-1.11 (1H, m), 1.12-1.40(3H, m), 1.58-1.71 (3H, m), 1.76-1.93 (4H, m), 2.27 (1H, dd, J=10.4, 3.6Hz), 2.32 (3H, s), 2.35-2.54 (6H, m), 2.54-2.65 (3H, m), 2.65-2.75 (2H,m), 2.78-2.91 (2H, m), 3.25-3.33 (1H, m), 4.08-4.19 (2H, m), 5.76 (1H,s), 7.09 (2H, d, J=8.8 Hz), 7.12 (2H, d, J=8.8 Hz).

Examples 2 to 16

The compounds of Examples 2 to 16 shown in the table below were preparedin the same manner as Example 1, by using commercial compounds orReference example compounds which correspond to Material A and MaterialB described in Example 1.

Structure Material A Material B Example Spectral data ReferenceCommercial 2 example 3 product

¹H-NMR (CDCl₃) δ: 1.07 (3H, t, J = 7.3 Hz), 1.12-1.35 (6H, m), 1.36-1.45(2H, m), 1.56-1.69 (2H, m), 1.80- 1.88 (2H, m), 1.89-1.96 (1H, m),2.12-2.20 (1H, m), 2.30-2.58 (11H, m), 2.59-2.70 (2H, m), 2.80-2.91 (2H,m), 3.98-4.04 (1H, m), 4.07-4.15 (2H, m), 5.16 (1H, s), 7.10 (2H, d, J =8.5 Hz), 7.13 (2H, d, J = 8.5 Hz). Reference Commercial 3 example 1product

¹H-NMR (CDCl₃) δ: 1.03 (6H, d, J = 6.1 Hz), 1.14-1.28 (3H, m), 1.32 (3H,s), 1.58-1.68 (3H, m), 1.76-1.82 (1H, m), 1.83-1.91 (1H, m), 2.19-2.30(3H, m), 2.34- 2.53 (6H, m), 2.53-2.62 (6H, m), 2.62-2.71 (2H, m), 3.07(2H, ddd, J = 13.2, 10.4, 2.8 Hz), 3.20-3.31 (1H, m), 3.63-3.74 (2H, m),5.70 (1H, s). Reference Commercial 4 example 4 product

¹H-NMR (CDCl₃) δ: 1.01 (6H, d, J = 6.1 Hz), 1.15-1.35 (4H, m), 1.42-1.58(2H, m), 1.58-1.71 (2H, m), 1.81- 1.90 (2H, m), 1.91-2.01 (1H, m), 2.32(3H, s), 2.38- 2.63 (8H, m), 2.63-2.71 (3H, m), 2.72-2.95 (3H, m), 3.35(3H, s), 3.50-3.57 (1H, m), 4.01-4.06 (1H, m), 4.06-4.23 (2H, m), 5.53(1H, d, J = 3.7 Hz), 7.09 (2H, d, J = 8.2 Hz), 7.12 (2H, d, J = 8.2 Hz).Reference Commercial 5 example 5 product

¹H-NMR (CDCl₃) δ: 1.06 (6H, d, J = 6.1 Hz), 1.35-1.48 (1H, m), 1.48-1.73(5H, m), 1.78-1.91 (2H, m), 2.12- 2.25 (1H, m), 2.32 (3H, s), 2.39-2.79(12H, m), 2.79- 2.93 (2H, m), 3.96-4.12 (3H, m), 4.63 (1H, s), 7.09 (2H,d, J = 7.9 Hz), 7.12 (2H, d, J = 7.9 Hz). Reference Reference 6 example5 example 20

¹H-NMR (CDCl₃) δ: 0.92-0.99 (2H, m), 0.99-1.09 (8H, m), 1.26 (3H, s),1.35-1.45 (1H, m), 1.46-1.76 (6H, m), 1.80-1.90 (1H, m), 1.94-2.10 (3H,m), 2.10-2.21 (1H, m), 2.37-2.84 (9H, m), 3.08-3.17 (2H, m), 3.52- 3.64(2H, m), 3.98-4.08 (1H, m), 4.61 (1H, s), 5.77 (1H, s). ReferenceReference 7 example 7 example 8

¹H-NMR (CDCl₃) δ: 0.80-0.91 (1H, m), 1.02 (3H, d, J = 6.0 Hz), 1.03 (3H,d, J = 6.0 Hz), 1.18-1.23 (4H, m), 1.24-1.28 (2H, m), 1.31 (3H, s),1.53-1.70 (2H, m), 1.92-2.28 (5H, m), 2.28-2.69 (7H, m), 2.73-2.81 (2H,m), 3.02-3.14 (4H, m), 3.52-3.63 (1H, m), 3.63-3.75 (2H, m), 5.52 (1H,s). Reference Commercial 8 example 14 product

¹H-NMR (CDCl₃) δ: 0.96-1.52 (11H, m), 1.70-1.93 (3H, m), 1.94-2.08 (2H,m), 2.13-2.26 (1H, m), 2.32 (3H, s), 2.42-3.27 (12H, m), 4.02-4.26 (3H,m), 4.61 (1H, d, J = 6.7 Hz), 7.08 (2H, d, J = 8.5 Hz), 7.12 (2H, d, J =8.5 Hz). Reference Reference 9 example 6 example 8

¹H-NMR (CDCl₃) δ: 1.46-1.63 (6H, m), 1.12-1.24 (4H, m), 1.24-1.39 (5H,m), 1.39-1.50 (1H, m), 1.51-1.71 (3H, m), 1.86-1.96 (1H, m), 2.07-2.29(4H, m), 2.31- 2.59 (6H, m), 2.59-2.74 (2H, m), 2.74-2.89 (2H, m),2.93-3.17 (1H, m), 3.18-3.41 (1H, m), 3.62-3.83 (1H, m), 3.83-4.00 (1H,m), 4.82-5.00 (1H, m). Reference Commercial 10 example 6 product

¹H-NMR (CDCl₃) δ: 0.88-1.10 (6H, m), 1.23-1.39 (1H, m), 1.33 (3H, s),1.40-1.51 (1H, m), 1.53-2.99 (2H, m), 1.73-1.83 (1H, m), 1.83-1.96 (1H,m), 2.06-2.31 (3H, m), 2.31-2.60 (9H, m), 2.60-2.86 (3H, m), 2.90- 3.16(1H, m), 3.16-3.42 (1H, m), 3.63-3.86 (1H, m), 3.86-4.03 (1H, m),4.83-5.00 (1H, m). Reference Reference 11 example 6 example 20

¹H-NMR (CDCl₃) δ: 0.90-1.10 (10H, m), 1.15-1.37 (5H, m), 1.37-1.50 (1H,m), 1.53-1.81 (4H, m), 1.83-1.95 (1H, m), 1.95-2.24 (4H, m), 2.24-2.71(7H, m), 2.71- 2.87 (2H, m), 3.01-3.49 (2H, m), 3.60-3.81 (1H, m),3.81-3.97 (1H, m), 4.83-5.00 (1H, m), 5.77 (1H, s). Reference Reference12 example 6 example 10

¹H-NMR (CDCl₃) δ: 0.82-1.12 (6H, m), 1.23-1.50 (5H, m), 1.56-1.83 (4H,m), 1.85-1.97 (1H, m), 2.10-2.33 (3H, m), 2.33-2.73 (8H, m), 2.73-2.88(2H, m), 2.95- 3.22 (1H, m), 3.21-3.48 (1H, m), 3.65-3.84 (1H, m),3.86-4.04 (1H, m), 4.85-5.00 (1H, m), 6.79 (1H, t, J = 52.3 Hz).Reference Reference 13 example 6 example 27

¹H-NMR (CDCl₃) δ: 0.83-1.15 (10H, m), 1.18-1.34 (1H, m), 1.29 (3H, s),1.34-1.50 (1H, m), 1.52-1.72 (3H, m), 1.72-1.82 (1H, m), 1.83-1.97 (1H,m), 2.08-2.21 (1H, m), 2.21-2.60 (8H, m), 2.60-2.73 (2H, m), 2.73- 2.89(2H, m), 2.91-3.11 (1H, m), 3.14-3.37 (1H, m), 3.42-3.59 (1H, m),3.59-3.83 (1H, m), 3.83-4.03 (1H, m), 4.79-5.02 (1H, m), 8.00 (1H, s).Reference Reference 14 example 42 example 8

¹H-NMR (CDCl₃) δ: 1.46-1.63 (6H, m), 1.12-1.24 (4H, m), 1.24-1.39 (5H,m), 1.39-1.50 (1H, m), 1.51-1.71 (3H, m), 1.86-1.96 (1H, m), 2.07-2.29(4H, m), 2.31- 2.59 (6H, m), 2.59-2.74 (2H, m), 2.74-2.89 (2H, m),2.93-3.17 (1H, m), 3.18-3.41 (1H, m), 3.62-3.83 (1H, m), 3.83-4.00 (1H,m), 4.82-5.00 (1H, m). Reference Reference 15 example 44 example 20

¹H-NMR (CDCl₃) δ: 0.89-0.98 (2H, m), 0.98-1.06 (2H, m), 1.18 (3H, s),1.28 (6H, d, J = 7.3 Hz), 1.32-1.41 (1H, m), 1.41-1.54 (1H, m),1.54-1.79 (2H, m), 1.79- 2.05 (5H, m), 2.12-2.32 (2H, m), 2.91-3.09 (3H,m), 3.35-3.44 (1H, m), 3.50-3.59 (1H, m), 4.37 (1H, d, J = 7.9 Hz),4.90-4.97 (1H, m), 5.72 (1H, s), 6.26 (1H, dd, J = 3.7, 3.7 Hz), 7.10(1H, d, J = 8.3 Hz), 7.61 (1H, dd, J = 8.3, 2.0 Hz), 8.55 (1H, d, J =2.0 Hz). Reference Reference 16 example 44 example 8

¹H-NMR (CDCl₃) δ: 1.15-1.20 (4H, m), 1.23 (3H, s), 1.24-1.32 (1H, m),1.28 (6H, d, J = 6.7 Hz), 1.37 (1H, ddd, J = 14.1, 10.3, 3.6 Hz), 1.50(1H, ddd, J = 14.1, 10.3, 3.8 Hz), 1.69-1.79 (1H, m), 1.79-1.97 (2H, m),2.02-2.18 (3H, m), 2.18-2.34 (2H, m), 2.84- 3.09 (3H, m), 3.39-3.48 (1H,m), 3.53-3.61 (1H, m), 4.36 (1H, d, J = 7.9 Hz), 4.91-4.98 (1H, m), 6.27(1H, dd, J = 4.0, 4.0 Hz), 7.10 (1H, d, J = 8.2 Hz), 7.61 (1H, dd, J =8.2, 2.1 Hz), 8.56 (1H, d, J = 2.1 Hz).

The chemical names of Example 2 to Example 16 are listed below.

Example 2:rac-N-[(1R,2S)-2-(4-ethylpiperazin-1-yl)cyclohexyl]-4-(4-methylphenyl)piperidine-1-carboxamideExample 3:rac-4-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)-N-{(1S,2S)-2-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}piperidine-1-carboxamideExample 4:rac-N-{(1R,2S,6S)-2-methoxy-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(4-methylphenyl)piperidine-1-carboxamideExample 5:rac-4-(4-methylphenyl)-N-{(1S,2S)-2-[4-(propan-2-yl)piperazin-1-yl]cyclopentyl}piperidine-1-carboxamideExample 6:rac-4-(5-cyclopropyl-1,2-oxazol-3-yl)-4-methyl-N-{(1S,2S)-2-[4-(propan-2-yl)piperazin-1-yl]cyclopentyl}piperidine-1-carboxamideExample 7:rac-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,2S)-3,3-difluoro-2-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 8:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(4-methylphenyl)piperidine-1-carboxamideExample 9:rac-(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxylateExample 10:rac-(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl4-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)piperidine-1-carboxylateExample 11:rac-(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl4-(5-cyclopropyl-1,2-oxazol-3-yl)-4-methylpiperidine-1-carboxylateExample 12:rac-(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-7-yl]cyclohexyl4-[5-(difluoromethyl)-1,2,4-oxadiazol-3-yl]-4-methylpiperidine-1-carboxylateExample 13:rac-(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl4-(1-cyclopropyl-1H-1,2,4-triazol-3-yl)-4-methylpiperidine-1-carboxylateExample 14:(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxylateExample 15:rac-4-(5-cyclopropyl-1,2-oxazol-3-yl)-4-methyl-N-{2-[6-(propan-2-yl)pyridin-3-yl]cyclohex-2-en-1-yl}piperidine-1-carboxamideExample 16:rac-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methyl-N-{2-[6-(propan-2-yl)pyridin-3-yl]cyclohex-2-en-1-yl}piperidine-1-carboxamideExample 17rac-N-[(1S,2S)-2-(4-Ethylpiperazin-1-yl)cyclohexyl]-4-(4-methylphenyl)piperidine-1-carboxamide

To a mixture of Reference example 2 (73.7 mg), sodium acetate (18.9 mg),acetaldehyde (0.054 ml), and dichloromethane (2 mL) was added sodiumtriacetoxyborohydride (122 mg) at 0° C., and the mixture was warmed toroom temperature and stirred for 1.5 hours. Water was added to thereaction mixture at 0° C., and the mixture was extracted withchloroform. The organic layer was dried over anhydrous sodium sulfate,concentrated in vacuo, and then the obtained residue was purified byamino silica gel column chromatography (eluate: hexane/ethyl acetate) togive the title compound (24 mg).

¹H-NMR (CDCl₃) δ: 1.02-1.12 (1H, m), 1.07 (3H, t, J=7.3 Hz), 1.14-1.41(3H, m), 1.57-1.71 (3H, m), 1.75-1.96 (5H, m), 2.16-2.78 (15H, m),2.78-2.90 (2H, m), 3.24-3.39 (1H, m), 4.05-4.18 (2H, m), 5.72 (1H, s),7.09 (2H, d, J=7.9 Hz), 7.12 (2H, d, J=7.9 Hz).

Example 18rac-4-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methyl-N-{2-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]cyclohex-2-en-1-yl}piperidine-1-carboxamide

To a solution of Reference example 13 (13.5 mg) in chloroform (2 mL) wasadded hydrogen chloride/acetic acid solution (4 M, 0.198 mL), and themixture was stirred at room temperature. After the reaction wasterminated as judged by the consumption of the starting material, thereaction mixture was concentrated in vacuo. To the obtained residue wereadded sodium acetate (8.66 mg), acetone (0.058 mL), and chloroform (2mL). To the mixture was added sodium triacetoxyborohydride (33.6 mg) at0° C., and the mixture was warmed to room temperature and stirred. Afterthe reaction was completed, water was added to the reaction mixtureunder ice temperature, and the mixture was extracted with chloroform.The organic layer was dried over anhydrous sodium sulfate, concentratedin vacuo, and then the obtained residue was purified by amino silica gelcolumn chromatography (eluate: hexane/ethyl acetate) to give the titlecompound (10 mg).

¹H-NMR (CDCl₃) δ: 1.07 (6H, d, J=6.1 Hz), 1.17-1.22 (4H, m), 1.23-1.32(2H, m), 1.29 (3H, s), 1.43-1.66 (3H, m), 1.91-1.98 (1H, m), 2.08-2.26(6H, m), 2.26-2.41 (1H, m), 2.50 (1H, ddd, J=11.2, 7.2, 4.8 Hz),2.63-2.76 (2H, m), 2.97-3.13 (3H, m), 3.13-3.23 (1H, m), 3.52-3.63 (2H,m), 4.43 (1H, d, J=7.3 Hz), 4.63-4.69 (1H, m), 5.78-5.84 (1H, m),5.85-5.91 (1H, m).

Example 19rac-4-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

To a mixture of Reference example 14 (84.6 mg) (Material A),triethylamine (0.318 mL), and chloroform (2 mL) was added triphosgene(27.1 mg) at 0° C., and the mixture was stirred at the same temperaturefor 40 minutes. To the reaction mixture was added Reference example 8(66.7 mg) (Material B) at 0° C., and the mixture was stirred at roomtemperature for one hour. Water was added to the reaction mixture, andthe mixture was extracted with chloroform. The organic layer was driedover anhydrous sodium sulfate, concentrated in vacuo, and then theobtained residue was purified by silica gel column chromatography(eluate: chloroform/methanol) to give the title compound (99.1 mg).

¹H-NMR (CDCl₃) δ: 1.00 (3H, d, J=6.0 Hz), 1.01 (3H, d, J 6.0 Hz),1.17-1.22 (4H, m), 1.23-1.30 (1H, m), 1.30-1.48 (2H, m), 1.31 (3H, s),1.57-1.70 (2H, m), 1.75-1.84 (1H, m), 1.89-1.97 (1H, m), 2.10-2.27 (4H,m), 2.32-2.53 (7H, m), 2.53-2.64 (1H, m), 2.68-2.78 (2H, m), 3.08 (1H,ddd, J=13.6, 10.7, 3.1 Hz), 3.16 (1H, ddd, J=13.6, 10.7, 3.1 Hz), 3.66(1H, ddd, J=13.6, 4.7, 4.1 Hz), 3.77 (1H, ddd, J 13.6, 4.7, 4.1 Hz),4.10-4.21 (1H, m), 4.54 (1H, d, J=7.3 Hz).

Examples 20 to 76

The compounds of Examples 20 to 76 shown in the table below wereprepared in the same manner as Example 19, by using commercial compoundsor Reference example compounds which correspond to Material A andMaterial B described in Example 19.

Ex- Structure Material A Material B ample Spectral data ReferenceReference 20 example 14 example 20

¹H-NMR (CDCl₃) δ: 0.92-1.19 (10H, m), 1.27 (3H, s), 1.30-1.74 (3H, m),1.75-1.88 (3H, m), 1.89-1.97 (1H, m), 1.97-2.04 (1H, m), 2.05-2.27 (3H,m), 2.32-2.67 (8H, m), 2.69-2.81 (2H, m), 3.12-3.29 (2H, m), 3.57- 3.68(1H, m), 3.68-3.80 (1H, m), 4.08-4.25 (1H, m), 4.54 (1H, d, J = 7.3 Hz),5.77 (1H, s). Reference Reference 21 example 14 example 21

¹H-NMR (CDCl₃) δ: 0.93 (6H, d, J = 6.1 Hz), 1.22- 1.43 (2H, m), 1.45(3H, s), 1.63-1.86 (4H, m), 1.89- 1.97 (1H, m), 2.11-2.22 (1H, m),2.28-2.54 (10H, m), 2.68-2.78 (2H, m), 3.11-3.26 (2H, m), 3.76 (1H, ddd,J = 13.5, 4.1, 4.0 Hz), 3.84 (1H, ddd, J = 13.5, 4.1, 4.0 Hz), 4.09-4.22(1H, m), 4.56 (1H, d, J = 7.3 Hz), 7.29-7.35 (2H, m), 7.47-7.53 (1H, m),7.67- 7.72 (1H, m). Reference Reference 22 example 15′ example 20

¹H-NMR (CDCl₃) δ: 0.92-0.98 (2H, m), 1.00-1.08 (2H, m), 1.13 (6H, d, J =6.0 Hz), 1.28 (3H, s), 1.28- 1.47 (3H, m), 1.47-1.88 (5H, m), 1.90-2.25(5H, m), 2.25-3.07 (8H, m), 3.13-3.03 (2H, m), 3.58-3.74 (2H, m),4.07-4.23 (1H, m), 4.54 (1H, d, J = 8.0 Hz), 5.78 (1H, s). ReferenceReference 23 example 15′ example 8

¹H-NMR (CDCl₃) δ: 0.97-1.16 (6H, m), 1.16-1.26 (4H, m), 1.26-1.44 (3H,m), 1.31 (3H, s), 1.47-1.75 (5H, m), 1.75-1.88 (2H, m), 1.88-2.03 (1H,m), 2.09-2.28 (4H, m), 2.28-3.01 (6H, m), 3.01-3.26 (2H, m), 3.58- 3.84(2H, m), 4.06-4.26 (1H, m), 4.54 (1H, d, J = 8.0 Hz). ReferenceReference 24 example 15 example 8

¹H-NMR (CDCl₃) δ: 1.00 (3H, d, J = 6.0 Hz), 1.01 (3H, d, J = 6.0 Hz),1.17-1.22 (4H, m), 1.23-1.30 (1H, m), 1.30-1.48 (2H, m), 1.31 (3H, s),1.57-1.70 (2H, m), 1.75-1.84 (1H, m), 1.89-1.97 (1H, m), 2.10-2.27 (4H,m), 2.32-2.53 (7H, m), 2.53-2.64 (1H, m), 2.68- 2.78 (2H, m), 3.08 (1H,ddd, J = 13.6, 10.7, 3.1 Hz), 3.16 (1H, ddd, J = 13.6, 10.7, 3.1 Hz),3.66 (1H, ddd, J = 13.6, 4.7, 4.1 Hz), 3.77 (1H, ddd, J = 13.6, 4.7, 4.1Hz), 4.10-4.21 (1H, m), 4.54 (1H, d, J = 7.3 Hz). Reference Reference 25example 15 example 20

¹H-NMR (CDCl₃) δ: 0.92-1.19 (10H, m), 1.27 (3H, s), 1.30-1.74 (3H, m),1.75-1.88 (3H, m), 1.89-1.97 (1H, m), 1.97-2.04 (1H, m), 2.05-2.27 (3H,m), 2.32-2.67 (8H, m), 2.69-2.81 (2H, m), 3.12-3.29 (2H, m), 3.57- 3.68(1H, m), 3.68-3.80 (1H, m), 4.08-4.25 (1H, m), 4.54 (1H, d, J = 7.3 Hz),5.77 (1H, s). Reference Reference 26 example 14 example 22

¹H-NMR (CDCl₃) δ: 0.84-0.91 (4H, m), 1.02 (6H, d, J = 6.7 Hz), 1.20-1.31(3H, m), 1.31-1.41 (2H, m), 1.45 (3H, s), 1.46-1.59 (3H, m), 1.66-1.85(3H, m), 1.89-1.97 (1H, m), 2.10-2.22 (1H, m), 2.35-2.55 (7H, m),2.55-2.66 (1H, m), 2.67-2.79 (2H, m), 2.98-3.13 (2H, m), 3.18 (1H, ddd,J = 13.8, 10.5, 3.6 Hz), 3.59 (1H, ddd, J = 13.8, 4.6, 3.6 Hz),3.63-3.79 (2H, m), 4.10-4.22 (1H, m), 4.53 (1H, d, J = 7.9 Hz).Reference Reference 27 example 14 example 19

¹H-NMR (CDCl₃) δ: 1.00 (6H, d, J = 6.8 Hz), 1.28- 1.46 (2H, m), 1.32(3H, s), 1.57-1.66 (2H, m), 1.74- 1.88 (6H, m), 1.89-1.97 (1H, m),2.10-2.21 (1H, m), 2.22-2.31 (2H, m), 2.35-2.54 (9H, m), 2.54-2.63 (3H,m), 2.69-2.78 (2H, m), 3.09 (1H, ddd, J = 13.8, 10.5, 2.9 Hz), 3.17 (1H,ddd, J = 13.8, 10.5, 2.9 Hz), 3.65 (1H, ddd, J = 13.8, 4.1, 4.1 Hz),3.79 (1H, ddd, J = 13.8, 4.1, 4.1 Hz), 4.08-4.22 (1H, m), 4.53 (1H, d, J= 7.9 Hz). Reference Reference 28 example 14 example 9

¹H-NMR (CDCl₃) δ: 1.00 (3H, d, J = 6.0 Hz), 1.00 (3H, d, J = 6.0 Hz),1.20-1.43 (3H, m), 1.33 (3H, s), 1.39 (3H, t, J = 7.7 Hz), 1.61-1.74(2H, m), 1.75- 1.86 (1H, m), 1.89-1.98 (1H, m), 2.10-2.21 (1H, m),2.21-2.30 (2H, m), 2.34-2.54 (7H, m), 2.54-2.64 (1H, m), 2.70-2.78 (2H,m), 2.89 (2H, q, J = 7.7 Hz), 3.09 (1H, ddd, J = 13.8, 10.7, 3.1 Hz),3.17 (1H, ddd, J = 13.8, 10.7, 3.1 Hz), 3.66 (1H, ddd, J = 13.6, 4.4,4.4 Hz), 3.79 (1H, ddd, J = 13.6, 4.4, 4.4 Hz), 4.08-4.22 (1H, m), 4.53(1H, d, J = 7.9 Hz). Reference Reference 29 example 14 example 27

¹H-NMR (CDCl₃) δ: 0.94-1.15 (10H, m), 1.16-1.47 (3H, m), 1.29 (3H, s),1.52-1.87 (5H, m), 1.87-1.99 (1H, m), 2.10-2.22 (1H, m), 2.23-2.36 (2H,m), 2.37-2.92 (8H, m), 2.97-3.08 (1H, m), 3.08-3.19 (1H, m), 3.43- 3.65(2H, m), 3.72-3.84 (1H, m), 4.07-4.23 (1H, m), 4.52 (1H, d, J = 7.9 Hz),8.00 (1H, s). Reference Reference 30 example 14 example 23

¹H-NMR (CDCl₃) δ: 1.03 (6H, d, J = 6.1 Hz), 1.10- 1.21 (1H, m),1.22-1.51 (9H, m), 1.54-1.86 (5H, m), 1.61 (3H, s), 1.89-1.98 (1H, m),2.08-2.23 (3H, m), 2.32-2.55 (7H, m), 2.55-2.65 (1H, m), 2.68-2.79 (2H,m), 3.01-3.19 (2H, m), 3.66 (1H, ddd, J = 13.6, 4.4, 3.2 Hz), 3.78 (1H,ddd, J = 13.6, 4.4, 3.2 Hz), 4.09-4.23 (1H, m), 4.52 (1H, d, J = 7.3Hz). Reference Reference 31 example 14 example 28

¹H-NMR (CDCl₃) δ: 1.00 (3H, d, J = 6.1 Hz), 1.01 (3H, d, J = 6.1 Hz),1.11-1.18 (2H, m), 1.22-1.35 (4H, m), 1.30 (3H, s), 1.35-1.47 (1H, m),1.62-1.75 (2H, m), 1.75-1.85 (1H, m), 1.88-1.97 (1H, m), 2.10-2.22 (1H,m), 2.31-2.62 (11H, m), 2.67-2.78 (2H, m), 3.01 (1H, ddd, J = 13.8,10.7, 3.1 Hz), 3.10 (1H, ddd, J = 13.8, 10.7, 3.1 Hz), 3.65 (1H, ddd, J= 14.0, 4.3, 4.3 Hz), 3.79 (1H, ddd, J = 14.0, 4.3, 4.3 Hz), 4.08-4.22(1H, m), 4.53 (1H, d, J = 7.3 Hz). Reference Commercial 32 example 14product

¹H-NMR (CDCl₃) δ: 1.01 (6H, d, J = 6.8 Hz), 1.21- 1.49 (2H, m),1.62-1.88 (4H, m), 1.89-2.06 (3H, m), 2.10-2.23 (1H, m), 2.34-2.66 (8H,m), 2.70-2.83 (2H, m), 2.85-3.07 (3H, m), 4.05-4.30 (3H, m), 4.60 (1H,d, J = 8.0 Hz), 7.10-7.18 (2H, m), 7.62 (1H, ddd, J = 8.0, 8.0, 1.6 Hz),8.52 (1H, dd, J = 4.8, 1.6 Hz). Reference Commercial 33 example 14product

¹H-NMR (CDCl₃) δ: 1.03 (6H, d, J = 6.4 Hz), 1.20- 1.53 (10H, m),1.54-1.66 (4H, m), 1.66-1.86 (3H, m), 1.88-1.98 (1H, m), 2.08-2.24 (1H,m), 2.26-2.56 (6H, m), 2.56-2.69 (1H, m), 2.69-2.82 (2H, m), 3.20-3.51(4H, m), 4.06-4.25 (1H, m), 4.52 (1H, d, J = 8.0 Hz). ReferenceReference 34 example 14 example 24

¹H-NMR (CDCl₃) δ: 1.01-1.23 (10H, m), 1.23-1.46 (4H, m), 1.43 (3H, s),1.60-1.74 (1H, m), 1.74-1.87 (3H, m), 1.92-2.03 (1H, m), 2.11-2.29 (3H,m), 2.31-2.40 (1H, m), 2.40-3.14 (8H, m), 3.26-3.38 (2H, m), 3.58- 3.71(2H, m), 4.08-4.23 (1H, m), 4.52 (1H, d, J = 7.9 Hz). ReferenceCommercial 35 example 14 product

¹H-NMR (CDCl₃) δ: 0.82-1.07 (3H, m), 1.03 (6H, d, J = 6.8 Hz), 1.07-1.49(11H, m), 1.49-1.86 (6H, m), 1.89-1.99 (1H, m), 2.09-2.25 (1H, m),2.34-2.56 (7H, m), 2.56-2.67 (1H, m), 2.67-2.87 (4H, m), 3.89-3.99 (1H,m), 4.05-4.27 (2H, m), 4.49 (1H, d, J = 8.0 Hz). Reference Commercial 36example 14 product

¹H-NMR (CDCl₃) δ: 0.99 (6H, d, J = 6.4 Hz), 1.21- 1.49 (2H, m),1.61-2.00 (5H, m), 2.01-2.12 (2H, m), 2.12-2.24 (1H, m), 2.29-2.64 (8H,m), 2.68-2.81 (2H, m), 2.87-3.00 (1H, m), 3.00-3.14 (2H, m), 3.97-4.09(1H, m), 4.09-4.29 (2H, m), 4.58 (1H, d, J = 8.0 Hz), 7.13 (1H, t, J =4.8 Hz), 8.67 (2H, d, J = 4.8 Hz). Reference Commercial 37 example 14product

¹H-NMR (CDCl₃) δ: 1.03 (6H, d, J = 6.4 Hz), 1.22- 1.51 (2H, m),1.59-1.90 (4H, m), 1.90-2.07 (3H, m), 2.10-2.24 (1H, m), 2.34-2.65 (8H,m), 2.69-2.82 (2H, m), 3.33-3.50 (2H, m), 3.92-4.10 (2H, m), 4.13-4.28(1H, m), 4.64 (1H, d, J = 8.0 Hz), 5.30 (1H, bs), 7.23 (1H, ddd, J =8.0, 8.0, 1.6 Hz), 7.32 (1H, dd, J = 8.0, 1.6 Hz), 7.71 (1H, ddd, J =8.0, 8.0, 1.6 Hz), 8.51-8.55 (1H, m). Reference Commercial 38 example 14product

¹H-NMR (CDCl₃) δ: 1.02 (6H, d, J = 6.4 Hz), 1.22- 1.50 (2H, m),1.61-1.77 (3H, m), 1.77-2.00 (4H, m), 2.11-2.24 (1H, m), 2.31-2.64 (8H,m), 2.65-2.82 (3H, m), 2.83-3.04 (2H, m), 4.02-4.13 (1H, m), 4.13-4.33(2H, m), 4.60 (1H, d, J = 8.0 Hz), 7.17-7.24 (3H, m), 7.27-7.34 (2H, m).Reference Commercial 39 example 14 product

¹H-NMR (CDCl₃) δ: 0.95 (6H, d, J = 6.4 Hz), 1.18- 1.48 (4H, m),1.60-1.86 (5H, m), 1.87-1.98 (1H, m), 2.07-2.23 (3H, m), 2.25-2.55 (8H,m), 2.66-2.78 (2H, m), 3.28-3.62 (4H, m), 4.07-4.24 (1H, m), 4.54 (1H,d, J = 8.0 Hz), 7.16-7.24 (1H, m), 7.28-7.38 (4H, m). ReferenceCommercial 40 example 14 product

¹H-NMR (CDCl₃) δ: 0.99 (6H, d, J = 6.4 Hz), 1.22- 1.49 (2H, m),1.56-1.88 (5H, m), 1.89-2.00 (1H, m), 2.01-2.24 (3H, m), 2.29-2.61 (8H,m), 2.68-2.81 (2H, m), 3.30-3.47 (2H, m), 3.85-4.05 (2H, m), 4.11-4.27(1H, m), 4.62 (1H, d, J = 8.0 Hz), 7.25-7.31 (1H, m), 7.36 (2H, t, J =8.0 Hz), 7.48 (2H, d, J = 8.0 Hz). Reference Commercial 41 example 14product

¹H-NMR (CDCl₃) δ: 0.99 (6H, d, J = 6.0 Hz), 1.21- 1.49 (2H, m),1.60-1.88 (5H, m), 1.88-1.97 (1H, m), 1.97-2.09 (2H, m), 2.10-2.23 (1H,m), 2.27-2.61 (8H, m), 2.66-2.80 (2H, m), 3.25-3.43 (2H, m), 3.84-4.03(2H, m), 4.07-4.24 (1H, m), 4.61 (1H, d, J = 8.0 Hz), 7.37 (2H, d, J =8.8 HZ), 7.41 (2H, d, J = 8.8 Hz). Reference Reference 42 example 14example 31

¹H-NMR (CDCl₃) δ: 1.01 (6H, d, J = 6.1 Hz), 1.19- 1.47 (3H, m), 1.65(3H, s), 1.67-1.84 (3H, m), 1.90- 1.97 (1H, m), 2.09-2.21 (1H, m),2.36-2.53 (9H, m), 2.55-2.66 (1H, m), 2.70-2.80 (2H, m), 3.19-3.36 (2H,m), 3.66 (1H, ddd, J = 13.0, 4.1, 3.5 Hz), 3.76 (1H, ddd, J = 13.0, 4.1,3.5 Hz), 4.11-4.26 (1H, m), 4.52 (1H, d, J = 7.3 Hz), 6.68 (1H, d, J =8.3 Hz), 6.81 (1H, dd, J = 6.7, 5.5 Hz), 7.49-7.54 (1H, m), 8.10 (1H,dd, J = 5.5, 1.7 Hz). Reference Reference 43 example 15 example 28

¹H-NMR (CDCl₃) δ: 1.00 (3H, d, J = 6.1 Hz), 1.01 (3H, d, J = 6.1 Hz),1.11-1.18 (2H, m), 1.22-1.35 (4H, m), 1.30 (3H, s), 1.35-1.47 (1H, m),1.62-1.75 (2H, m), 1.75-1.85 (1H, m), 1.88-1.97 (1H, m), 2.10-2.22 (1H,m), 2.31-2.62 (11H, m), 2.67-2.78 (2H, m), 3.01 (1H, ddd, J = 13.8,10.7, 3.1 Hz), 3.10 (1H, ddd, J = 13.8, 10.7, 3.1 Hz), 3.65 (1H, ddd, J= 14.0, 4.3, 4.3 Hz), 3.79 (1H, ddd, J = 14.0, 4.3, 4.3 Hz), 4.08-4.22(1H, m), 4.53 (1H, d, J = 7.3 Hz). Reference Reference 44 example 15example 24

¹H-NMR (CDCl₃) δ: 1.01-1.23 (10H, m), 1.23-1.46 (4H, m), 1.43 (3H, s),1.60-1.74 (1H, m), 1.74-1.87 (3H, m), 1.92-2.03 (1H, m), 2.11-2.29 (3H,m), 2.31-2.40 (1H, m), 2.40-3.14 (8H, m), 3.26-3.38 (2H, m), 3.58- 3.71(2H, m), 4.08-4.23 (1H, m), 4.52 (1H, d, J = 7.9 Hz). ReferenceReference 45 example 14 example 29

¹H-NMR (CDCl₃) δ: 1.04-1.19 (6H, m), 1.21-1.47 (3H, m), 1.31 (3H, s),1.53-1.87 (3H, m), 1.89-2.01 (1H, m), 2.10-2.23 (1H, m), 2.28-2.40 (2H,m), 2.40-2.74 (7H, m), 2.74-3.03 (3H, m), 3.05-3.22 (2H, m), 3.58- 3.77(2H, m), 4.05-4.22 (1H, m), 4.14 (3H, s), 4.53 (1H, s). ReferenceCommercial 46 example 14 product

¹H-NMR (CDCl₃) δ: 1.02 (6H, d, J = 6.4 Hz), 1.22- 1.49 (2H, m),1.62-1.88 (2H, m), 1.88-2.01 (3H, m), 2.10-2.23 (1H, m), 2.23-2.66 (10H,m), 2.70-2.83 (2H, m), 3.20-3.43 (2H, m), 3.89-4.01 (1H, m), 4.06- 4.27(2H, m), 4.62 (1H, d, J = 8.0 Hz), 7.20 (1H, ddd, J = 8.0, 4.8, 1.2 Hz),7.55 (1H, dd, J = 8.0, 1.2 Hz), 7.72 (1H, ddd, J = 8.0, 8.0, 1.2 Hz),8.51 (1H, d, J = 4.8 Hz). Reference Reference 47 example 14 example 26

¹H-NMR (CDCl₃) δ: 0.96-1.02 (2H, m), 0.99 (6H, d, J = 6.0 Hz), 1.05-1.16(2H, m), 1.18-1.48 (3H, m), 1.28 (3H, s), 1.62-1.76 (3H, m), 1.89-1.99(1H, m), 2.08-2.23 (3H, m), 2.24-2.32 (1H, m), 2.32-2.63 (8H, m),2.68-2.80 (2H, m), 3.24 (1H, ddd, J = 13.1, 9.2, 3.7 Hz), 3.34 (1H, ddd,J = 13.1, 9.2, 3.7 Hz), 3.43-3.52 (1H, m), 3.57-3.67 (1H, m), 4.07-4.22(1H, m), 4.54 (1H, d, J = 7.3 Hz), 6.63 (1H, s). Reference Reference 48example 14 example 25

¹H-NMR (CDCl₃) δ: 0.68-0.78 (2H, m), 0.95-1.16 (8H, m), 1.22-1.50 (3H,m), 1.35 (3H, s), 1.62-1.86 (3H, m), 1.88-1.97 (1H, m), 1.97-2.08 (1H,m), 2.10-2.30 (3H, m), 2.32-2.66 (8H, m), 2.68-2.86 (2H, m), 3.23 (1H,ddd, J = 13.6, 9.6, 3.2 Hz), 3.32 (1H, ddd, J = 13.6, 9.6, 3.2 Hz),3.55-3.66 (1H, m), 3.66-3.76 (1H, m), 4.08-4.23 (1H, m), 4.54 (1H, d, J= 7.3 Hz), 7.32 (1H, s). Reference Commercial 49 example 15 product

¹H-NMR (CDCl₃) δ: 0.95 (6H, d, J = 6.4 Hz), 1.19- 1.47 (3H, m), 1.25(3H, s), 1.61-1.85 (3H, m), 1.88- 1.97 (1H, m), 2.06-2.22 (3H, m),2.28-2.53 (8H, m), 2.32 (3H, s), 2.67-2.76 (2H, m), 3.32 (1H, ddd, J =11.6, 8.0, 3.6 Hz), 3.40-3.49 (2H, m), 3.56 (1H, ddd, J = 11.6, 8.0, 3.6Hz), 4.09-4.22 (1H, m), 4.53 (1H, d, J = 7.8 Hz), 7.14 (2H, d, J = 8.2Hz), 7.22 (2H, d, J = 8.2 Hz). Reference Commercial 50 example 14product

¹H-NMR (CDCl₃) δ: 0.99 (6H, d, J = 6.0 Hz), 1.21- 1.49 (2H, m),1.62-1.89 (4H, m), 1.89-2.06 (3H, m), 2.09-2.23 (1H, m), 2.30 (3H, s),2.34-2.63 (8H, m), 2.67-2.80 (2H, m), 2.80-3.06 (3H, m), 4.03-4.29 (3H,m), 4.59 (1H, d, J = 8.0 Hz), 7.04 (1H, d, J = 8.0 Hz), 7.42 (1H, dd, J= 8.0, 2.4 Hz), 8.34 (1H, d, J = 2.4 Hz). Reference Reference 51 example14 example 41

¹H-NMR (CDCl₃) δ: 1.01 (6H, d, J = 6.8 Hz), 1.21- 1.48 (2H, m),1.61-1.88 (4H, m), 1.88-2.04 (3H, m), 2.09-2.24 (1H, m), 2.31 (3H, s),2.35-2.66 (8H, m), 2.69-2.81 (2H, m), 2.85-3.09 (2H, m), 3.10-3.23 (1H,m), 4.00-4.10 (1H, m), 4.10-4.33 (2H, m), 4.58 (1H, d, J = 8.0 Hz), 7.14(1H, d, J = 11.2 Hz), 8.14 (1H, s). Reference Commercial 52 example 14product

¹H-NMR (CDCl₃) δ: 1.00 (6H, d, J = 6.4 Hz), 1.22- 1.50 (2H, m),1.62-1.87 (4H, m), 1.90-2.06 (3H, m), 2.10-2.23 (1H, m), 2.33-2.65 (8H,m), 2.69-2.81 (2H, m), 2.85-3.06 (3H, m), 4.04-4.30 (3H, m), 4.59 (1H,d, J = 8.0 Hz), 7.15 (1H, dd, J = 8.4, 4.4 Hz), 7.33 (1H, ddd, J = 8.4,8.4, 2.8 Hz), 8.38 (1H, d, J = 2.8 Hz). Reference Commercial 53 example14 product

¹H-NMR (CDCl₃) δ: 1.00 (6H, d, J = 6.4 Hz), 1.21- 1.49 (2H, m),1.63-1.87 (4H, m), 1.88-2.03 (3H, m), 2.09-2.23 (1H, m), 2.34-2.64 (8H,m), 2.68-2.80 (2H, m), 2.80-3.06 (3H, m), 3.84 (3H, s), 4.03-4.29 (3H,m), 4.59 (1H, d, J = 8.0 Hz), 7.07 (1H, d, J = 8.4 Hz), 7.14 (1H, dd, J= 8.4, 2.8 Hz), 8.22 (1H, d, J = 2.8 Hz). Reference Commercial 54example 14 product

¹H-NMR (CDCl₃) δ: 0.99 (6H, d, J = 6.4 Hz), 1.21- 1.49 (2H, m),1.60-1.99 (5H, m), 1.99-2.10 (2H, m), 2.10-2.22 (1H, m), 2.27 (3H, s),2.30-2.63 (8H, m), 2.67-2.81 (2H, m), 2.85-3.11 (2H, m), 3.95-4.08 (1H,m), 4.09-4.26 (3H, m), 4.58 (1H, d, J = 8.0 Hz), 8.48 (2H, s). ReferenceCommercial 55 example 14 product

¹H-NMR (CDCl₃) δ: 1.00 (6H, d, J = 6.4 Hz), 1.22- 1.50 (2H, m),1.63-1.90 (4H, m), 1.90-2.06 (3H, m), 2.10-2.25 (1H, m), 2.31-2.65 (8H,m), 2.69-2.81 (2H, m), 2.89-3.08 (3H, m), 4.06-4.32 (3H, m), 4.60 (1H,d, J = 8.0 Hz), 7.29 (1H, d, J = 8.4 Hz), 7.86 (1H, d, J = 8.4, 2.4 Hz),8.79 (1H, s). Reference Reference 56 example 15 example 32

¹H-NMR (CDCl₃) δ: 0.94 (6H, d, J = 6.1 Hz), 1.23- 1.47 (3H, m), 1.34(3H, s), 1.67-1.86 (3H, m), 1.88- 1.97 (1H, m), 2.10-2.23 (3H, m), 2.31(3H, s), 2.31- 2.52 (8H, m), 2.67-2.76 (2H, m), 3.36 (1H, ddd, J = 11.6,8.0, 3.6 Hz), 3.40-3.52 (2H, m), 3.53-3.59 (1H, m), 4.07-4.23 (1H, m),4.54 (1H, d, J = 7.9 Hz), 6.81-6.91 (2H, m), 7.11 (1H, dd, J = 7.6, 7.6Hz). Reference Reference 57 example 15 example 30

¹H-NMR (CDCl₃) δ: 0.86-0.93 (2H, m), 0.94-1.07 (2H, m), 1.00 (3H, d, J =6.4 Hz), 1.01 (3H, d, J = 6.4 Hz), 1.20-1.48 (3H, m), 1.30 (3H, s),1.54-1.85 (3H, m), 1.89-1.97 (1H, m), 2.09-2.22 (1H, m), 2.31-2.54 (9H,m), 2.54-2.64 (1H, m), 2.68-2.79 (2H, m), 3.06 (1H, ddd, J = 13.8, 10.7,3.1 Hz), 3.16 (1H, ddd, J = 13.8, 10.7, 3.1 Hz), 3.58-3.68 (1H, m),3.74-3.84 (1H, m), 4.09-4.23 (2H, m), 4.53 (1H, d, J = 7.9 Hz).Reference Commercial 58 example 14 product

¹H-NMR (CDCl₃) δ: 0.95 (6H, d, J = 6.4 Hz), 1.19- 1.47 (3H, m), 1.25(3H, s), 1.61-1.85 (3H, m), 1.88- 1.97 (1H, m), 2.06-2.22 (3H, m),2.28-2.53 (8H, m), 2.32 (3H, s), 2.67-2.76 (2H, m), 3.32 (1H, ddd, J =11.6, 8.0, 3.6 Hz), 3.40-3.49 (2H, m), 3.56 (1H, ddd, J = 11.6, 8.0, 3.6Hz), 4.09-4.22 (1H, m), 4.53 (1H, d, J = 7.8 Hz), 7.14 (2H, d, J = 8.2Hz), 7.22 (2H, d, J = 8.2 Hz). Reference Reference 59 example 14 example33

¹H-NMR (CDCl₃) δ: 0.92 (3H, d, J = 6.7 Hz), 0.93 (3H, d, J = 6.7 Hz),1.22-1.46 (3H, m), 1.29 (3H, s), 1.64-1.85 (3H, m), 1.88-1.96 (1H, m),2.06-2.22 (3H, m), 2.25-2.54 (8H, m), 2.66-2.76 (2H, m), 3.36 (1H, ddd,J = 11.2, 7.6, 3.6 Hz), 3.41-3.59 (3H, m), 4.08-4.22 (1H, m), 4.54 (1H,d, J = 7.9 Hz), 6.63 (1H, t, J = 56.5 Hz), 7.42 (2H, d, J = 8.5 Hz),7.48 (2H, d, J = 7.9 Hz). Reference Reference 60 example 15 example 34

¹H-NMR (CDCl₃) δ: 0.95 (6H, d, J = 6.7 Hz), 1.23- 1.48 (2H, m), 1.52(3H, s), 1.59-1.74 (1H, m), 1.74- 1.84 (1H, m), 1.89-1.98 (1H, m),2.00-2.10 (2H, m), 2.10-2.20 (1H, m), 2.21-2.32 (2H, m), 2.32-2.58 (8H,m), 2.35 (3H, s), 2.69-2.80 (2H, m), 3.43 (1H, ddd, J = 13.1, 9.2, 3.7Hz), 3.48-3.61 (3H, m), 4.09-4.23 (1H, m), 4.52 (1H, d, J = 7.3 Hz),7.29-7.36 (2H, m), 7.51 (1H, s). Reference Commercial 61 example 16product

¹H-NMR (CDCl₃) δ: 0.95-1.14 (6H, m), 1.17-1.31 (2H, m), 1.24 (3H, s),1.33-1.80 (5H, m), 1.80-1.88 (1H, m), 2.05-2.25 (3H, m), 2.32 (3H, s),2.53-2.63 (1H, m), 2.63-2.73 (1H, m), 2.78-2.88 (1H, m), 2.89-3.14 (2H,m), 3.20-3.34 (3H, m), 3.34-3.54 (3H, m), 3.84- 3.98 (2H, m), 4.22-4.37(1H, m), 4.61 (1H, d, J = 8.5 Hz), 7.15 (2H, d, J = 8.5 Hz), 7.20 (2H,d, J = 8.5 Hz). Reference Reference 62 example 17 example 8

¹H-NMR (CDCl₃) δ: 0.89 (3H, d, J = 6.0 Hz), 0.90 (3H, d, J = 6.0 Hz),1.15-1.22 (4H, m) 1.22-1.35 (1H, m), 1.29 (3H, s), 1.35-1.44 (1H, m),1.44-1.53 (1H, m), 1.61-1.70 (3H, m), 1.70-1.85 (5H, m), 2.04-2.19 (3H,m), 2.20-2.29 (3H, m), 2.41-2.57 (4H, m), 3.03- 3.19 (3H, m), 3.19-3.24(1H, m), 3.68-3.83 (2H, m), 3.94-4.07 (1H, m), 4.72 (1H, d, J = 7.3 Hz).Reference Commercial 63 example 17 product

¹H-NMR (CDCl₃) δ: 0.84 (3H, d, J = 6.8 Hz), 0.85 (3H, d, J = 6.8 Hz),1.19-1.35 (1H, m), 1.24 (3H, s), 1.35-1.43 (1H, m), 1.43-1.53 (1H, m),1.59-1.85 (7H, m), 2.02-2.18 (4H, m), 2.21-2.27 (1H, m), 2.32 (3H, s),2.34-2.59 (5H, m), 3.03-3.09 (1H, m), 3.18-3.25 (1H, m), 3.34-3.45 (2H,m), 3.46-3.59 (2H, m), 3.94- 4.08 (1H, m), 4.73 (1H, d, J = 7.3 Hz),7.13 (2H, d, J = 7.9 Hz), 7.21 (2H, d, J = 7.9 Hz). Reference Reference64 example 38 example 8

¹H-NMR (CDCl₃) δ: 1.06 (6H, d, J = 6.0 Hz), 1.18- 1.24 (4H, m), 1.30(3H, s), 1.35-1.48 (2H, m), 1.56- 1.68 (2H, m), 1.68-1.78 (3H, m),1.93-2.27 (6H, m), 2.31-2.41 (2H, m), 2.46-2.58 (1H, m), 2.63-2.72 (1H,m), 2.92-3.24 (4H, m), 3.63-3.75 (2H, m), 4.08-4.28 (2H, m), 4.51-4.60(1H, m). Reference Reference 65 example 17 example 20

¹H-NMR (CDCl₃) δ: 0.88 (3H, d, J = 6.4 Hz), 0.89 (3H, d, J = 6.4 Hz),0.91-0.99 (2H, m), 0.99-1.07 (2H, m), 1.20-1.35 (1H, m), 1.25 (3H, s),1.35-1.42 (1H, m), 1.42-1.53 (1H, m), 1.58-1.84 (8H, m), 1.95-2.03 (1H,m), 2.03-2.16 (4H, m), 2.24-2.29 (1H, m), 2.41- 2.57 (4H, m), 3.04-3.10(1H, m), 3.10-3.30 (3H, m), 3.67 (1H, ddd, J = 13.6, 4.5, 4.5 Hz), 3.75(1H, ddd, J = 13.6, 4.5, 4.5 Hz), 3.93-4.07 (1H, m), 4.72 (1H, d, J =7.3 Hz), 5.75 (1H, s). Reference Reference 66 example 15 example 11

¹H-NMR (DMSO-d6) δ: 0.87 (6H, d, J = 6.4 Hz), 1.18- 1.36 (2H, m), 1.26(3H, s), 1.47-1.66 (3H, m), 1.66- 1.88 (4H, m), 1.95-2.11 (3H, m),2.17-2.40 (6H, m), 2.43-2.63 (5H, m), 2.95-3.19 (2H, m), 3.55-3.77 (2H,m), 3.98-4.18 (1H, m), 5.16 (1H, dddd, J = 65.0, 6.0, 6.0, 3.2 Hz), 5.88(1H, d, J = 8.0 Hz). Reference Commercial 67 example 38 product

¹H-NMR (CDCl₃) δ: 1.02 (6H, d, J = 7.3 Hz), 1.21- 1.30 (1H, m), 1.25(3H, s), 1.35-1.48 (2H, m), 1.65- 1.84 (3H, m), 1.98-2.19 (6H, m),2.25-2.36 (2H, m), 2.32 (3H, s), 2.48 (1H, dd, J = 16.4, 8.0 Hz), 2.59-2.69 (1H, m), 2.94 (1H, dd, J = 10.1, 6.4 Hz), 3.14- 3,23 (1H, m),3.27-3.42 (2H, m), 3.42-3.56 (2H, m), 4.07-4.28 (2H, m), 4.56 (1H, d, J= 9.2 Hz), 7.14 (2H, d, J = 8.2 Hz), 7.21 (2H, d, J = 8.2 Hz). ReferenceReference 68 example 15 example 12′

¹H-NMR (CDCl₃) δ: 0.95-1.06 (8H, m), 1.13 (3H, d, J = 6.0 Hz), 1.21-1.57(7H, m), 1.58-1.73 (2H, m), 1.73-1.87 (1H, m), 1.87-1.98 (1H, m),2.08-2.30 (4H, m), 2.31-2.66 (8H, m), 2.66-2.83 (2H, m), 3.01-3.19 (2H,m), 3.61-3.72 (1H, m), 3.74-3.85 (1H, m), 4.03- 4.24 (1H, m), 4.53 (1H,d, J = 8.0 Hz). Reference Reference 69 example 15 example 12

¹H-NMR (CDCl₃) δ: 0.97-1.06 (8H, m), 1.13 (3H, d, J = 6.4 Hz), 1.22-1.58(7H, m), 1.58-1.73 (2H, m), 1.73-1.87 (1H, m), 1.89-1.99 (1H, m),2.08-2.30 (4H, m), 2.31-2.66 (8H, m), 2.66-2.84 (2H, m), 3.00-3.22 (2H,m), 3.61-3.72 (1H, m), 3.74-3.85 (1H, m), 4.03- 4.23 (1H, m), 4.53 (1H,d, J = 8.0 Hz). Reference Commercial 70 example 15 product

¹H-NMR (CDCl₃) δ: 0.97-1.04 (6H, m), 1.20-1.48 (7H, m), 1.62-1.87 (3H,m), 1.89-1.98 (1H, m), 2.10-2.21 (1H, m), 2.21-2.31 (2H, m) 2.31-2.54(6H, m) 2.58 (1H, sept, J = 6.4 Hz), 2.68-2.80 (2H, m), 3.10 (1H, ddd, J= 12.8, 10.0, 2.4 Hz), 3.17 (1H, ddd, J = 13.2, 10.4, 2.8 Hz), 3.63-3.73(1H, m) 3.73-3.83 (3H, m), 4.08-4.23 (1H, m), 4.54 (1H, d, J = 8.0 Hz).Reference Reference 71 example 37 example 8

¹H-NMR (CDCl₃) δ: 1.05 (3H, d, J = 6.4 Hz), 1.06 (3H, d, J = 6.4 Hz),1.17-1.23 (4H, m), 1.30 (3H, s), 1.36-1.47 (2H, m), 1.56-1.81 (5H, m),1.98 (1H, ddd, J = 16.0, 13.6, 8.0 Hz), 2.03-2.26 (5H, m), 2.31- 2.42(2H, m), 2.51 (1H, dd, J = 16.0, 8.0 Hz), 2.60- 2.67 (1H, m), 2.97 (1H,dd, J = 10.1, 6.4 Hz), 3.04- 3.23 (3H, m), 3.63-3.75 (2H, m), 4.07-4.27(2H, m), 4.55 (1H, d, J = 9.2 Hz). Reference Reference 72 example 37example 11

¹H-NMR (CDCl₃) δ: 1.04 (3H, d, J = 6.0 Hz), 1.05 (3H, d, J = 6.0 Hz),1.33 (3H, s), 1.35-1.53 (3H, m), 1.57-1.82 (5H, m), 1.90-2.03 (2H, m),2.03-2.20 (2H, m), 2.21-2.30 (2H, m), 2.30-2.41 (3H, m), 2.50 (1H, dd, J= 18.4, 8.4 Hz), 2.64 (1H, ddd, J = 8.5, 8.4, 4.6 Hz), 2.98 (1H, dd, J =10.1, 6.4 Hz), 3.03-3.25 (3H, m), 3.65-3.75 (2H, m), 4.06-4.27 (2H, m),4.55 (1H, d, J = 9.1 Hz), 4.91 (1H, dddd, J = 63.7, 6.4, 6.4, 4.0 Hz).Reference Reference 73 example 38 example 11

¹H-NMR (CDCl₃) δ: 1.61 (6H, d, J = 6.4 Hz), 1.89 (3H, s), 1.92-2.10 (3H,m), 2.15-2.41 (5H, m), 2.47-2.77 (4H, m), 2.78-2.86 (2H, m), 2.86-2.97(3H, m), 3.01- 3.13 (1H, m), 3.17-3.27 (1H, m), 3.53 (1H, ddd, J = 19.8,9.9, 6.5 Hz), 3.59-3.81 (3H, m), 4.20-4.34 (2H, m), 4.64-4.86 (2H, m),5.07-5.17 (1H, m), 5.48 (1H, dddd, J = 63.7, 6.0, 6.0, 3.6 Hz).Reference Reference 74 example 37 example 12

¹H-NMR (CDCl₃) δ: 1.06-1.12 (1H, m), 1.13 (3H, d, J = 6.1 Hz), 1.24-1.38(11H, m), 1.39-1.55 (3H, m), 1.56-1.66 (2H, m), 1.67-1.79 (1H, m),1.93-2.02 (1H, m), 2.04-2.19 (311, m), 2.19-2.28 (3H, m), 2.78-2.81 (1H,m), 2.88 (1H, ddd, J = 10.4, 10.4, 6.8 Hz), 3.02-3.19 (3H, m), 3.20-3.36(2H, m), 3.56-3.73 (3H, m), 4.12-4.28 (2H, m), 4.74 (1H, d, J = 9.2 Hz).Reference Reference 75 example 39 example 8

¹H-NMR (CDCl₃) δ: 1.01-1.09 (6H, m), 1.17-1.23 (4H, m), 1.30 (3H, s),1.37-1.50 (2H, m), 1.55-1.67 (2H, m), 1.67-1.81 (2H, m), 2.05-2.27 (6H,m), 2.32-2.42 (1H, m), 2.54-2.69 (1H, m), 2.93-3.36 (5H, m), 3.63- 3.76(2H, m), 4.06-4.31 (2H, m), 4.59-4.68 (1H, m), 4.76-4.96 (1H, m).Reference Reference 76 example 40 example 8

¹H-NMR (CDCl₃) δ: 1.02 (3H, d, J = 6.1 Hz), 1.04 (3H, d, J = 6.7 Hz),1.17-1.23 (4H, m), 1.30 (3H, s), 1.32-1.51 (2H, m), 1.58-1.70 (2H, m),1.71-1.87 (2H, m), 2.11-2.26 (5H, m), 2.35-2.50 (2H, m), 2.61-2.74 (1H,m), 3.04-3.27 (4H, m), 3.41-3.50 (1H, m), 3.62- 3.75 (2H, m), 4.00-4.10(1H, m), 4.19-4.32 (1H, m), 4.64 (1H, d, J = 8.5 Hz).

The chemical names of Example 20 to Example 76 are listed below.

Example 20:rac-4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 21:rac-4-(1,3-benzoxazol-2-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 22:4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 23:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 24:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 25:4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 26:rac-4-cyclopentyl-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 27:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-(4,5,6,7-tetrahydro-1,3-benzoxazol-2-yl)piperidine-1-carboxamideExample 28:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(5-ethyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamideExample 29:rac-4-(l-cyclopropyl-?H-1,2,4-triazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 30:rac-4-(4,4-difluorocyclohexyl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 31:rac-4-(5-cyclopropyl-1,2,4-thiadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 32:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(pyridin-2-yl)piperidine-1-carboxamideExample 33:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-8-azaspiro[4.5]decane-8-carboxamideExample 34:rac-4-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 35:rac-4-cyclohexyl-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}piperidine-1-carboxamideExample 36:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(pyrimidin-2-yl)piperidine-1-carboxamideExample 37:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-hydroxy-4-(pyridin-2-yl)piperidine-1-carboxamideExample 38:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-phenylpiperidine-1-carboxamideExample 39:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-phenylpiperidine-1-carboxamideExample 40:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-hydroxy-4-phenylpiperidine-1-carboxamideExample 41:rac-4-(4-chlorophenyl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-hydroxypiperidine-1-carboxamideExample 42:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-[(pyridin-2-yl)oxy]piperidine-1-carboxamideExample 43:4-(5-cyclopropyl-1,2,4-thiadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 44:4-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 45:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(5-methoxy-1,2,4-thiadiazol-3-yl)-4-methylpiperidine-1-carboxamideExample 46:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-fluoro-4-(pyridin-2-yl)piperidine-1-carboxamideExample 47:rac-4-(2-cyclopropyl-1,3-thiazol-4-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 48:rac-4-(5-cyclopropyl-1,3-thiazol-2-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 49:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamideExample 50:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(5-methylpyridin-2-yl)piperidine-1-carboxamideExample 51:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(3-fluoro-5-methylpyridin-2-yl)piperidine-1-carboxamideExample 52:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(5-fluoropyridin-2-yl)piperidine-1-carboxamideExample 53:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(5-methoxypyridin-2-yl)piperidine-1-carboxamideExample 54:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(5-methylpyrimidin-2-yl)piperidine-1-carboxamideExample 55:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-[5-(trifluoromethyl)pyridin-2-yl]piperidine-1-carboxamideExample 56:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-(2-fluoro-4-methylphenyl)-4-methylpiperidine-1-carboxamideExample 57:4-[5-(cyclopropyloxy)-1,2,4-thiadiazol-3-yl]-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 58:rac-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamideExample 59:rac-4-[4-(difluoromethyl)phenyl]-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 60:4-(2-cyano-4-methylphenyl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 61:N-{(1R,6S)-2,2-difluoro-6-[6-(propan-2-yl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]cyclohexyl}-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamideExample 62:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 63:N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamideExample 64:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamideExample 65:4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 66:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 67:N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamideExample 68:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-{5-[(1S,2R)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamideExample 69:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-{5-[(1R,2S)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamideExample 70:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-[5-(2,2,2-trifluoroethyl)-1,2,4-oxadiazol-3-yl]piperidine-1-carboxamideExample 71:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamideExample 72:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 73:N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 74:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methyl-4-{5-[(1R,2S)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamideExample 75:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S,4S)-4-fluoro-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamideExample 76:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-6-{[(3R)-4,4-difluoro-1-(propan-2-yl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-methylpiperidine-1-carboxamideExample 77rac-N-{(1R,6S)-2,2-Difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4′-methyl-1,2,3,6-tetrahydro[1,1′-biphenyl]-4-carboxamide

To a solution of 4-(4-methylphenyl)-cyclohex-1-ene-carboxylic acid (64.3mg) in chloroform (2 mL) were added oxalyl chloride (0.036 mL) and DMF(5 μL), and the mixture was stirred at room temperature for 3 hours.Then, the reaction solution was concentrated in vacuo, and chloroform (2mL), triethylamine (0.120 mL), and Reference example 14 (53.3 mg) wereadded to the reaction residue. The mixture was stirred. After thereaction was completed, water was added to the reaction mixture, and themixture was extracted with chloroform. The organic layer was dried overanhydrous sodium sulfate, and concentrated in vacuo, and then theobtained residue was purified by amino silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound (55.6 mg).

¹H-NMR (CDCl₃) δ: 1.02 (6H, d, J=6.7 Hz), 1.23-1.50 (2H, m), 1.71-1.91(4H, m), 1.93-2.11 (2H, m), 2.13-2.68 (14H, m), 2.69-2.89 (4H, m),4.27-4.44 (1H, m), 5.68-5.77 (1H, m), 6.67-6.77 (1H, m), 7.09-7.20 (4H,m).

Example 78rac-(1R,6S)-2,2-Difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl4′-methyl-1,2,3,6-tetrahydro[1,1′-biphenyl]-4-carboxylate

The compound of Example 78 shown in the table below was prepared in thesame manner as Example 77, by using Reference example 6 instead ofReference example 14 in Example 77.

Example Structure Instrumental analytical data 78

¹H-NMR (CDCl₃) δ: 1.02 (3H, d, J = 6.0 Hz), 1.03 (3H, d, J = 6.0 Hz),1.29-1.53 (2H, m), 1.58-1.85 (4H, m), 1.88-1.97 (1H, m), 1.98-2.08 (1H,m), 2.14-2.25 (1H, m), 2.25-2.53 (11H, m), 2.53-2.66 (2H, m), 2.67-2.83(4H, m), 5.04-5.16 (1H, m), 7.09-7.16 (5H, m).

Example 79rac-4-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carbothioamide

To a mixture of Reference example 14 (10.0 mg) (Material A),N,N-diisopropylamine (0.034 mL), and chloroform (0.2 mL) was addedthiophosgene (4.40 mg) at 0° C., and the mixture was stirred at the sametemperature for 40 minutes. To the reaction mixture was added Referenceexample 8 (66.7 mg)(Material B) at 0° C., and the mixture was stirred atroom temperature for one hour. The mixture was directly purified byamino silica gel column chromatography (eluate: hexane/ethyl acetate) togive the title compound (9.6 mg).

¹H-NMR (CDCl₃) δ: 1.02 (6H, d, J=5.6 Hz), 1.14-1.27 (4H, m), 1.27-1.50(2H, m), 1.50-1.91 (8H, m), 1.91-2.04 (1H, m), 2.08-2.24 (2H, m),2.24-2.35 (2H, m), 2.35-2.55 (5H, m), 2.55-2.70 (2H, m), 2.79-3.00 (2H,m), 3.33 (1H, t, J=11.2 Hz), 3.49 (1H, t, J=11.2 Hz), 4.16 (1H, d,J=12.8 Hz), 4.49 (1H, d, J=12.8 Hz), 5.02-5.26 (1H, m), 5.42 (1H, d,J=8.0 Hz).

Example 804-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carbothioamide

The compound of Example 80 shown in the table below was prepared in thesame manner as Example 79, by using Reference example 15 correspondingto Material A in Example 79 and Reference example 8 corresponding toMaterial B in Example 79.

Structure Material A Material B Example Spectral data ReferenceReference 80 example 15 example 8

¹H-NMR (CDCl₃) δ: 1.02 (6H, d, J = 5.6 Hz), 1.14- 1.27 (4H, m),1.27-1.50 (2H, m), 1.50-1.91 (8H, m), 1.91-2.04 (1H, m), 2.08-2.24 (2H,m), 2.24-2.35 (2H, m), 2.35-2.55 (5H, m), 2.55-2.70 (2H, m), 2.79-3.00(2H, m), 3.33 (1H, t, J = 11.2 Hz), 3.49 (1H, t, J = 11.2 Hz), 4.16 (1H,d, J = 12.8 Hz), 4.49 (1H, d, J = 12.8 Hz), 5.02-5.26 (1H, m), 5.42 (1H,d, J = 8.0 Hz).

Example 81rac-4-(4-Methylphenyl)-N-[(1S,4R)-3-{[4-(propan-2-yl)piperazin-1-yl]methyl}bicyclo[2.2.1]heptan-2-yl]piperidine-1-carboxamide

To a solution of Reference example 40 (20 mg) in chloroform (0.5 mL) wasadded TFA (0.057 ml) at room temperature, and the mixture was stirred atthe same temperature for one hour. The reaction solution wasconcentrated in vacuo, and the obtained residue was purified by aminosilica gel column chromatography (eluate: hexane/ethyl acetate). Theobtained residue was dissolved in chloroform (0.284 mL). To the solutionwere added N,N-diisopropylethylamine (36.8 mg) and triphosgene (8.4 mg)at 0° C., and the mixture was stirred at the same temperature for onehour. Then, 4-(4-methylphenyl)piperidine (0.057 mL) was added to thereaction mixture, which was stirred at room temperature for one hour.The reaction mixture was directly purified by amino silica gel columnchromatography (eluate: hexane/ethyl acetate) to give the title compound(8 mg).

¹H-NMR (CDCl₃) δ: 1.24 (6H, d, J=7.3 Hz), 1.31-1.49 (7H, m), 1.54-1.67(4H, m), 1.84 (2H, m), 2.24 (1H, m), 2.32 (3H, s), 2.63 (2H, m),2.80-2.99 (4H, m), 3.06-3.49 (8H, m), 4.05-4.14 (3H, m), 7.07-7.13 (4H,m).

Examples 82-156

The compounds of Examples 82 to 156 shown in the table below wereprepared in the same manner as Example 19, by using commercial compoundsor Reference example compounds which correspond to Material A andMaterial B described in Example 19.

Structure Material A Material B Example Spectral data ReferenceReference 82 example 58 example 116

¹H-NMR (DMSO-d6) δ: 0.87 (6H, d, J = 6.4 Hz), 1.18- 1.36 (2H, m), 1.26(3H, s), 1.47-1.66 (3H, m), 1.66- 1.88 (4H, m), 1.95-2.11 (3H, m),2.17-2.40 (6H, m), 2.43-2.63 (5H, m), 2.95-3.19 (2H, m), 3.55-3.77 (2H,m), 3.98-4.18 (1H, m), 5.16 (1H, dddd, J = 65.0, 6.0, 6.0, 3.2 Hz), 5.88(1H, d, J = 8.0 Hz). Reference Reference 83 example 96 example 115

¹H-NMR (CDCl₃) δ: 1.00 (5H, d, J = 6.4 Hz), 1.13 d, J = 6.4 Hz), 1.33(3H, s), 1.38-1.85 (9H, m), 1.90-2.30 (8H, m), 2.32-2.41 (1H, m),2.60-2.74 (4H, m), 3.03-3.15 (2H, m), 3.17-3.28 (1H, m), 3.33-3.44 (1H,m), 3.65-3.76 (2H, m), 4.13-4.30 (1H, m), 4.51 (1H, d, J = 9.2 Hz), 4.91(1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 84 example96 example 8

¹H-NMR (CDCl₃) δ: 1.00 (6H, dd, J = 6.8, 1.2 Hz), 1.17-1.25 (4H, m),1.30 (3H, s), 1.38-1.46 (2H, m), 1.50-1.69 (4H, m), 1.69-1.85 (4H, m),2.00-2.30 (7H, m), 2.60-2.74 (3H, m), 3.03-3.15 (2H, m), 3.17-3.28 (1H,m), 3.33-3.42 (1H, m), 3.64-3.74 (2H, m), 4.13- 4.30 (1H, m), 4.50 (1H,d, J = 9.2 Hz). Reference Reference 85 example 91 example 8

¹H-NMR (CDCl₃) δ: 1.16-1.23 (4H, m), 1.27 (3H, s), 1.36 (6H, d, J = 6.8Hz), 1.44-1.58 (2H, m), 1.58- 1.75 (1H, m), 1.80-2.06 (4H, m), 2.09-2.23(3H, m), 2.23-2.35 (1H, m), 2.88-3.08 (3H, m), 3.11-3.25 (1H, m),3.48-3.67 (2H, m), 4.41-4.57 (1H, m), 4.57-4.67 (1H, m). ReferenceReference 86 example 91 example 115

¹H-NMR (CDCl₃) δ: 1.30 (3H, s), 1.35 (6H, d, J = 6.4 Hz), 1.42-1.62 (3H,m), 1.62-7.75 (1H, m), 1.80-2.07 (5H, m), 2.11-2.22 (2H, m), 2.22-2.41(2H, m), 2.89- 3.08 (3H, m), 3.11-3.24 (1H, m), 3.50-3.66 (2H, m),4.41-4.56 (1H, m), 4.58-4.67 (1H, m), 4.93 (1H, dddd, J = 63.6, 6.0,6.0, 3.6 Hz). Reference Reference 87 example 97 example 115

¹H-NMR (CDCl₃) δ: 1.25 (3H, s), 1.26-1.37 (1H, m), 1.30 (3H, d, J = 6.4Hz), 1.31 (3H, d, J = 6.4 Hz), 1.39-1.74 (4H, m), 1.74-2.01 (3H, m),2.10-2.19 (2H, m), 2.19-2.30 (1H, m), 2.30-2.39 (2H, m), 2.86 (1H, ddd,J = 14.0, 11.0, 3.1 Hz), 2.96-3.08 (2H, m), 3.41-3.50 (1H, m), 3.63-3.72(1H, m), 4.46-4.60 (1H, m), 4.78-4.86 (1H, m), 4.41 (1H, dddd, J = 64.0,6.0, 6.0, 3.6 Hz), 5.06-5.15 (1H, m). Reference Reference 88 example 98example 115

¹H-NMR (CDCl₃) δ: 1.30 (3H, s), 1.41-1.89 (14H, m), 1.90-2.02 (1H, m),2.13-2.30 (4H, m), 2.31-2.41 (1H, m), 2.99-3.13 (2H, m), 3.60-3.78 (2H,m), 4.32-4.50 (2H, m), 4.63 (1H, d, J = 9.2 Hz), 4.91 (1H, dddd, J =63.6, 6.0, 6.0, 3.6 Hz), 7.17 (1H, s), 7.21 (1H, s). Reference Reference89 example 99 example 115

¹H-NMR (CDCl₃) δ: 1.13 (6H, d, J = 6.0 Hz), 1.32 (3H, s), 1.42-1.83 (5H,m), 1.87-2.04 (2H, m), 2.06-2.17 (2H, m), 2.18-2.28 (4H, m), 2.31-2.41(1H, m), 2.60- 2.73 (1H, m), 2.88-3.17 (5H, m), 3.30-3.80 (6H, m),4.80-5.04 (1H, m). Reference Reference 90 example 98 example 8

¹H-NMR (CDCl₃) δ: 1.17-1.23 (4H, m), 1.27 (3H, s), 1.44 (3H, d, J = 6.7Hz), 1.45 (3H, d, J = 6.7 Hz), 1.46-1.65 (4H, m), 1.69-1.91 (2H, m),2.12-2.30 (5H, m), 2.99-3.12 (2H, m), 3.59-3.69 (2H, m), 3.69-3.77 (1H,m), 4.31-4.50 (2H, m), 4.63 (1H, d, J = 9.2 Hz), 7.16 (1H, s), 7.20 (1H,s). Reference Reference 91 example 89 example 115

¹H-NMR (CDCl₃) δ: 1.09-1.43 (11H, m), 1.43-1.56 (2H, m), 1.56-1.76 (3H,m), 1.76-2.24 (7H, m), 2.24-2.48 (5H, m), 2.48-2.75 (1H, m), 2.75-3.06(1H, m), 3.06- 3.45 (4H, m), 3.45-3.71 (1H, m), 3.71-3.87 (1H, m),3.87-4.13 (1H, m), 4.13-4.50 (1H, m), 4.94 (1H, dddd, J = 64.4, 6.0,6.0, 4.0 Hz), 7.13-7.44 (5H, m), 11.97 (1H, brs). Reference Reference 92example 119 example 115

¹H-NMR (CDCl₃) δ: 1.18-1.29 (1H, m), 1.22 (3H, s), 1.30 (3H, d, J = 6.4Hz), 1.31 (3H, d, J = 6.4 Hz), 1.40-1.53 (3H, m), 1.58-1.71 (1H, m),1.78-2.03 (3H, m), 2.05-2.12 (2H, m), 2.17-2.28 (1H, m), 2.30-2.40 (2H,m), 2.81 (1H, ddd, J = 13.6, 10.8, 2.9 Hz), 2.93-3.06 (2H, m), 3.37-3.47(1H, m), 3.54-3.61 (1H, m), 4.41-4.54 (1H, m), 4.74 (1H, d, J = 9.2 Hz),4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz), 5.40-5.48 (1H, m), 6.53(1H, d, J = 5.5 Hz), 8.35 (1H, d, J = 5.5 Hz). Reference Reference 93example 92 example 115

¹H-NMR (CDCl₃) δ: 1.24-1.30 (9H, m), 1.35-1.53 (3H, m), 1.65-2.04 (6H,m), 2.07-2.20 (2H, m), 2.27-2.40 (2H, m), 2.83 (1H, ddd, J = 14.0, 11.6,3.2 Hz), 2.95-3.10 (2H, m), 3.40-3.49 (1H, m), 3.57-3.67 (1H, m),4.60-4.71 (3H, m), 4.90 (1H, dddd, J = 64.0, 6.0, 6.0, 4.0 Hz), 7.42(1H, s). Reference Reference 94 example 93 example 115

¹H-NMR (CDCl₃) δ: 0.89 (6H, t, J = 6.8 Hz), 1.27 (3H, s), 1.36-1.53 (3H,m), 1.64-2.04 (6H, m), 2.07-2.20 (2H, m), 2.27-2.40 (3H, m), 2.48-2.63(2H, m), 2.84 (1H, ddd, J = 14.0, 11.2, 3.2 Hz), 2.98 (1H, ddd, J =14.0, 11.2, 3.2 Hz), 3.40-3.50 (1H, m), 3.54-3.65 (1H, m), 4.60-4.76(3H, m), 4.90 (1H, dddd, J = 64.0, 6.0, 6.0, 3.6 Hz), 7.43 (1H, s).Reference Reference 95 example 81 example 115

¹H-NMR (CDCl₃) δ: 1.00-1.11 (6H, m), 1.15-1.54 (7H, m), 1.54-1.75 (4H,m), 1.75-2.07 (5H, m), 2.15 (3H, s), 2.20-2.30 (3H, m), 2.30-2.42 (2H,m), 2.42-2.57 (1H, m), 2.59-2.70 (1H, m), 2.73-2.85 (1H, m), 2.90 (1H,t, J = 8.0 Hz), 3.02-3.18 (2H, m), 3.23 (1H, tt, J = 15.2, 7.2 Hz),3.63-3.79 (2H, m), 4.07-4.22 (1H, m), 4.54 (1H, d, J = 7.6 Hz), 4.91(1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 96 example59 example 115

¹H-NMR (CDCl₃) δ: 0.92-1.02 (6H, m), 1.20-1.54 (6H, m), 1.54-2.03 (8H,m), 2.08 (3H, s), 2.10-2.27 (3H, m), 2.32-2.48 (2H, m), 2.60-2.70 (2H,m), 2.76-3.23 (6H, m), 3.62-3.77 (2H, m), 4.07-4.22 (1H, m), 4.53 (1H,d, J = 8.0 Hz), 4.91 (1H, dddd, J = 64.0, 6.4, 6.4, 3.6 Hz). ReferenceReference 97 example 18 example 117

¹H-NMR (CDCl₃) δ: 1.00 (6H, d, J = 6.4 Hz), 1.22-1.48 (2H, m), 1.34 (3H,s), 1.49-1.60 (1H, m), 1.61-1.75 (2H, m), 1.75-1.87 (1H, m), 1.87-1.98(1H, m), 1.98- 2.22 (3H, m), 2.22-2.33 (2H, m), 2.33-2.54 (11H, m),2.54-2.64 (1H, m), 2.68-2.81 (2H, m), 3.14 (2H, dddd, J = 32.4, 14.0,10.8, 3.2 Hz), 3.62-3.84 (3H, m), 4.16 (1H, dddd, J = 23.6, 11.2, 8.0,3.6 Hz), 4.54 (1H, d, J = 8.0 Hz). Reference Reference 98 example 100example 115

¹H-NMR (CDCl₃) δ: 1.00-1.11 (6H, m), 1.33 (3H, s), 1.36-1.84 (13H, m),1.85-2.07 (4H, m), 2.07-2.20 (1H, m), 2.22-2.31 (2H, m), 2.31-2.41 (1H,m), 2.90 (1H, sep, J = 6.4 Hz), 3.03-3.26 (3H, m), 3.42-3.52 (2H, m),3.59-3.78 (3H, m), 4.10-4.24 (1H, m), 4.50 (1H, d, J = 9.2 Hz), 4.91(1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 99 example59 example 8

¹H-NMR (CDCl₃) δ: 0.92-1.00 (6H, m), 1.13 (2H, d, J = 6.0 Hz), 1.17-1.24(4H, m), 1.30 (3H, s), 1.32-1.50 (2H, m), 1.56-1.70 (2H, m), 1.70-1.86(1H, m), 1.86- 1.97 (2H, m), 2.08 (3H, s), 2.11-2.26 (4H, m), 2.44 (1H,t, J = 7.6 Hz), 2.60-2.70 (2H, m), 2.76-2.86 (1H, m), 2.86-2.92 (2H, m),2.92-3.17 (3H, m), 3.60- 3.77 (2H, m), 4.07-4.23 (1H, m), 4.53 (1H, d, J= 7.6 Hz). Reference Reference 100 example 101 example 115

¹H-NMR (CDCl₃) δ: 0.91-0.97 (6H, m), 1.32 (3H, s), 1.37-1.86 (11H, m),1.90-2.04 (3H, m), 2.07-2.21 (2H, m), 2.21-2.41 (5H, m), 2.49 (1H, sep,J = 6.0 Hz), 2.62 (2H, dd, J = 15.6, 10.8 Hz), 3.02-3.16 (2H, m),3.21-3.32 (1H, m), 3.59 (1H, t, J = 4.4 Hz), 3.63- 3.78 (2H, m),4.22-4.37 (1H, m), 4.56 (1H, d, J = 8.8 Hz), 4.91 (1H, dddd, J = 63.6,6.0, 6.0, 4.0 Hz). Reference Reference 101 example 60 example 115

¹H-NMR (CDCl₃) δ: 1.11 (6H, d, J = 6.4 Hz), 1.20-1.54 (8H, m), 1.60-1.74(2H, m), 1.74-1.85 (4H, m), 1.85- 2.04 (2H, m), 2.09-2.20 (2H, m),2.21-2.30 (2H, m), 2.32-2.42 (1H, m), 2.46-2.63 (3H, m), 2.76-2.85 (1H,m), 3.01-3.17 (2H, m), 3.28 (1H, sep, J = 4.4 Hz), 3.61-3.82 (3H, m),4.08-4.23 (1H, m), 4.56 (1H, d, J = 7.2 Hz), 4.92 (1H, dddd, J = 64.0,6.0, 6.0, 3.6 Hz). Reference Reference 102 example 37 example 117

¹H-NMR (CDCl₃) δ: 1.05 (3H, d, J = 6.0 Hz), 1.06 (3H, d, J = 6.0 Hz),1.33 (3H, s), 1.36-1.51 (2H, m), 1.59-1.86 (5H, m), 1.92-2.12 (5H, m),2.69 (2H, d, J = 13.2 Hz), 2.31-2.40 (2H, m), 2.40-2.55 (5H, m),2.61-2.73 (1H, m), 2.95-3.27 (4H, m), 3.62-3.80 (3H, m), 4.06-4.30 (2H,m), 4.54 (1H, d, J = 9.2 Hz). Reference Reference 103 example 37 example118

¹H-NMR (CDCl₃) δ: 0.71 (3H, t, J = 7.2 Hz), 1.05 (3H, d, J = 6.0 Hz),1.06 (3H, d, J = 6.0 Hz), 1.32-1.54 (3H, m), 1.54-1.87 (7H, m),1.91-2.04 (2H, m), 2.04- 2.21 (2H, m), 2.30 (2H, d, J = 18.0 Hz),2.33-2.42 (3H, m), 2.47 (1H, dd, J = 16.4, 8.0 Hz), 2.60-2.76 (1H, m),2.88-3.11 (3H, m), 3.14-3.26 (1H, m), 3.79 (2H, d, J = 13.6 Hz),4.06-4.29 (2H, m), 4.53 (1H, d, J = 9.2 Hz), 4.92 (1H, dddd, J = 63.6,6.0, 6.0, 3.6 Hz). Reference Reference 104 example 102 example 115

¹H-NMR (CDCl₃) δ: 0.95 (6H, d, J = 6.1 Hz), 1.29-1.87 (12H, m), 1.33(3H, s), 1.90-2.04 (1H, m), 2.04-2.31 (8H, m), 2.31-2.43 (1H, m),2.52-2.67 (2H, m), 3.00- 3.31 (3H, m), 3.35-3.43 (1H, m), 3.63-3.79 (2H,m), 4.12-4.29 (1H, m), 4.49 (1H, d, J = 9.2 Hz), 4.80- 5.02 (1H, m).Reference Reference 105 example 103 example 115

¹H-NMR (CDCl₃) δ: 1.12 (6H, br s), 1.29-1.42 (2H, m), 1.33 (3H, s),1.42-1.53 (2H, m), 1.54-1.85 (8H, m), 1.90-2.21 (6H, m), 2.21-2.30 (2H,m), 2.32-2.41 (1H, m), 2.59-2.71 (1H, m), 3.03-3.20 (3H, m), 3.25-3.60(2H, m), 3.61-3.74 (3H, m), 4.17-4.30 (1H, m), 4.56 (1H, d, J = 9.2 Hz),4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 106example 104 example 115

¹H-NMR (CDCl₃) δ: 1.01 (6H, d, J = 5.5 Hz), 1.24-1.84 (8H, m), 1.33 (3H,s), 1.90-2.03 (1H, m), 2.07-2.30 (5H, m), 2.30-2.47 (4H, m), 2.96-3.77(4H, m), 3.22- 3.30 (1H, m), 3.49-3.57 (1H, m), 3.66-3.75 (2H, m),4.10-4.24 (1H, m), 4.56 (1H, d, J = 8.5 Hz), 4.91 (1H, dddd, J = 63.6,6.0, 6.0, 3.6 Hz). Reference Reference 107 example 105 example 115

¹H-NMR (CDCl₃) δ: 0.92 (3H, d, J = 4.3 Hz), 0.94 (3H, d, J = 4.3 Hz),1.34 (3H, s), 1.36-1.54 (3H, m), 1.58-1.84 (7H, m), 1.91-2.21 (4H, m),2.22-2.46 (6H, m), 2.46-2.58 (1H, m), 2.97-3.24 (4H, m), 3.65-3.74 (2H,m), 4.15-4.25 (2H, m), 4.58 (1H, d, J = 9.2 Hz), 4.92 (1H, dddd, J =63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 108 example 106 example 115

¹H-NMR (CDCl₃) δ: 1.10 (6H, br s), 1.34 (3H, s), 1.39- 1.54 (3H, m),1.54-1.85 (6H, m), 1.91-2.04 (1H, m), 2.04-2.21 (2H, m), 2.21-2.31 (2H,m), 2.32-2.58 (2H, m), 2.62-2.80 (1H, m), 3.05-3.19 (3H, m), 3.24-3.35(1H, m), 3.29 (3H, s), 3.61-3.79 (3H, m), 3.92-4.01 (1H, m), 4.15-4.30(1H, m), 4.65 (1H, d, J = 9.2 Hz), 4.92 (1H, dddd, J = 63.6, 6.0, 6.0,3.6 Hz). Reference Reference 109 example 107 example 115

¹H-NMR (CDCl₃) δ: 0.94-1.29 (8H, m), 1.33 (3H, s), 1.38-1.86 (14H, m),1.89-2.18 (2H, m), 2.18-2.31 (2H, m), 2.31-2.75 (4H, m), 2.98-3.51 (4H,m), 3.57-3.79 (2H, m), 4.08-4.26 (1H, m), 4.51 (1H, d, J = 8.4 Hz), 4.91(1H, dddd, J = 63.6, 6.4, 6.4, 4.0 Hz). Reference Reference 110 example61 example 115

¹H-NMR (CDCl₃) δ: 0.93-1.04 (9H, m), 1.23-1.53 (6H, m), 1.61-1.75 (2H,m), 1.75-1.87 (4H, m), 1.90-2.04 (2H, m), 2.10-2.22 (1H, m), 2.22-2.30(2H, m), 2.30- 2.41 (2H, m), 2.54 (1H, sep, J = 6.4 Hz), 2.62-2.81 (4H,m), 2.88 (1H, t, J = 11.0 Hz), 3.02-3.12 (1H, m), 3.12-3.22 (1H, m),3.62-3.72 (1H, m), 3.74-3.84 (1H, m), 4.10-4.24 (1H, m), 4.48 (1H, d, J= 7.4 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). ReferenceReference 111 example 62 example 115

¹H-NMR (CDCl₃) δ: 0.92-1.00 (6H, m), 1.09 (3H, d, J = 6.0 Hz), 1.33 (3H,s), 1.42-1.54 (3H, m), 1.60-1.89 (5H, m), 1.90-2.22 (3H, m), 2.22-2.42(4H, m), 2.42- 2.67 (4H, m), 2.68-2.79 (2H, m), 2.83-2.94 (1H, m),3.03-3.18 (2H, m), 3.64-3.77 (2H, m), 4.10-4.27 (1H, m), 4.53 (1H, d, J= 8.4 Hz), 4.91 (1H, dddd, J = 64.0, 6.0, 6.0, 3.6 Hz). ReferenceReference 112 example 82 example 115

¹H-NMR (CDCl₃) δ: 0.92-1.02 (6H, m), 1.33 (3H, s), 1.35-1.53 (3H, m),1.54-1.85 (5H, m), 1.86-2.04 (3H, m), 2.08 (3H, s), 2.10-2.20 (1H, m),2.20-2.28 (2H, m), 2.31-2.42 (1H, m), 2.56-2.68 (2H, m), 2.70-2.80 (3H,m), 2.85-2.97 (1H, m), 3.02-3.16 (3H, m), 3.66- 3.77 (2H, m), 4.05-4.20(1H, m), 4.59 (1H, d, J = 7.2 Hz), 4.92 (1H, dddd, J = 64.0, 6.0, 6.0,4.0 Hz). Reference Reference 113 example 83 example 115

¹H-NMR (CDCl₃) δ: 1.02-1.12 (6H, m), 1.30-1.54 (6H, m), 1.58-1.89 (6H,m), 1.89-2.04 (2H, m), 2.09-2.29 (7H, m), 2.29-2.41 (2H, m), 2.42-2.52(1H, m), 2.52- 2.62 (1H, m), 2.72-2.87 (2H, m), 3.03-3.18 (2H, m), 3.23(1H, quint, J = 7.6 Hz), 3.63-3.78 (2H, m), 4.07-4.22 (1H, m), 4.55 (1H,d, J = 7.2 Hz), 4.91 (1H, dddd, J = 64.0, 6.0, 6.0, 3.6 Hz). ReferenceReference 114 example 84 example 115

¹H-NMR (CDCl₃) δ: 0.93-1.05 (6H, m), 1.19-1.30 (2H, m), 1.33 (3H, s),1.37-1.53 (3H, m), 1.60-1.84 (6H, m), 1.85-2.04 (2H, m), 2.05-2.21 (5H,m), 2.21-2.30 (2H, m), 2.30-2.42 (2H, m), 2.46-2.58 (2H, m), 2.61- 2.69(1H, m), 2.76-2.86 (1H, m), 2.91-3.03 (1H, m), 3.03-3.17 (2H, m),3.68-3.80 (2H, m), 4.07-4.22 (1H, m), 4.55 (1H, d, J = 7.2 Hz), 4.91(1H, dddd, J = 64.0, 6.0, 6.0, 3.6 Hz). Reference Reference 115 example85 example 115

¹H-NMR (CDCl₃) δ: 0.36-0.43 (2H, m), 0.43-0.50 (2H, m), 1.33 (3H, s),1.34-1.53 (3H, m), 1.55-1.77 (5H, m), 1.77-1.86 (1H, m), 1.86-2.04 (3H,m), 2.10-2.30 (6H, m), 2.31-2.42 (1H, m), 2.52-2.73 (3H, m), 2.81 (1H,td, J = 8.4, 4.4 Hz), 2.89 (1H, t, J = 7.6 Hz), 2.98-3.17 (3H, m),3.62-3.77 (2H, m), 4.09-4.23 (1H, m), 4.54 (1H, d, J = 8.0 Hz), 4.91(1H, dddd, J = 64.0 6.0, 6.0, 4.0 Hz). Reference Reference 116 example105 example 8

¹H-NMR (CDCl₃) δ: 0.89 (3H, d, J = 6.8 Hz), 0.90 (3H, d, J = 6.8 Hz),1.17-1.24 (4H, m), 1.30 (3H, s), 1.35-1.49 (2H, m), 1.56-1.85 (6H, m),1.93-2.28 (8H, m), 2.28-2.37 (1H, m), 2.40-2.49 (1H, m), 2.56-2.68 (1H,m), 2.89-2.99 (1H, m), 3.02-3.24 (3H, m), 3.61- 3.76 (2H, m), 4.08-4.28(2H, m), 4.55 (1H, d, J = 9.2 Hz). Reference Reference 117 example 95example 115

¹H-NMR (CDCl₃) δ: 1.05 (6H, d, J = 6.7 Hz), 1.33 (3H, s), 1.43-1.54 (2H,m), 1.57-1.84 (7H, m), 1.88-2.03 (2H, m), 2.10-2.22 (2H, m), 2.22-2.30(2H, m), 2.31- 2.71 (10H, m), 3.02-3.17 (2H, m), 3.64-3.79 (2H, m),3.88-4.03 (1H, m), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz), 5.05(1H, d, J = 7.3 Hz). Reference Reference 118 example 108 example 115

¹H-NMR (CDCl₃) δ: 0.13 (2H, d, J = 4.3 Hz), 0.50 (2H, d, J = 7.3 Hz),0.84-0.95 (1H, m), 1.33 (3H, s), 1.36-1.54 (3H, m), 1.56-1.87 (7H, m),1.91-2.21 (4H, m), 2.21-2.30 (2H, m), 2.31-2.46 (3H, m), 2.47-2.60 (1H,m), 2.95-3.27 (4H, m), 3.64-3.74 (2H, m), 4.10- 4.25 (2H, m), 4.56 (1H,d, J = 8.5 Hz), 4.92 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). ReferenceReference 119 example 109 example 8

¹H-NMR (CDCl₃) δ: 0.86 (9H, s), 1.18-1.24 (4H, m), 1.30 (s, 3H),1.35-1.50 (2H, m), 1.55-1.72 (3H, m), 1.72-1.86 (2H, m), 1.86-2.00 (1H,m), 2.00-2.29 (7H, m), 2.46 (1H, dd, J = 10.0, 4.0 Hz), 2.53-2.62 (1H,m), 2.62-2.71 (1H, m), 2.98 (1H, dd, J = 10.0, 6.4 Hz), 3.03-3.27 (313,m), 3.61-3.78 (2H, m), 4.03-4.12 (1H, m), 4.13-4.29 (1H, m), 4.53 (1H,d, J = 9.2 Hz). Reference Reference 120 example 109 example 115

¹H-NMR (CDCl₃) δ: 0.87 (9H, s), 1.33 (3H, s), 1.33- 1.54 (3H, m),1.56-1.85 (6H, m), 1.86-2.31 (7H, m), 2.32-2.42 (1H, m), 2.43-2.52 (1H,m), 2.54-2.75 (2H, m), 2.89-3.26 (413, m), 3.63-3.80 (2H, m), 4.02-4.12(1H, m), 4.13-4.29 (1H, m), 4.54 (1H, d, J = 9.2 Hz), 4.92 (1H, dddd, J= 63.6, 6.4, 6.4, 4.0 Hz). Reference Reference 121 example 110 example115

¹H-NMR (CDCl₃) δ: 0.19-0.38 (4H, m), 1.03-1.17 (3H, m), 1.32-1.54 (4H,m), 1.34 (3H, s), 1.56-1.84 (6H, m), 1.90-2.56 (10H, m), 3.01-3.24 (4H,m), 3.63-3.75 (213, m), 4.10-4.27 (2H, m), 4.57 (1H, d, J = 9.2 Hz),4.92 (1H, dddd, J = 63.5, 6.0, 6.0, 3.7 Hz). Reference Reference 122example 108 example 8

¹H-NMR (CDCl₃) δ: 0.06-0.16 (2H, m), 0.44-0.52 (2H, m), 0.81-0.93 (1H,m), 1.09-1.23 (5H, m), 1.30 (3H, s), 1.34-1.49 (2H, m), 1.54-1.85 (4H,m), 1.94-2.26 (6H, m), 2.26-2.42 (3H, m), 2.46-2.54 (1H, m), 2.70- 2.79(1H, m), 3.02-3.26 (4H, m), 3.61-3.74 (2H, m), 4.09-4.27 (2H, m), 4.56(1H, d, J = 9.2 Hz). Reference Reference 123 example 63 example 115

¹H-NMR (CDCl₃) δ: 0.97-1.09 (6H, m), 1.32 (3H, s), 1.36-1.53 (4H, m),1.53-1.69 (3H, m), 1.69-1.87 (4H, m), 1.91-2.04 (2H, m), 2.04-2.20 (3H,m), 2.20-2.28 (5H, m), 2.30-2.42 (2H, m), 2.62-2.77 (2H, m), 2.82- 2.95(2H, m), 3.03-3.15 (2H, m), 3.63- 3.76 (2H, m), 4.03-4.18 (1H, m), 4.52(1H, d, J = 7.2 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz).Reference Reference 124 example 64 example 115

¹H-NMR (CDCl₃) δ: 1.18-1.36 (5H, m), 1.36-1.54 (3H, m), 1.60-2.05 (13H,m), 2.06-2.20 (2H, m), 2.21-2.30 (2H, m), 2.34-2.43 (1H, m), 2.45-2.66(7H, m), 2.74- 2.83 (1H, m), 3.01-3.16 (2H, m), 3.72-3.82 (1H, m),3.72-3.82 (1H, m), 4.09-4.23 (1H, m), 4.57 (1H, d, J = 7.2 Hz), 4.92(1H, dddd, J = 64.0, 6.0, 6.0, 3.6 Hz). Reference Reference 125 example65 example 115

¹H-NMR (CDCl₃) δ: 0.97-1.10 (6H, m), 1.21-1.35 (4H, m), 1.35-1.52 (2H,m), 1.62-1.76 (4H, m), 1.76-1.87 (2H, m), 1.87-2.22 (4H, m), 2.22-2.31(2H, m), 2.31- 2.42 (3H, m), 2.48-2.64 (3H, m), 2.64-2.80 (2H, m),2.98-3.09 (1H, m), 3.09-3.24 (3H, m), 3.58-3.70 (1H, m), 3.76-3.88 (1H,m), 4.07-4.24 (1H, m), 4.52 (1H, d, J = 8.0 Hz), 4.91 (1H, dddd, J =64.0, 6.0, 6.0, 3.6 Hz). Reference Reference 126 example 110 example 8

¹H-NMR (CDCl₃) δ: 0.22-0.34 (4H, m), 1.04-1.24 (8H, m), 1.31 (3H, s),1.33-1.49 (2H, m), 1.54-1.84 (6H, m), 1.93-2.55 (9H, m), 3.02-3.24 (4H,m), 3.61-3.74 (2H, m), 4.11-4.27 (2H, m), 4.56 (1H, d, J = 9.2 Hz).Reference Reference 127 example 66 example 115

¹H-NMR (CDCl₃) δ: 1.00-1.12 (6H, m), 1.21-1.40 (5H, m), 1.40-1.59 (6H,m), 1.59-1.74 (4H, m), 1.74-1.84 (1H, m), 1.84-2.06 (2H, m), 2.08-2.22(1H, m), 2.22- 2.43 (8H, m), 2.43-2.65 (5H, m), 3.03-3.12 (1H, m),3.12-3.22 (1H, m), 3.63-3.73 (1H, m), 3.73-3.83 (1H, m), 4.07-4.23 (1H,m), 4.56 (1H, d, J = 8.0 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6Hz). Reference Reference 128 example 86 example 115

¹H-NMR (CDCl₃) δ: 0.86 (6H, d, J = 6.8 Hz), 1.29-1.53 (6H, m), 1.53-1.76(4H, m), 1.76-2.08 (7H, m), 2.08- 2.28 (6H, m), 2.32-2.41 (1H, m),2.42-2.52 (1H, m), 2.52-2.63 (1H, m), 2.63--2.73 (1H, m), 2.76-2.90 (3H,m), 3.02-3.17 (2H, m), 3.70 (2H, tt, J = 14.8, 4.55 (1H, 4.0 Hz),4.07-4.22 (1H, m), d, J = 8.0 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0,3.6 Hz) Reference Reference 129 example 67 example 115

¹H-NMR (CDCl₃) δ: 0.90-1.84 (20H, m), 1.84-2.04 (3H, m), 2.05-2.31 (5H,m), 2.32-2.43 (1H, m), 2.43-2.77 (6H, m), 2.79-2.95 (1H, m), 3.03-3.19(2H, m), 3.65- 3.81 (2H, m), 4.08-4.24 (1H, m), 4.54 (1H, d, J = 7.9Hz), 4.93 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Commercial130 example 110 product

¹H-NMR (CDCl₃) δ: 0.16-0.48 (4H, m), 0.98-1.28 (4H, m), 1.25 (3H, s),1.30-1.50 (2H, m), 1.50-1.89 (7H, m), 1.95-2.21 (5H, m), 2.22-2.65 (2H,m), 2.33 (3H, s), 3.11-3.24 (1H, m), 3.25-3.41 (2H, m), 3.41-3.67 (3H,m), 4.10-4.27 (2H, m), 4.58 (1H, d, J = 7.9 Hz), 7.16 (2H, d, J = 7.9Hz), 7.21 (2H, d, J = 7.9 Hz). Reference Reference 131 example 68example 115

¹H-NMR (CDCl₃) δ: 0.88 (3H, s), 0.92-0.98 (6H, m), 1.22-1.52 (8H, m),1.60-1.84 (6H, m), 1.89-2.03 (2H, m), 2.04 (3H, s), 2.09-2.31 (4H, m),2.31-2.41 (1H, m), 2.41-2.55 (3H, m), 2.70-2.80 (1H, m), 3.00-3.23 (3H,m), 3.64-3.75 (1H, m), 3.75-3.85 (1H, m), 4.06- 4.22 (1H, m), 4.58 (1H,d, J = 7.2 Hz), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). ReferenceReference 132 example 94 example 115

¹H-NMR (CDCl₃) δ: 1.04 (6H, d, J = 6.7 Hz), 1.31 (3H, s), 1.41-2.05 (9H,m), 2.14-2.27 (3H, m), 2.31-2.59 (5H, m), 2.64-2.77 (1H, m), 2.85-2.96(1H, m), 2.99- 3.10 (2H, m), 3.46-3.74 (6H, m), 4.46-4.53 (1H, m),4.53-4.68 (1H, m), 4.91 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz).Reference Reference 133 example 111 example 115

¹H-NMR (CDCl₃) δ: 0.57-0.69 (2H, m), 0.99-1.10 (2H, m), 1.33 (3H, s),1.35-1.53 (3H, m), 1.58-1.89 (4H, m), 1.91-2.20 (5H, m), 2.20-2.30 (2H,m), 2.32-2.41 (1H, m), 2.41-2.49 (1H, m), 2.51-2.61 (1H, m), 2.75- 2.94(3H, m), 3.04-3.26 (4H, m), 3.65-3.75 (2H, m), 4.13-4.27 (2H, m), 4.58(1H, d, J = 9.2 Hz), 4.92 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz).Reference Reference 134 example 69 example 115

¹H-NMR (CDCl₃) δ: 0.14-0.34 (4H, m), 0.98-1.10 (3H, m), 1.18-1.37 (6H,m), 1.37-1.54 (3H, m), 1.54-1.74 (2H, m), 1.74-1.84 (2H, m), 1.84-2.03(2H, m), 2.03- 2.42 (12H, m), 2.46-2.57 (2H, m), 2.62-2.72 (1H, m),2.79-2.90 (1H, m), 3.01-3.20 (2H, m), 3.65-3.74 (1H, m), 3.74-3.85 (1H,m), 4.07-4.21 (1H, m), 4.55 (1H, d, J = 7.3 Hz), 4.92 (1H, dddd, J =63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 135 example 112 example 115

¹H-NMR (CDCl₃) δ: 0.58-0.72 (2H, m), 0.93-1.02 (2H, m), 1.29-1.54 (4H,m), 1.33 (3H, s), 1.55-1.84 (4H, m), 1.90-2.03 (2H, m), 2.03-2.21 (2H,m), 2.21-2.30 (2H, m), 2.30-2.50 (3H, m), 2.55-2.82 (3H, m), 3.00- 3.24(4H, m), 3.65-3.75 (2H, m), 4.08-4.27 (2H, m), 4.56 (1H, d, J = 9.2 Hz),4.92 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 136example 70 example 115

¹H-NMR (CDCl₃) δ: 0.52-0.66 (2H, m), 0.99-1.09 (2H, m), 1.16-1.36 (3H,m), 1.33 (3H, s), 1.36-1.53 (3H, m), 1.53-1.84 (5H, m), 1.84-2.03 (2H,m), 2.04-2.20 (2H, m), 2.21-2.31 (2H, m), 2.31-2.47 (5H, m), 2.47- 2.60(2H, m), 2.63-2.92 (4H, m), 3.04-3.19 (2H, m), 3.68-3.79 (2H, m),4.08-4.23 (1H, m), 4.49-4.62 (1H, m), 4.92 (1H, dddd, J = 63.6, 6.0,6.0, 3.6 Hz). Reference Reference 137 example 87 example 115

¹H-NMR (CDCl₃) δ: 0.13-0.33 (2H, m), 0.52-0.74 (2H, m), 0.90-1.14 (1H,m), 1.23-1.38 (5H, m), 1.38-1.55 (2H, m), 1.57-1.69 (2H, m), 1.69-1.87(2H, m), 1.87- 2.05 (4H, m), 2.10-2.27 (4H, m), 2.32-2.41 (2H, m),2.41-2.62 (4H, m), 2.62-2.73 (2H, m), 2.90-3.04 (2H, m), 3.04-3.17 (2H,m), 3.52-3.75 (2H, m), 4.06-4.23 (1H, m), 4.51-4.64 (1H, m), 4.92 (1H,dddd, J = 64.0, 6.0, 6.0, 3.6 Hz). Reference Reference 138 example 87example 8

¹H-NMR (CDCl₃) δ: 0.05-0.24 (2H, m), 0.44-0.63 (2H, m), 0.80-1.00 (1H,m), 1.13 (4H, d, J = 6.0 Hz), 1.17-1.23 (4H, m), 1.24-1.50 (5H, m),1.54-1.86 (4H, m), 1.86-1.99 (2H, m), 2.11-2.24 (4H, m), 2.24-2.45 (4H,m), 2.52-2.73 (2H, m), 2.82-2.96 (2H, m), 3.00- 3.16 (2H, m), 3.58-3.72(2H, m), 4.06-4.22 (1H, m), 4.55 (1H, d, J = 8.0 Hz). ReferenceReference 139 example 123 example 8

¹H-NMR (CDCl₃) δ: 1.01 (6H, d, J = 6.4 Hz), 1.16-1.24 (6H, m), 1.30 (3H,s), 1.54-1.70 (3H, m), 1.81-1.88 (2H, m), 2.09-2.31 (5H, m), 2.34-2.53(6H, m), 2.53- 2.63 (1H, m), 2.67-2.76 (2H, m), 3.04-3.18 (2H, m),3.62-3.72 (1H, m), 3.72-3.88 (2H, m), 4.19 (1H, dddd, J = 63.6, 6.0,6.0, 3.6 Hz), 4.68 (1H, d, J = 6.1 Hz). Reference Reference 140 example71 example 115

¹H-NMR (CDCl₃) δ: 0.57-0.64 (2H, m), 0.87-0.93 (2H, m), 1.10-1.53 (9H,m), 1.54-1.73 (4H, m), 1.74-1.84 (1H, m), 1.84-1.91 (1H, m), 1.91-2.11(2H, m), 2.11- 2.30 (7H, m), 2.31-2.40 (1H, m), 2.45-2.55 (2H, m),2.55-2.69 (3H, m), 2.80-2.87 (1H, m), 3.02-3.19 (2H, m), 3.65-3.83 (2H,m), 4.06-4.21 (1H, m), 4.53 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz),4.83-5.00 (1H, m). Reference Reference 141 example 72 example 115

¹H-NMR (CDCl₃) δ: 0.00-0.06 (2H, m), 0.42-0.49 (2H, m), 0.72-0.83 (1H,m), 1.19-1.42 (3H, m), 1.31 (3H, s), 1.42-1.82 (13H, m), 1.89-2.02 (1H,m), 2.05-2.16 (1H, m), 2.16-2.28 (7H, m), 2.30-2.40 (1H, m), 2.51- 2.60(1H, m), 2.72-2.85 (1H, m), 2.99-3.09 (1H, m), 3.09-3.18 (1H, m),3.20-3.26 (1H, m), 3.36-3.41 (1H, m), 3.65-3.74 (1H, m), 3.77-3.85 (1H,m), 3.97-4.10 (1H, m), 4.67 (1H, d, J = 7.3 Hz), 4.90 (1H, dddd, J =63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 142 example 73 example 115

¹H-NMR (CDCl₃) δ: 0.01-0.22 (2H, m), 0.39-0.64 (2H, m), 0.77-0.97 (1H,m), 1.13-1.52 (6H, m), 1.52-1.87 (13H, m), 1.89-2.03 (1H, m), 2.03-2.72(10H, m), 3.01-3.32 (4H, m), 3.33-3.50 (1H, m), 3.60-3.72 (1H, m),3.74-3.87 (1H, m), 3.95-4.12 (1H, m), 4.65 (1H, d, J = 7.9 Hz), 4.91(1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 143 example113 example 115

¹H-NMR (CDCl₃) δ: 1.17-1.86 (18H, m), 1.88-2.20 (5H, m), 2.20-2.30 (2H,m), 2.30-2.42 (1H, m), 2.44-3.03 (3H, m), 3.04-3.24 (4H, m), 3.61-3.75(2H, m), 4.09- 4.28 (2H, m), 4.60 (1H, d, J = 9.2 Hz), 4.91 (1H, dddd, J= 63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 144 example 74 example115

¹H-NMR (CDCl₃) δ: 0.02-0.10 (2H, m), 0.44-0.52 (2H, m), 0.76-0.87 (1H,m), 1.24-1.52 (10H, m), 1.58-1.87 (5H, m), 1.89-2.01 (2H, m), 2.06-2.16(1H, m), 2.16- 2.30 (8H, m), 2.30-2.40 (1H, m), 2.46-2.79 (6H, m),3.03-3.19 (2H, m), 3.65-3.78 (2H, m), 4.02-4.16 (1H, m), 4.61 (1H, d, J= 7.3 Hz), 4.90 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). ReferenceReference 145 example 75 example 115

¹H-NMR (CDCl₃) δ: 0.05-0.19 (2H, m), 0.47-0.60 (2H, m), 0.83-0.98 (1H,m), 1.21-1.53 (10H, m), 1.53-2.03 (7H, m), 2.07-2.19 (1H, m), 2.19-2.66(13H, m), 2.68- 2.83 (2H, m), 3.03-3.15 (2H, m), 3.62-3.80 (2H, m),4.01-4.18 (1H, m), 4.59 (1H, d, J = 7.9 Hz), 4.91 (1H, dddd, J = 63.6,6.0, 6.0, 3.6 Hz). Reference Reference 146 example 120 example 115

¹H-NMR (CDCl₃) δ: 1.03 (6H, d, J = 6.7 Hz), 1.27-1.39 (5H, m), 1.39-1.51(1H, m), 1.52-1.83 (4H, m), 1.89- 2.13 (3H, m), 2.17-2.28 (2H, m),2.29-2.58 (7H, m), 2.58-2.69 (1H, m), 2.75-2.99 (7H, m), 2.99-3.09 (1H,m), 3.34-3.46 (2H, m), 4.35-4.49 (1H, m), 4.89 (1H, dddd, J = 63.6, 6.0,6.0, 3.6 Hz). Reference Reference 147 example 121 example 8

¹H-NMR (CD₃OD) δ: 0.86 (3H, s), 0.90 (3H, s), 1.01 (3H, d, J = 6.8 Hz),1.02 (3H, d, J = 6.8 Hz), 1.10- 1.33 (6H, m), 1.31 (3H, s), 1.35-1.49(2H, m), 1.55- 1.72 (3H, m), 1.84-1.93 (1H, m), 2.13-2.28 (3H, m),2.30-2.59 (8H, m), 2.66-2.75 (2H, m), 3.09-3.18 (2H, m), 3.28-3.35 (1H,m), 3.53 (1H, d, J = 11.6 Hz), 3.67-3.79 (2H, m). Reference Reference148 example 76 example 115

¹H-NMR (CDCl₃) δ: 1.15-1.30 (6H, m), 1.33 (3H, s), 1.37-1.57 (3H, m),1.57-1.85 (6H, m), 1.85-2.03 (3H, m), 2.11-2.30 (3H, m), 2.30-2.61 (4H,m), 3.10-3.22 (2H, m), 3.22-3.42 (1H, m), 3.47-3.68 (4H, m), 3.68- 3.77(1H, m), 3.77-3.84 (1H, m), 4.04-4.25 (1H, m) 4.91 (1H, dddd, J = 63.6,6.0, 6.0, 3.6 Hz). Reference Reference 149 example 77 example 115

¹H-NMR (CDCl₃) δ: 0.02-0.19 (2H, m), 0.44-0.59 (2H, m), 0.75-0.90 (1H,m), 1.12-1.28 (1H, m), 1.32 (3H, s), 1.40-1.55 (2H, m), 1.55-1.70 (3H,m), 1.70-1.82 (2H, m), 1.84-2.04 (4H, m), 2.08-2.29 (8H, m), 2.98- 3.20(4H, m), 3.46-3.56 (2H, m), 3.66-3.76 (2H, m), 4.08-4.23 (1H, m),4.59-4.73 (1H, m) 4.91 (1H, dddd, J = 64.0, 6.0, 6.0, 4.0 Hz). ReferenceReference 150 example 114 example 115

¹H-NMR (CDCl₃) δ: 1.32-1.55 (6H, m), 1.35 (3H, s), 1.58-1.86 (6H, m),1.91-2.11 (3H, m), 2.11-2.21 (1H, m), 2.22-2.31 (2H, m), 2.32-3.05 (6H,m), 3.06-3.24 (3H, m), 3.64-3.76 (2H, m), 4.08-4.28 (2H, m), 4.30- 4.35(2H, m), 4.44-4.51 (2H, m), 4.60 (1H, d, J = 8.5 Hz), 4.93 (1H, dddd, J= 63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 151 example 122 example115

¹H-NMR (CDCl₃) δ: 1.07 (6H, d, J = 5.5 Hz), 1.14-1.25 (6H, m), 1.31 (3H,s), 1.31-1.43 (2H, m), 1.43-1.79 (4H, m), 1.83-1.93 (1H, m), 2.13-2.26(4H, m), 2.26- 2.82 (12H, m), 3.01-3.16 (2H, m), 3.29-3.42 (1H, m),3.59-3.76 (2H, m), 5.80-6.06 (1H, brs). Reference Reference 152 example78 example 115

¹H-NMR (CDCl₃) δ: 0.90-1.12 (6H, m), 1.22-1.53 (7H, m), 1.54-2.05 (7H,m), 2.08-2.20 (1H, m), 2.20-2.29 (2H, m), 2.30-2.40 (1H, m), 2.48-3.04(10H, m), 3.04- 3.17 (2H, m), 3.66-3.80 (2H, m), 4.02-4.17 (1H, m), 4.72(1H, s), 4.90 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). ReferenceReference 153 example 125 example 115

¹H-NMR (CDCl₃) δ: 0.89-1.17 (6H, m), 1.33 (3H, s), 1.42-1.69 (6H, m),1.69-1.89 (2H, m), 1.91-2.04 (1H, m), 2.04-2.14 (1H, m), 2.14-2.82 (8H,m), 2.99-3.13 (2H, m), 3.28-3.77 (6H, m), 4.20-4.35 (1H, m), 4.68- 4.80(1H, m), 4.92 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz), 4.94 (1H, d, J =8.5 Hz). Reference Reference 154 example 88 example 115

¹H-NMR (CDCl₃) δ: 1.03-1.21 (6H, m), 1.35 (3H, s), 1.41-1.90 (8H, m),1.91-2.61 (11H, m), 2.61-2.71 (1H, m), 2.71-3.04 (4H, m), 3.05-3.21 (2H,m), 3.64-3.79 (2H, m), 4.11-4.27 (1H, m , 4.63 (1H, d, J = 9.8 Hz), 4.93(1H, dddd, J = 63.6, 6.0, 6.0, 3.6 Hz). Reference Reference 155 example126 example 115

¹H-NMR (CDCl₃) δ: 0.93-1.14 (6H, m), 1.33 (3H, s), 1.43-1.54 (1H, m),1.54-1.81 (5H, m), 1.82-2.32 (11H, m), 2.32-2.45 (2H, m), 2 71-2.85 (1H,m), 2.96-3.24 (6H, m), 3.66-3.82 (2H, m), 4.67-4.80 (1H, m), 4.92 (1H,dddd, J = 63.6, 6.0, 6.0, 3.6 Hz), 4.93 (1H, d, J = 9.2 Hz). ReferenceReference 156 example 124 example 115

¹H-NMR (CDCl₃) δ: 0.98-1.38 (10H, m), 1.40-1.78 (10H, m), 1.89-2.11 (3H,m), 2.16-2.32 (2H, m), 2.32-2.42 (1H, m), 2.43-3.44 (9H, m), 3.54-3.77(2H, m), 4.89- 5.26 (2H, m), 4.93 (1H, dddd, J = 63.6, 6.0, 6.0, 3.6Hz).

The chemical names of Example 82 to Example 155 are listed below.

Example 82:N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1R,2R)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 83:N-[(1R,6S)-2,2-difluoro-6-{[1-(propan-2-yl)piperidin-4-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 84:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[1-(propan-2-yl)piperidin-4-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamideExample 85:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[5-(propan-2-yl)-1,2,4-oxadiazol-3-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 86:N-{(1R,6S)-2,2-difluoro-6-[5-(propan-2-yl)-1,2,4-oxadiazol-3-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 87:N-[(1R,6S)-2,2-difluoro-6-{[3-(propan-2-yl)-1,2,4-thiadiazol-5-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 88:N-[(1R,6S)-2,2-difluoro-6-{[1-(propan-2-yl)-1H-pyrazol-4-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 89:N-[(1R,6S)-2,2-difluoro-6-{[1-(propan-2-yl)azetidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 90:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[1-(propan-2-yl)-1H-pyrazol-4-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamideExample 91:N-[(1R,6S)-6-{benzyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 92:N-[(1R,6S)-2,2-difluoro-6-{[2-(propan-2-yl)pyrimidin-4-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 93:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 94:N-{(1R,6S)-2,2-difluoro-6-[4-(2-methylpropyl)-1H-1,2,3-triazol-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 95:N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 96:N-[(1R,6S)-2,2-difluoro-6-{(3S)-3-[methyl(propan-2-yl)amino]pyrrolidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 97:4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 98:N-[(1R,6S)-2,2-difluoro-6-{[(1R,3S,5S)-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 99:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{(3S)-3-[methyl(propan-2-yl)amino]pyrrolidin-1-yl}cyclohexyl]-4-methylpiperidine-1-carboxamideExample 100:N-[(1R,6S)-2,2-difluoro-6-{[(1R,5S,8R)-3-(propan-2-yl)-3-azabicyclo[3.2.1]octan-8-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 101:N-[(1R,6S)-2,2-difluoro-6-{4-[(propan-2-yl)oxy]piperidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 102:4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamideExample 103:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-ethyl-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamideExample 104:N-[(1R,6S)-2,2-difluoro-6-{[(1R,5S,8S)-3-(propan-2-yl)-3-azabicyclo[3.2.1]octan-8-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 105:N-[(1R,6S)-2,2-difluoro-6-{[(1R,3R,5S)-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 106:N-[(1R,6S)-2,2-difluoro-6-{[(1R,5S,6S)-3-(propan-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 107:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(2-methylpropyl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 108:N-[(1R,6S)-2,2-difluoro-6-{[(3R,4R)-4-methoxy-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 109:N-[(1R,6S)-2,2-difluoro-6-{[4-methyl-1-(propan-2-yl)piperidin-4-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 110:N-{(1R,6S)-2,2-difluoro-6-[(2S)-2-methyl-4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 111:N-{(1R,6S)-2,2-difluoro-6-[(2R)-2-methyl-4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 112:N-[(1R,6S)-2,2-difluoro-6-{(3R)-3-[methyl(propan-2-yl)amino]pyrrolidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 113:N-[(1R,6S)-2,2-difluoro-6-{methyl[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 114:N-[(1R,6S)-2,2-difluoro-6-{4-[methyl(propan-2-yl)amino]piperidin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 115:N-[(1R,6S)-6-{(3S)-3-[cyclopropyl(methyl)amino]pyrrolidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 116:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(2-methylpropyl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamideExample 117:N-[(1R,6R)-2,2-difluoro-6-{[4-(propan-2-yl)piperazin-1-yl]methyl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 118:N-[(1R,6S)-6-{[(3S)-1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 119:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-6-{[(3S)-1-(2,2-dimethylpropyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-methylpiperidine-1-carboxamideExample 120:N-[(1R,6S)-6-{[(3S)-1-(2,2-dimethylpropyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 121:N-[(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-methylcyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 122:N-[(1R,6S)-6-{[(3S)-1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamideExample 123:N-[(1R,6S)-2,2-difluoro-6-{methyl[1-(propan-2-yl)piperidin-4-yl]amino}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 124:N-{(1R,6S)-2,2-difluoro-6-[4-(pyrrolidin-1-yl)piperidin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 125:N-{(1R,6S)-2,2-difluoro-6-[5-(propan-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 126:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-methylcyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-methylpiperidine-1-carboxamideExample 127:N-{(1R,6S)-2,2-difluoro-6-[2-(propan-2-yl)-2,8-diazaspiro[4.5]decan-8-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 128:N-[(1R,6S)-2,2-difluoro-6-{(3S)-3-[methyl(2-methylpropyl)amino]pyrrolidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 129:N-{(1R,6S)-6-[4-(diethylamino)piperidin-1-yl]-2,2-difluorocyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 130:N-[(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-methylcyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamideExample 131:N-[(1R,6S)-2,2-difluoro-6-{4-methyl-4-[methyl(propan-2-yl)amino]piperidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 132:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazine-1-carbonyl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 133:N-[(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-fluorocyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 134:N-[(1R,6S)-2,2-difluoro-6-(4-{methyl[(1-methylcyclopropyl)methyl]amino}piperidin-1-yl)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 135:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-{[1-(trifluoromethyl)cyclopropyl]methyl}pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 136:N-[(1R,6S)-2,2-difluoro-6-(4-{[(1-fluorocyclopropyl)methyl](methyl)amino}piperidin-1-yl)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 137:N-[(1R,6S)-6-{(3S)-3-[(cyclopropylmethyl)(methyl)amino]pyrrolidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 138:N-[(1R,6S)-6-{(3S)-3-[(cyclopropylmethyl)(methyl)amino]pyrrolidin-1-yl}-2,2-difluorocyclohexyl]-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamideExample 139:rac-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,2R,6S)-2-fluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 140:N-{(1R,6S)-2,2-difluoro-6-[4-(methyl{[1-(trifluoromethyl)cyclopropyl]methyl}amino)piperidin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 141:N-[(1R,6S)-6-{(1R,3R,5S)-3-[(cyclopropylmethyl)(methyl)amino]-8-azabicyclo[3.2.1]octan-8-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 142:N-[(1R,6S)-6-{(1R,3S,5S)-3-[(cyclopropylmethyl)(methyl)amino]-8-azabicyclo[3.2.1]octan-8-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 143:N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(2-fluoro-2-methylpropyl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 144:N-[(1R,6S)-6-{(4S)-4-[(cyclopropylmethyl)(methyl)amino]azepan-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 145:N-[(1R,6S)-6-{(4R)-4-[(cyclopropylmethyl)(methyl)amino]azepan-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 146:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N,4-dimethylpiperidine-1-carboxamideExample 147:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1S,6S)-2,2-dimethyl-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamideExample 148:N-[(1R,6S)-2,2-difluoro-6-{3-[methyl(propan-2-yl)amino]azetidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 149:N-[(1R,6S)-6-{3-[(cyclopropylmethyl)(methyl)amino]azetidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 150:N-[(1R,6S)-2,2-difluoro-6-({(3S)-1-[(3-methyloxetan-3-yl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 151:rac-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methyl-N-{(1S,2S)-2-[4-(propan-2-yl)piperazin-1-yl]cycloheptyl}piperidine-1-carboxamideExample 152:N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)-1,4-diazepan-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 153:(1S,2R)-3,3-difluoro-2-[(4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carbonyl)amino]cyclohexyl4-(propan-2-yl)piperazine-1-carboxylate Example 154:N-[(1S,6S)-2,2-difluoro-6-{[1-(propan-2-yl)piperidin-4-yl]sulfanyl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 155:N-{(1S,6S)-2,2-difluoro-6-[1-(propan-2-yl)piperidine-4-sulfonyl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

The compound of the above Reference example 124 which is adiastereomixture and its intermediates for preparing the compound can beobtained as a sole enantiomer by optical resolution with chiral columnchromatography or by crystallization with an acid having a chiralcenter. In addition, the compound of Reference example 124 can be alsoprepared as a sole enantiomer by using optically-active epoxide as astarting material. Thus, when Reference example 124 as a startingMaterial A is further determined through separation or asymmetricsynthesis, the diastereomixture of Example 156 can be prepared as eachdiastereomer.

In addition, the compound of Example 156 which is a diastereomixture canbe obtained as a sole enantiomer by optical resolution with chiralcolumn chromatography or by crystallization with an acid having a chiralcenter. Thus, the two diastereomers of Example 156 can be separated aseach diastereomer.

The compound of Example 156 is a diastereomixture comprising twodifferent diastereomers. These diastereomers can be separated throughits process or by optical resolution with chiral column chromatography.It means that the two different diastereomers were substantiallyprepared.

Chemical structure of No. diastereomer Chemical name 156-A

4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4- oxadiazol-3-yl}-N-{(1R,2S,6S)-2-fluoro-6-[4- (propan-2-yl)piperazin-1- yl]cyclohexyl}-4-methylpiperidine-1- carboxamide 156-B

4-{5-[(1S,2S)-2- fluorocyclopropyl]-1,2,4- oxadiazol-3-yl}-N-{(1S,2R,6R)-2-fluoro-6-[4- (propan-2-yl)piperazin-1- yl]cyclohexyl}-4-methylpiperidine-1- carboxamide

Examples 157-160

The compounds of Examples 157-160 shown in the table below were preparedaccording to the process in Example 17 by using the compound ofReference example 80 and each appropriate commercial aldehyde or ketonecompound.

Exam- ple Chemical structure Spectral data 157

¹H-NMR (CDCl₃) δ: 0.84 (6H, d, J = 6.0 Hz), 1.18-1.35 (4H, m), 1.35-1.54(3H, m), 1.60-1.84 (8H, m), 1.83-2.04 (2H, m), 2.04-2.31 (11H, m),2.31-2.41 (1H, m), 2.45-2.56 (1H, m), 2.61-2.71 (1H, m), 2.77-2.87 (1H,m), 3.01-3.20 (2H, m), 3.65-3.75 (1H, m), 3.75-3.86 (1H, m), 4.06-4.22(1H, m), 4.55 (1H, d, J = 8.0 Hz), 4.91 (1H, ddd, J = 63.6, 6.0, 6.0,3.6 Hz). 158

¹H-NMR (CDCl₃) δ: 0.06-0.13 (2H, m), 0.47-0.55 (2H, m), 0.80-0.91 (1H,m), 1.19-1.36 (6H, m), 1.36-1.53 (4H, m), 1.53-1.84 (3H, m), 1.84-2.03(2H, m) , 2.04-2.21 (2H, m), 2.21-2.45 (10H, m), 2.46-2.58 (2H, m),2.64-2.71 (1H, m), 2.81-2.89 (1H, m), 3.04-3.19 (2H, m), 3.67-3.79 (2H,m), 4.07-4.22 (1H, m), 4.55 (1H, d, J = 7.9 Hz), 4.92 (1H, dddd, J =63.6, 6.0, 6.0, 3.6 Hz). 159

¹H-NMR (CDCl₃) δ: 1.15-1.35 (5H, m), 1.35-1.53 (3H, m), 1.53-1.74 (4H,m), 1.74-2.21 (14H, m), 2.21-2.30 (2H, m), 2.30-2.43 (2H, m), 2.44-2.57(2H, m, 2.61-2.72 (1H, m), 2.74-2.88 (1H, m), 3.00-3.20 (3H, m),3.65-3.82 (2H, m), 4.05-4.21 (1H, m), 4.54 (1H, d, J = 8.0 Hz), 4.91(1H, dddd, J = 64.0, 6.0, 6.0, 3.6 Hz). 160

¹H-NMR (CDCl₃) δ: 1.08-1.83 (16H, m), 1.84-2.03 (3H, m), 2.07-2.43 (9H,m), 2.45-2.76 (5H, m), 2.86-2.98 (1H, m), 3.06-3.20 (2H, m), 3.62-3.77(2H, m), 4.08-4.23 (1H, m), 4.53 (1H, d, J = 7.9 H), 4.93 (1H, dddd, J =63.6, 6.0, 6.0, 3.6 Hz).

The chemical names of Example 157 to Example 160 are listed below.

Example 157:N-[(1R,6S)-2,2-difluoro-6-{4-[methyl(2-methylpropyl)amino]piperidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 158:N-[(1R,6S)-6-{4-[(cyclopropylmethyl)(methyl)amino]piperidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 159:N-[(1R,6S)-6-{4-[cyclobutyl(methyl)amino]piperidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 160:N-[(1R,6S)-6-{4-[ethyl(methyl)amino]piperidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamideExample 161N-[(1R,6S)-2,2-Difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

To a mixture of Reference example 90 (175 mg) and ethanol (1.3 mL) wasadded palladium carbon (6.4 mg) at room temperature, and the mixture wasstirred under hydrogen atmosphere. After the reaction was terminated asjudged by LC-MS, the reaction mixture was filtrated with Celite, andconcentrated in vacuo. Then, the obtained residue was purified by HPLC(eluate: acetonitrile/water/TFA) to give the title compound (44.1 mg).

¹H-NMR (CDCl₃) δ: 1.03-1.31 (2H, m), 1.13 (6H, d, J=6.0 Hz), 1.34 (3H,s), 1.38-1.88 (13H, m), 1.91-2.23 (3H, m), 2.27 (2H, d, J=13.2 Hz),2.33-2.42 (1H, m), 2.42-2.54 (1H, m), 2.95-3.21 (2H, m), 3.32-3.54 (1H,brs), 3.58-3.80 (2H, m), 3.91-4.08 (1H, m), 4.65 (1H, d, J=9.2 Hz), 4.93(1H, dddd, J=63.6, 6.4, 6.4, 4.0 Hz).

Reference Example 1rac-(1S,2S)-2-[4-(Propan-2-yl)piperazin-1-yl]cyclohexan-1-amine

Step (i):

To a mixture of Compound 1 (1.13 g) and dichloromethane (2 mL) was added1-isopropylpiperazine (1.14 g) at room temperature, and the mixture wasstirred for 17 hours. After the reaction was terminated as judged by theconsumption of the starting material, diethyl ether was added to thereaction mixture. The precipitate was removed by filtration, and thefiltrate was concentrated in vacuo to give a crude product. The obtainedcrude product was purified by amino silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound 2 (1.82 g).

LCMS: [M+H]⁺/Rt (min): 256/0.48

Step (ii):

To a mixture of Compound 2 (1.14 g), acetic acid (2.04 mL), and ethanol(15 mL) was added palladium/carbon (0.95 g) at room temperature, and themixture was stirred under hydrogen atmosphere for 18 hours. After thereaction was terminated as judged by LC-MS, the reaction mixture wasfiltrated with Celite, and concentrated in vacuo. Then, the obtainedresidue was purified by amino silica gel column chromatography (eluate:chloroform) to give the title compound 3 (0.370 g).

LCMS: [M+H]⁺/Rt (min): 226/0.31

Reference Example 2rac-4-(4-Methylphenyl)-N-[(1S,2S)-2-(piperazin-1-yl)cyclohexyl]piperidine-1-carboxamidedihydrochloride

Step (i):

The title compound 4 (1.28 g) was prepared in the same manner as Step(i) in Reference example 1 by using Compound 1 (1.17 g) and1-Boc-piperazine (1.72 g).

Step (ii):

To a solution of Compound 4 (593 mg) in ethanol (9 mL) was addedpalladium hydroxide (266 mg) at room temperature, and the mixture wasstirred under hydrogen atmosphere. After the reaction was terminated asjudged by LC-MS, the reaction mixture was filtrated with Celite, and thefiltrate was concentrated in vacuo to give the title compound 5 (560mg).

Step (iii):

To a mixture of Compound 5 (370 mg), triethylamine (0.91 mL), anddichloromethane (5 mL) was added 4-nitrophenyl chloroformate (316 mg) at0° C., and the mixture was stirred for 2 hours. Then,4-(4-methylphenyl)piperidine (297 mg) was added to the reaction mixtureat 0° C., and the stirring was continued at room temperature. After thereaction was terminated as judged by the consumption of the reactionintermediate, water was added to the reaction mixture, and the mixturewas extracted with chloroform. The organic layer was dried overanhydrous sodium sulfate and concentrated in vacuo, and then theobtained residue was purified by amino silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound 6 (435 mg).

Step (iv):

To a mixture of Compound 6 (430 mg) and chloroform (3 mL) was addedhydrogen chloride/dioxane solution (4 M, 2.22 mL) at 0° C., and themixture was stirred for 16 hours. Then, the reaction mixture wasconcentrated in vacuo to give the title compound 7 (310 mg).

LCMS: [M+H]⁺/Rt (min): 385/0.71

Reference Example 3rac-(1R,2S)-2-(4-Ethylpiperazin-1-yl)cyclohexan-1-amine

Step (i):

To a mixture of Compound 8 (312 mg) and acetic acid (5 mL) was addedplatinum(IV) oxide (86 mg), and mixture was stirred at 70° C. underhydrogen atmosphere for 6 hour. Then, the reaction mixture was filtratedwith Celite, and the filtrate was concentrated in vacuo to give a crudeproduct. The obtained crude product was purified by amino silica gelcolumn chromatography (eluate: hexane/ethyl acetate) to give the titlecompound 9 (9 mg).

LCMS: [M+H]⁺/Rt (min): 212/0.15

Reference Example 4rac-(1R,2S,6S)-2-Methoxy-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-aminetrihydrochloride

Step (i):

The title compound 11 (424 mg) was prepared in the same manner as Step(i) in Reference example 3 by using Compound (407 mg).

LCMS: [M+H]⁺/Rt (min): 146/0.15

Step (ii):

To a mixture of Compound 11 (424 mg), triethylamine (1.22 mL), andacetonitrile (10 mL) was added Boc₂O (765 mg) at room temperature, andthe mixture was stirred at room temperature. After the reaction wasterminated as judged by LC-MS, water was added to the reaction mixtureand the mixture was extracted with ethyl acetate. The organic layer wasdried over anhydrous sodium sulfate and concentrated in vacuo, and thenthe obtained residue was purified by silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound 12 (310 mg).

LCMS: [M+H]⁺/Rt (min): 246/0.78

Step (iii):

To a mixture of Compound 12 (141 mg), triethylamine (0.160 mL), and THF(3 mL) was added ethanesulfonyl chloride (0.160 mL) under icetemperature, and the mixture was warmed to room temperature and thestirring was continued. After the reaction was terminated as judged byLC-MS, water was added to the reaction mixture, and the mixture wasextracted with chloroform. The organic layer was dried over anhydroussodium sulfate and concentrated in vacuo, and then the obtained residuewas purified by silica gel column chromatography (eluate: hexane/ethylacetate) to give the title compound 13 (180 mg).

LCMS: [M+H]⁺/Rt (min): 338/0.86

Step (iv):

To a mixture of Compound 13 (155 mg), 1-isopropylpiperazine (236 mg),and 1,4-dioxane (4 mL) was added potassium carbonate (76 mg) at roomtemperature, and the mixture was stirred for 13 hours heating at 150° C.with a microwave device. Then, water was added to the reaction mixture,and the mixture was extracted with chloroform. The organic layer wasdried over anhydrous sodium sulfate and concentrated in vacuo, and thenthe obtained residue was purified by amino silica gel columnchromatography (eluate: hexane/ethyl acetate) to give the title compound14 (17 mg).

LCMS: [M+H]⁺/Rt (min): 356/0.81

Step (v):

The title compound 15 (16.8 mg) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound 14 (16.3 mg).

LCMS: [M+H]⁺/Rt (min): 256/0.32

Reference Example 5rac-(1S,2S)-2-[4-(Propan-2-yl)piperazin-1-yl]cyclopentane-1-amine

Step (i):

To a mixture of Compound 16 (315 mg), triethylamine (0.289 mL), and THF(5 mL) was added ethanesulfonyl chloride (0.15 mL), and the mixture wasstirred at room temperature for 15 hours. After the reaction wasterminated as judged by the consumption of the starting material, waterwas added to the reaction mixture, and the mixture was extracted withchloroform. The organic layer was dried over anhydrous sodium sulfateand concentrated in vacuo, and then the obtained residue was purified byamino silica gel column chromatography (eluate: ethyl acetate/hexane) togive the title compound 17 (140 mg).

LCMS: [M+H]⁺/Rt (min): 230/0.44

Step (ii):

To a mixture of Compound 17 (136 mg) and DMF (4 mL) was added sodiumazide (77 mg), and the mixture was stirred at 80° C. for 3.5 hours.After the reaction was terminated as judged by the consumption of thestarting material, water was added to the reaction mixture, and themixture was extracted with chloroform. The organic layer was dried overanhydrous sodium sulfate, and concentrated in vacuo to give the titlecompound 18 (137 mg).

LCMS: [M+H]⁺/Rt (min): 238/0.42

Step (iii):

To a mixture of Compound 18 (42.4 mg), hydrogen chloride/ethyl acetatesolution (4.0 M, 0.711 mL), and ethanol (2.8 mL) was addedpalladium/carbon (202 mg), and the mixture was stirred under hydrogenatmosphere for 8 hours. After the reaction was terminated as judged byLC-MS, methanol and aqueous sodium bicarbonate were added to thereaction mixture, and the mixture was filtrated with Celite andextracted with chloroform/methanol (6/1). The organic layer was driedover anhydrous sodium sulfate and concentrated in vacuo, and then theobtained residue was purified by amino silica gel column chromatography(eluate: chloroform/methanol) to give the title compound 19 (98.7 mg).

LCMS: [M+H]⁺/Rt (min): 212/0.15

Reference Example 6rac-(1R,6S)-2,2-Difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-ol

Step (i):

To a mixture of Compound 20 (688 mg) and ethanol (20 mL) was added1-isopropylpiperazine (723 mg) at room temperature, and the mixture wasstirred for 9 hours heating at 80° C. The reaction mixture was cooled toroom temperature, and then concentrated in vacuo. And, the obtainedresidue was purified by amino silica gel column chromatography (eluate:hexane/ethyl acetate) to give the title compound 21 (830 mg).

LCMS: [M+H]⁺/Rt (min): 263/0.35

Reference Example 7rac-(1R,2S)-3,3-Difluoro-2-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-amine

Step (i):

To a mixture of DMSO (0.081 mL) and dichloromethane (2 mL) was addedoxalyl chloride (0.075 mL) at −78° C., and the mixture was stirred for20 minutes. Then, a solution of Compound 21 (150 mL) in dichloromethane(2 mL) was added to the reaction mixture, and the mixture was stirred at−78° C. further for 30 minutes. Triethylamine (0.398 mL) was added tothe reaction mixture, and the the mixture was warmed to 0° C. Then, themixture was stirred for 30 minutes, and sodium borohydride was addedthereto. The mixture was stirred for 30 minutes. And, water was added tothe reaction mixture, and the mixture was extracted with chloroform. Theorganic layer was dried over anhydrous sodium sulfate, concentrated invacuo, and then the obtained residue was purified by silica gel columnchromatography (eluate: chloroform/methanol) to give the title compound22 (27 mg).

LCMS: [M+H]⁺/Rt (min): 263/0.38

Step (i):

To a mixture of Compound 22 (27 mg), triethylamine (0.029 mL), and THF(2 mL) was added ethanesulfonyl chloride (0.015 mL), and the mixture wasstirred at room temperature. After the reaction was terminated as judgedby the consumption of the starting material, water was added to thereaction mixture, and the mixture was extracted with chloroform. Theorganic layer was dried over anhydrous sodium sulfate and concentratedin vacuo, and then the obtained residue was purified by amino silica gelcolumn chromatography (eluate: chloroform/methanol) to give the titlecompound 23 (23 mg).

LCMS: [M+H]⁺/Rt (min): 354/0.65

Step (iii):

The title compound 24 (16.0 mg) was prepared in the same manner as Step(ii) in Reference example 5 by using Compound 23 (23.4 mg).

LCMS: [M+H]⁺/Rt (min): 288/0.60

Step (iv):

To a mixture of Compound 24 (14 mg), THF (1 mL), and water (1 mL) wasadded triphenylphosphine (25.6 mg) at room temperature, and the mixturewas stirred for 4.5 hours heating at 50° C. Then, the reaction mixturewas cooled to room temperature, and aqueous hydrochloric acid was addedthereto. The mixture was washed with ethyl acetate, and aqueous sodiumbicarbonate was added to the aqueous layer. The obtained mixture wasextracted with chloroform/methanol (3/1). The organic layer was driedover anhydrous sodium sulfate, and concentrated in vacuo to give thetitle compound 25 (7.8 mg).

LCMS: [M+H]⁺/Rt (min): 262/0.31

Reference Example 84-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidinemonohydrochloride

Step (i):

To a solution of Compound 26 (50.0 g) in ethanol (446 mL) was added 50%aqueous hydroxylamine (132 mL), and the mixture was stirred at 70° C.for 8 hours. The reaction mixture was cooled to room temperature, andwater (892 mL) was added to the reaction mixture. The mixture wasstirred at room temperature for 30 minutes. The precipitated whitecrystal was collected on a filter, the obtained crystal was suspended inwater (344 mL) again, and the suspension was stirred at room temperaturefor 30 minutes. The precipitated white solid was collected on a filterand dried to give the title compound 27 (52.3 g).

LCMS: [M+H]⁺/Rt (min): 258/0.52 (Method C)

Step (ii):

To a mixture of Compound 27 (52.3 g), cyclopropanecarboxylic acid (18.4g), HATU (85 g), and THF (406 mL) in ice bath was added slowly dropwisetriethylamine (142 mL), and the mixture was stirred at room temperaturefor 12 hours. To the reaction mixture was added ethyl acetate (406 mL),and the mixture was washed with water (406 mL) and brine (406 mL). Theorganic layer was dried over anhydrous sodium sulfate, concentrated invacuo, and then the obtained residue was purified by silica gel columnchromatography (eluate: hexane/ethyl acetate) to give the title compound28 (59.1 g).

LCMS: [M+H]⁺/Rt (min): 326/0.77 (Method C)

Step (iii):

A mixture of Compound 28 (59.1 g), DBU (54.2 mL), and toluene (727 mL)was stirred under reflux for one hour. The reaction mixture was cooledto room temperature, and washed with water (727 mL). The organic layerwas concentrated in vacuo, and then the obtained residue was purified bysilica gel column chromatography (eluate: hexane/ethyl acetate) to givethe title compound 29 (54.5 g).

LCMS: [M+H]⁺/Rt (min): 308/1.11

Step (iv):

The title compound 30 (35.3 g) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound 29 (54.5 g).

LCMS: [M+H]⁺/Rt (min): 208/0.30 (Method C)

Reference Examples 9 to 12′

The compounds of Reference examples 9 to 12′ shown in the table belowwere prepared according to the process in the above Reference example 8,by using each appropriate starting compound instead ofcyclopropanecarboxylic acid at Step (ii) in Reference example 8.

Instrumental Reference Starting analytical example compound Chemicalstructure data  9

LCMS: [M + H]⁺/Rt (min): 196/0.32 (Method C) 10

LCMS: [M + H]⁺/Rt (min): 218/0.44 11

LCMS: [M + H]⁺/Rt (min): 226/0.29 (Method C) 12

LCMS: [M + H]⁺/Rt (min): 222/0.46 (Method C) 12′

LCMS: [M + H]⁺/Rt (min): 222/0.46 (Method C)

Reference Example 9: 4-(5-ethyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidinemonohydrochloride Reference Example 10:4-[5-(difluoromethyl)-1,2,4-oxadiazol-3-yl]-4-methylpiperidinemonohydrochloride Reference Example 11:4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidinemonohydrochloride Reference Example 12:4-methyl-4-{5-[(1R,2S)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidinemonohydrochloride Reference Example 12′:4-methyl-4-{5-[(1S,2R)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidinemonohydrochloride Reference Example 13

rac-tert-Butyl4-(6-{[4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carbonyl]amino}cyclohex-1-en-1-yl)-3,6-dihydropyridine-1(2H)-carboxylate

Step (i):

To a mixture of Compound 35 (192 mg), cerium(III) chloride heptahydrate(309 mg), and methanol (3 mL) was added sodium borohydride (51.4 mg)under ice temperature, and the mixture was stirred at the sametemperature for 3 hours. To the reaction mixture was added aqueoussodium bicarbonate, and the mixture was extracted withchloroform/methanol (6/1). The organic layer was dried over anhydroussodium sulfate and concentrated in vacuo, and then the obtained residuewas purified by silica gel column chromatography (eluate: hexane/ethylacetate) to give the title compound 36 (120 mg).

LCMS: [M+H]⁺/Rt (min): 280/0.97

Step (ii):

To a mixture of Compound 36 (115 mg), triethylamine (0.143 mL), and THF(2 mL) was added ethanesulfonyl chloride (0.058 mL) under icetemperature, and the mixture was stirred for 30 minutes. Then, sodiumazide (107 mg) was added to the reaction solution. The mixture waswarmed to room temperature, and then the mixture was stirred. After thereaction was terminated as judged by the consumption of the reactionintermediate, water was added to the reaction mixture, and the mixturewas extracted with chloroform. The organic layer was dried overanhydrous sodium sulfate and concentrated in vacuo, and then theobtained residue was purified by silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound 37 (80 mg).

LCMS: [M+H]⁺/Rt (min): 305/1.25

Step (iii)

The title compound 38 (35 mg) was prepared in the same manner as Step(iv) in Reference example 7 by using Compound (73 mg).

LCMS: [M+H]⁺/Rt (min): 279/0.74

Step (iv)

The title compound 39 (14.0 mg) was prepared in the same manner as Step(iii) in Reference example 2 by using Compound 38 (14.4 mg).

LCMS: [M+H]⁺/Rt (min): 512/1.14

Reference Example 14rac-(1R,6S)-2,2-Difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-aminetrihydrochloride

Step (i):

The title compound 41 (1.59 g) was prepared in the same manner as Step(ii) in Reference example 4 by using Compound 40 (1.69 g).

LCMS: [M+H]⁺/Rt (min): 252/0.73

Step (ii):

To a mixture of Compound 41 (1.5 g) and THF (30 mL) was added potassiumtert-butoxide (1.01 g) under ice temperature, and the mixture wasstirred at the same temperature for 20 minutes. Then, tosyl chloride(1.37 g) was added to the reaction mixture under ice temperature, andthe reaction mixture was stirred further for 2.5 hours. Water was addedto the reaction mixture under ice temperature, and the mixture wasextracted with chloroform. The organic layer was dried over anhydroussodium sulfate, and concentrated in vacuo. The obtained residue wasdissolved in 1,4-dioxane (30 mL), and tosyl chloride (1.37 g) was addedto the solution under ice temperature. The solution was heated to 100°C. and stirred for 30 minutes. The reaction solution was cooled to roomtemperature, and aqueous ammonium chloride was added to the reactionsolution. The mixture was extracted with chloroform/ethanol (3/1). Theorganic layer was dried over anhydrous sodium sulfate and concentratedin vacuo, and then the obtained residue was purified by silica gelcolumn chromatography (eluate: hexane/ethyl acetate) to give the titlecompound 42 (1.09 g).

LCMS: [M+H]⁺/Rt (min): 234/1.01

Step (iii):

A mixture of Compound 42 (1.09 g), 1-isopropylpiperazine (0.899 g), andethanol (10 mL) was stirred for 8 hours heating at 120° C. with amicrowave device. Then, the reaction solution was concentrated in vacuo,and then the obtained residue was purified by amino silica gel columnchromatography (eluate: ethyl acetate/hexane) to give the title compound43 (1.32 g).

LCMS: [M+H]⁺/Rt (min): 362/0.74

Step (iv):

The title compound 44 (1.40 g) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound (1.31 g).

LCMS: [M+H]⁺/Rt (min): 262/0.19

Reference Examples 15 to 17

The compounds of Reference examples 15 to 17 shown in the table belowwere prepared according to the process in the above Reference example14, by using an optically active isomer of Compound 40 (as Material A)instead of Compound 40 at Step (i) in Reference example 14 and eachappropriate starting compound (as Material B) instead of1-isopropylpiperazine at Step (iii) in Reference example 14.

Instrumental Reference Material Material Chemical analytical example A Bstructure data 15

LCMS: [M + H]⁺/Rt (min): 262/0.19 15′

LCMS: [M + H]⁺/Rt (min): 262/0.19 (Method C) 16

LCMS: [M + H]⁺/Rt (min): 274/0.242 17

LCMS: [M + H]⁺/Rt (min): 288/0.239

Reference Example 15:(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-aminetrihydrochloride Reference Example 15′:(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-amineReference Example 16:(1R,6S)-2,2-difluoro-6-[6-(propan-2-yl)-3,6-diazabicyclo[3.1.1]heptan-3-yl]cyclohexan-1-amineReference Example 17:(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexan-1-amineReference Example 18(1R,6S)-2,2-Difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-amine

Step (i):

To a mixture of Compound 48 (5.94 g), sodium bicarbonate (13.2 g), andTHF (131 mL) was added 2-nitrobenzenesulfonyl chloride (10.5 g) at roomtemperature, and the mixture was stirred at the same temperature for 16hours. To the reaction mixture was added aqueous sodium bicarbonate, andthe mixture was extracted with chloroform. The organic layer was driedover anhydrous sodium sulfate and concentrated in vacuo. The obtainedresidue was dissolved in THF (131 mL), and triethylamine (11 mL) andmethanesulfonyl chloride (3.67 mL) were added to the solution under icetemperature. The mixture was stirred. After the reaction was terminatedas judged by the consumption of the starting material, water was addedto the reaction mixture, and the mixture was extracted with chloroform.The organic layer was dried over anhydrous sodium sulfate, andconcentrated in vacuo. The obtained residue was dissolved inacetonitrile (393 mL), and potassium carbonate (16.3 mg) was added tothe solution. The mixture was stirred for one hour heating at 80° C. Tothe reaction mixture was added water, and the mixture was extracted withchloroform. The organic layer was dried over anhydrous sodium sulfateand concentrated in vacuo, and then the obtained residue was purified bysilica gel column chromatography (eluate: hexane/ethyl acetate) to givethe title compound 49 (9.25 g).

LCMS: [M+H]⁺/Rt (min): 319/0.94

Step (ii):

A mixture of Compound 49 (7.1 g), 1-isopropylpiperazine (3.56 mL), andtoluene (22.3 mL) was stirred for one hour heating at 110° C. After thereaction was terminated as judged by the consumption of the startingmaterial, the reaction mixture was concentrated in vacuo, and theobtained residue was purified by amino silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound 50 (9.79 g).

LCMS: [M+H]⁺/Rt (min): 447/0.68

Step (iii):

To a mixture of benzenethiol (0.530 mL) and toluene (11.2 mL) was addedsodium hydride (55%, 0.215 g) under ice temperature, and the mixture waswarmed to room temperature and stirred for 10 minutes. Then, to thereaction mixture was added a solution of Compound 50 (1 g) in toluene (9mL), and the mixture was stirred heating at 60° C. After the reactionwas terminated as judged by the consumption of the starting material,the reaction solution was cooled to 0° C., and 40% aqueous sodiumhydroxide was added to the reaction mixture. The mixture was extractedwith toluene. To the organic layer was added 5 M hydrochloric acid underice temperature, and the aqueous layer was extracted from the mixture.To the obtained aqueous layer was added 40% aqueous sodium hydroxide,and the obtained mixture was again extracted with toluene. The organiclayer was dried over anhydrous sodium sulfate and concentrated in vacuo,and then the obtained residue was purified by amino silica gel columnchromatography (eluate: hexane/ethyl acetate) to give the title compound51 (0.47 g).

LCMS: [M+H]⁺/Rt (min): 262/0.17

Reference Example 192-(4-Methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1,3-benzoxazole

Step (i):

A mixture of Compound 52 (120 mg), 2-chlorocyclohexanone (68.9 mg), andDMF (1.5 mL) was stirred for 11 hours heating at 130° C. with amicrowave device. Then, to the reaction solution was added hydrogenchloride/1,4-dioxane solution (0.25 mL), and the mixture was stirred forhours heating at 130° C. with a microwave device. The reaction solutionwas concentrated in vacuo, and the obtained residue was dissolved inethanol. 15% Aqueous sodium hydroxide (2 mL) was added to the solution,and the mixture was stirred for 3 hours heating at 150° C. with amicrowave device. To the reaction mixture was added water, and themixture was extracted with chloroform. The organic layer was dried overanhydrous sodium sulfate and concentrated in vacuo, and then theobtained residue was purified by amino silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound 53 (14 mg).

LCMS: [M+H]⁺/Rt (min): 221/0.57

Reference Example 204-(5-Cyclopropyl-1,2-oxazol-3-yl)-4-methylpiperidine monohydrochloride

Step (i):

To a mixture of Compound 54 (900 mg), sodium acetate (650 mg), andmethanol (5 mL) was added hydroxylamine hydrochloride (550 mg), and themixture was stirred at room temperature for 24 hours. The reactionsolution was cooled to 0° C., and water was added thereto. The mixturewas extracted with chloroform, and the organic layer was dried overanhydrous sodium sulfate and concentrated in vacuo to give the titlecompound 55 (1.23 g).

Step (ii):

To a mixture of Compound 55 (416 mg) and DMF (4 mL) was addedN-chlorosuccinimide (252 mg), and the mixture was stirred for 3 hours.The reaction solution was cooled to 0° C., and water (6 mL) was addedthereto. The precipitated solid was collected on a filter, and dried togive the title compound 56 (326 mg).

Step (iii):

To a mixture of ethynylcyclopropane (117 mg) and toluene (5 mL) wereadded Compound 56 (326 mg) and sodium bicarbonate (198 mg), and themixture was stirred at room temperature. After the reaction wasterminated as judged by the consumption of the starting material, waterwas added to the reaction mixture and the mixture was extracted withethyl acetate. The organic layer was dried over anhydrous sodiumsulfate, and concentrated in vacuo. Then, the obtained residue waspurified by silica gel column chromatography (eluate: hexane/ethylacetate) to give the title compound 57 (348 mg).

LCMS: [M+H]⁺/Rt (min): 307/1.13

Step (iv):

The title compound 58 (307 mg) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound 57 (337 mg).

LCMS: [M+H]⁺/Rt (min): 207/0.49

Reference Example 21 2-(4-Methylpiperidin-4-yl)-1,3-benzoxazole

Step (i):

To a solution of Compound 59 (1.46 g) in THF (30 mL) were added isobutylchloroformate (819 mg) and diisopropylethylamine (3.88 g) under icetemperature, and the mixture was stirred for one hour. 2-Aminophenol(655 mg) was added to the reaction mixture under ice temperature, andthe mixture was stirred for 6 hours heating at 70° C. The reactionsolution was directly purified by amino silica gel column chromatography(eluate: ethyl acetate/hexane) to give the title compound 60 (710 mg).

LCMS: [M+H]⁺/Rt (min): 335/2.28 (Method B)

Step (ii):

A mixture of Compound 60 (204 mg) and acetic acid (1.10 mL) was stirredfor 2 hours heating at 90° C., and concentrated in vacuo. The obtainedresidue was dissolved in chloroform (2 mL), and trifluoromethanesulfonicacid (2.1 mL) was added to the solution. The mixture was stirred at roomtemperature for one hour. The reaction solution was concentrated invacuo, ethyl acetate and aqueous sodium bicarbonate were added to theresidue. The mixture was extracted with ethyl acetate. The organic layerwas dried over anhydrous sodium sulfate and concentrated in vacuo, andthen the obtained residue was purified by amino silica gel columnchromatography (eluate: ethyl acetate/hexane) to give the title compound61 (99 mg).

LCMS: [M+H]⁺/Rt (min): 217/1.36 (Method B)

Reference Example 22 4-Cyclopentyl-4-methylpiperidine monohydrochloride

Step (i):

To a mixture of Compound 62 (700 mg) and THF (14 mL) was added lithiumdiisopropylamide (2 M, 5.18 mL) at −78° C., and the mixture was stirredat the same temperature for 2 hours. To the reaction mixture were addedbromocyclopentane (1.23 mL) and potassium iodide (478 mg), and themixture was warmed to room temperature. The mixture was stirredovernight, and then water was added to the mixture. The mixture wasextracted with ethyl acetate. The organic layer was dried over anhydroussodium sulfate and concentrated in vacuo, and then the obtained residuewas purified by silica gel column chromatography (eluate: ethylacetate/hexane) to give the title compound 63 (468 mg).

LCMS: [M+H]⁺/Rt (min): 312/1.26

Step (ii):

To a mixture of lithium aluminium hydride (104 mg) and THF (3 mL) wereadded Compound 63 (371 mg) and THF (6 mL) under ice temperature, and themixture was stirred for 4 hours. After the reaction was terminated asjudged by the consumption of the starting material, water (0.104 mL),15% aqueous sodium hydroxide (0.104 mL), and then water (0.312 mL) wereadded to the reaction mixture at 0° C., and the mixture was stirred. Thereaction mixture was filtrated. The filtrate was concentrated in vacuo,and then the obtained residue was purified by silica gel columnchromatography (eluate: ethyl acetate/hexane) to give the title compound64 (320 mg).

LCMS: [M+H]⁺/Rt (min): 284/1.06

Step (iii):

To a mixture of Compound 64 (314 mg), triethylamine (0.309 mL), and THF(5 mL) was added methanesulfonyl chloride (0.104 mL), and the mixturewas stirred at room temperature. After the reaction was terminated asjudged by the consumption of the starting material, water was added tothe reaction mixture, and the mixture was extracted with chloroform. Theorganic layer was dried over anhydrous sodium sulfate and concentratedin vacuo, and then the obtained residue was purified by silica gelcolumn chromatography (eluate: ethyl acetate/hexane) to give the titlecompound 65 (290 mg).

LCMS: [M+H]⁺/Rt (min): 362/1.15

Step (iv):

To a mixture of Compound 65 (278 mg) and THF (3 mL) was added lithiumtriethylborohydride (0.99 M, 1.55 mL), and the mixture was stirred atroom temperature. Then, the reaction solution was heated to 70° C. Afterthe reaction was terminated as judged by the consumption of the startingmaterial, the reaction solution was cooled to 0° C., and aqueousammonium chloride was added to the reaction solution. The mixture wasextracted with chloroform, and the organic layer was dried overanhydrous sodium sulfate and concentrated in vacuo. Then, the obtainedresidue was purified by silica gel column chromatography (eluate:hexane/ethyl acetate) to give the title compound 66 (100 mg).

LCMS: [M+H]⁺/Rt (min): 268/1.42

Step (v):

The title compound 67 (58.5 mg) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound 66 (90 mg).

LCMS: [M+H]⁺/Rt (min): 168/0.62

Reference Example 23 4-(4,4-Difluorocyclohexyl)-4-methylpiperidinemonohydrochloride

The compound of Reference example 23 shown in the table below wasprepared according to the process in the above Reference example 22, byusing 1,1-difluoro-4-iodocyclohexane instead of bromocyclopentane atStep (i) in Reference example 22.

Instrumental Reference analytical example Chemical structure data 23

LCMS: [M + H]⁺/Rt (min): 218/0.57

Reference Example 244-(5-Cyclopropyl-1,3,4-thiadiazol-2-yl)-4-methylpiperidinemonohydrochloride

Step (i):

To a mixture of Compound 59 (399 mg), cyclopropanecarbohydrazidehydrochloride (269 mg), and DMF (5 mL) were added HATU (686 mg) anddiisopropylethylamine (1.15 mL), and the mixture was stirred at roomtemperature for 3 hours. Water was added to the reaction solution, andthe mixture was extracted with ethyl acetate. The organic layer wasdried over anhydrous sodium sulfate and concentrated in vacuo, and thenthe obtained residue was purified by silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound 69 (520 mg).

LCMS: [M+H]⁺/Rt (min): 326/0.74

Step (ii):

To a mixture of Compound 69 (255 mg) and toluene (6 mL) was addedLawesson's reagent (349 mg), and the mixture was stirred under refluxfor one hour. The reaction solution was cooled to 0° C., and aqueoussodium bicarbonate was added to the reaction solution. The mixture wasextracted with ethyl acetate. The organic layer was dried over anhydroussodium sulfate and concentrated in vacuo, and then the obtained residuewas purified by silica gel column chromatography (eluate: hexane/ethylacetate) and then by amino silica gel column chromatography (eluate:hexane/ethyl acetate) to give the title compound 70 (102 mg). LCMS:[M+H]⁺/Rt (min): 324/1.08

Step (iii):

The title compound 71 (78 mg) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound (92 mg).

LCMS: [M+H]⁺/Rt (min): 224/0.45

Reference Example 254-(5-Cyclopropyl-1,3-thiazol-2-yl)-4-methylpiperidine monohydrochloride

Step (i):

The title compound 72 (796 mg) was prepared in the same manner as Step(i) in Reference example 24 by using Compound (718 mg) and2-amino-1-cyclopropylethan-1-one hydrochloride (400 mg).

LCMS: [M+H]⁺/Rt (min): 325/0.83

Step (ii):

To a mixture of Compound 72 (127 mg), pyridine (0.063 mL), and toluene(3 mL) was added Lawesson's reagent (205 mg), and the mixture wasstirred under reflux for 14 hours. The reaction solution was cooled toroom temperature, and then aqueous sodium bicarbonate was added to thereaction solution. The mixture was extracted with ethyl acetate. Theorganic layer was dried over anhydrous sodium sulfate and concentratedin vacuo, and then the obtained residue was purified by amino silica gelcolumn chromatography (eluate: hexane/ethyl acetate) to give the titlecompound 73 (76.3 mg).

LCMS: [M+H]⁺/Rt (min): 323/1.43

Step (iii):

The title compound 74 (66.5 mg) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound 73 (77 mg).

LCMS: [M+H]⁺/Rt (min): 223/0.67

Reference Example 264-(2-Cyclopropyl-1,3-thiazol-4-yl)-4-methylpiperidine monohydrochloride

Step (i):

A solution of Compound 75 (532 mg) and cyclopropanecarbothioamide (168mg) in methanol (6 mL) was stirred under reflux for 2.5 hours. Thereaction mixture was allowed to cool to room temperature, and thensaturated aqueous sodium bicarbonate was added to the reaction mixture.The mixture was extracted with chloroform. The organic layer was driedover anhydrous sodium sulfate and concentrated in vacuo, and then theobtained residue was purified by silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound 76 (119 mg).

Step (ii):

The title compound 77 (137 mg) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound 76 (119 mg).

LCMS: [M+H]⁺/Rt (min): 223/0.572

Reference Example 274-(1-Cyclopropyl-1H-1,2,4-triazol-3-yl)-4-methylpiperidinedihydrochloride

Step (i):

The title compound 78 (648 mg) was prepared in the same manner as Step(i) in Reference example 24 by using Compound 59 (611 mg) andcyclopropylhydrazine hydrochloride (300 mg). LCMS: [M+H]⁺/Rt (min):298/0.80

Step (ii):

A mixture of Compound 78 (374 mg), ammonium formate (1.43 g), andtrimethyl orthoformate (2.78 mL) was stirred heating at 100° C. Afterthe reaction was completed, the reaction solution was concentrated. Tothe obtained residue was added water, and the mixture was extracted withchloroform. The organic layer was dried over anhydrous sodium sulfateand concentrated in vacuo, and then the obtained residue was purified bysilica gel column chromatography (eluate: hexane/ethyl acetate) to givethe title compound 79 (163 mg).

LCMS: [M+H]⁺/Rt (min): 307/0.89

Step (iii):

The title compound 80 (142 mg) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound 79 (144 mg).

LCMS: [M+H]⁺/Rt (min): 207/0.39

Reference Example 284-(5-Cyclopropyl-1,2,4-thiadiazol-3-yl)-4-methylpiperidine

Step (i):

To a solution of Compound 27 (1.04 g) in THF (15 mL) was addedthiocarbonylimidazole (0.864 mg) under ice temperature, and the mixturewas stirred at room temperature. After the reaction was terminated asjudged by the consumption of the starting material, the reactionsolution was cooled to 0° C., and water was added to the reactionsolution. The mixture was extracted with ethyl acetate. The organiclayer was dried over sodium sulfate, and concentrated in vacuo.

The obtained residue was dissolved in THF (15 mL), and borontrifluoride-diethyl ether complex (1.52 mL) was added to the solution at0° C. The mixture was warmed to room temperature under stirring. Afterthe reaction was completed, aqueous sodium bicarbonate was added to thereaction solution, and the mixture was extracted with chloroform. Theorganic layer was dried over sodium sulfate and concentrated in vacuo,and then the obtained residue was purified by amino silica gel columnchromatography (eluate: hexane/ethyl acetate).

To a solution of the purified compound in THF (15 mL) was added hydrogenchloride/dioxane solution (4 M, 5.05 mL) at 0° C., and the mixture waswarmed to room temperature and stirred. After the reaction wascompleted, the reaction solution was concentrated in vacuo, and theobtained residue was dissolved in THF (15 mL). To the solution wereadded triethylamine (3.38 ml) and 2-nitrobenzenesulfonyl chloride (0.985g), and the mixture was stirred at room temperature. After the reactionwas completed, water was added to the reaction solution, and the mixturewas extracted with chloroform. The organic layer was dried overanhydrous sodium sulfate and concentrated in vacuo, and then theobtained residue was purified by silica gel column chromatography(eluate: chloroform/methanol) to give the title compound 81 (627 mg).

LCMS: [M+H]⁺/Rt (min): 385/0.93

Step (ii):

To a mixture of Compound 81 (590 mg), pyridine (0.248 mL), and toluene(7 mL) was added phosphoryl chloride (0.572 mL), and the mixture wasstirred under reflux. After the reaction was completed, the reactionsolution was added to aqueous sodium bicarbonate at 0° C., and themixture was filtrated. The filtrate was extracted with ethyl acetate.The organic layer was dried over sodium sulfate and concentrated invacuo, and then the obtained residue was purified by amino silica gelcolumn chromatography (eluate: hexane/ethyl acetate) to give the titlecompound 82 (432 mg).

LCMS: [M+H]⁺/Rt (min): 403/1.21

Step (iii):

To a mixture of Compound 82 (210 mg), cyclopropylzinc(II) bromide (0.5M, 3.13 mL), and THF (2 mL) was addedtetrakis(triphenylphosphine)palladium(0) (30.1 mg), and the mixture wasstirred at 60° C. for 1.5 hours. After the reaction was completed,aqueous sodium bicarbonate was added to the reaction solution, and themixture was extracted with ethyl acetate. The organic layer was driedover sodium sulfate and concentrated in vacuo, and then the obtainedresidue was purified by amino silica gel column chromatography (eluate:hexane/ethyl acetate) to give the title compound 83 (84 mg).

LCMS: [M+H]⁺/Rt (min): 409/1.24

Step (iv):

To a mixture of Compound 83 (71.4 mg), 1-dodecanethiol (0.251 mL), andacetonitrile (3 mL) was added potassium carbonate (145 mg), and themixture was stirred at 80° C. After the reaction was completed, waterwas added to the reaction solution, and the mixture was extracted withchloroform/methanol (6/1). The organic layer was dried over sodiumsulfate and concentrated in vacuo, and then the obtained residue waspurified by amino silica gel column chromatography (eluate: hexane/ethylacetate=>chloroform/methanol) to give the title compound 84 (38 mg).LCMS: [M+H]⁺/Rt (min): 224/0.52

Reference Example 294-(5-Methoxy-1,2,4-thiadiazol-3-yl)-4-methylpiperidine

Step (i):

To a solution of Compound 82 (119 mg) in methanol (2 mL) was addedsodium methoxide (28%, 285 mg), and the mixture was stirred at roomtemperature. After the reaction was completed, water was added to thereaction solution, and the mixture was extracted with chloroform. Theorganic layer was concentrated in vacuo to give the title compound 85(97.1 mg).

LCMS: [M+H]⁺/Rt (min): 399/1.18

Step (ii):

The title compound 86 (14.9 mg) was prepared in the same manner as Step(iv) in Reference example 28 by using Compound 85 (91.6 mg).

LCMS: [M+H]⁺/Rt (min): 214/0.48

Reference Example 304-[5-(Cyclopropyloxy)-1,2,4-thiadiazol-3-yl]-4-methylpiperidine

The compound of Reference example 30 shown in the table below wasprepared according to the process in the above Reference example 29, byusing cyclopropyl alcohol and sodium hydride instead of sodium methoxideat Step (i) in Reference example 29.

Instrumental Reference analytical example Chemical structure data 30

LCMS: [M + H]⁺/Rt (min): 240/0.56

Reference Example 31 2-[(4-Methylpiperidin-4-yl)oxy]pyridinemonohydrochloride

Step (i):

To a solution of Compound 88 (183 mg) in DMF (2 mL) was added sodiumhydride (55%, 48.2 mg) under ice temperature, and the mixture wasstirred for 20 minutes. To the reaction mixture was added2-fluoropyridine (0.109 mL), and the mixture was stirred at roomtemperature. After the reaction was completed, the reaction mixture wascooled to 0° C. To the reaction mixture was added water, and the mixturewas extracted with chloroform. The organic layer was dried over sodiumsulfate and concentrated in vacuo, and then the obtained residue waspurified by silica gel column chromatography (eluate: hexane/ethylacetate) to give the title compound 89 (18 mg).

LCMS: [M+H]⁺/Rt (min): 293/1.29

Step (ii):

The title compound 90 (13.2 mg) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound 89 (14.7 mg).

LCMS: [M+H]⁺/Rt (min): 193/0.48

Reference Example 32 4-(2-Fluoro-4-methylphenyl)-4-methylpiperidine

Step (i):

To a mixture of Compound 91 (211 mg),1-methyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester (274mg), potassium carbonate (386 mg), 1,2-dimethoxymethane (4 mL), andwater (1 mL) was addeddichloro(1,1′-bis(diphenylphosphino)ferrocene)palladium (45.6 mg) atroom temperature, and then the mixture was heated under reflux. Afterthe reaction was completed, water was added to the reaction solution,and the mixture was extracted with chloroform. The organic layer wasdried over sodium sulfate and concentrated in vacuo, and then theobtained residue was purified by amino silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound 92 (32 mg).LCMS: [M+H]⁺/Rt (min): 206/0.51

Step (ii):

To a solution of Compound 92 (137 mg) in THF (3 mL) was addedn-butyllithium solution (1.57 M, 0.68 mL) at −18° C., and the mixturewas further cooled to −50° C. Dimethyl sulfate was added dropwise to thereaction solution, and the mixture was stirred at −50° C. for one hour.To the reaction solution was added aqueous ammonia, and the mixture wasextracted with ethyl acetate. The organic layer was dried over sodiumsulfate, and concentrated in vacuo to give a residue.

The obtained residue was dissolved in methanol (3 mL), and sodiumborohydride (80 mg) was added to the solution under ice temperature.After the reaction was completed, aqueous sodium bicarbonate was addedto the reaction solution, and the mixture was extracted with chloroform.The organic layer was dried over sodium sulfate and concentrated invacuo, and then the obtained residue was purified by amino silica gelcolumn chromatography (eluate: hexane/ethyl acetate) to give the titlecompound 93 (32 mg).

LCMS: [M+H]⁺/Rt (min): 222/0.63

Step (iii):

To a solution of Compound 93 (30.4 mg) in 1,2-dichloroethane (3 mL) wasadded 1-chloroethyl chloroformate (0.045 mL) at room temperature, andthe mixture was heated under reflux. The reaction solution wasconcentrated in vacuo, and chloroform and aqueous sodium hydroxide wereadded to the obtained residue. The mixture was stirred at roomtemperature, and then extracted with chloroform. The organic layer wasdried over sodium sulfate and concentrated in vacuo, and then theobtained residue was purified by amino silica gel column chromatography(eluate: chloroform/methanol) to give the title compound 94 (22 mg).LCMS: [M+H]⁺/Rt (min): 208/0.66

Reference Example 33 4-[4-(Difluoromethyl)phenyl]-4-methylpiperidinemonohydrochloride

Step (i):

To a solution of Compound 95 (490 mg) in THF (6 mL) was addedn-butyllithium solution (1.57 M, 1.15 mL) at −78° C., and the mixturewas stirred for 30 minutes. To the reaction solution was added DMF(0.535 mL), and the mixture was warmed to 0° C. After the reaction wascompleted, water was added to the reaction solution, and the mixture wasextracted with chloroform. The organic layer was dried over sodiumsulfate and concentrated in vacuo, and then the obtained residue waspurified by silica gel column chromatography (eluate: hexane/ethylacetate) to give the title compound 96 (256 mg).

LCMS: [M+H]′/Rt (min): 304/1.10

Step (ii):

To a solution of Compound 96 (157 mg) in dichloromethane (2 mL) wasadded Deoxo-Fluor® (0.285 mL) under ice temperature, and then themixture was stirred at room temperature. After the reaction wascompleted, the reaction solution was added to aqueous sodium bicarbonatein ice bath, and the mixture was extracted with chloroform. The organiclayer was dried over sodium sulfate and concentrated in vacuo, and thenthe obtained residue was purified by amino silica gel columnchromatography (eluate: hexane/ethyl acetate) to give the title compound97 (110 mg).

LCMS: [M+H]⁺/Rt (min): 326/1.20

Step (iii):

The title compound 98 (84.5 mg) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound 97 (104.8 mg).

LCMS: [M+H]⁺/Rt (min): 226/0.60

Reference Example 34 5-Methyl-2-(4-methylpiperidin-4-yl)benzonitrile

Step (i):

To a mixture of Compound 99 (267 mg) and m-cresol (1.20 mL) was addedtrifluoromethanesulfonic acid (1.01 mL), and the mixture was stirred atroom temperature. After the reaction was completed, the reactionsolution was added to aqueous sodium bicarbonate at 0° C., and themixture was extracted with chloroform. The organic layer was dried oversodium sulfate, concentrated in vacuo, and then the obtained residue waspurified by silica gel column chromatography (eluate: hexane/ethylacetate) to give the title compound 100 (388 mg).

LCMS: [M+H]⁺/Rt (min): 278/1.01

Step (ii):

To a mixture of Compound 100 (113 mg), potassium carbonate (169 mg), andTHF (4 mL) was added N-phenylbis(trifluoromethanesulfonimide) (175 mg),and the mixture was stirred heating at 120° C. with a microwave device.After the reaction was completed, water was added to the reactionsolution, and the mixture was extracted with chloroform. The organiclayer was dried over sodium sulfate and concentrated in vacuo, and thenthe obtained residue was purified by silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound 101 (138 mg).

LCMS: [M+H]⁺/Rt (min): 410/1.26

Step (iii):

The title compound 102 (40.8 mg) was prepared in the same manner as Step(iii) in Reference example 28 by using Compound 101 (130 mg) and zinccyanide (55.8 mg).

LCMS: [M+H]⁺/Rt (min): 287/1.07

Step (iv):

To a solution of Compound 102 (40 mg) in 2-propanol (3 ml) was addedpotassium hydroxide (78 mg) at room temperature, and then the mixturewas stirred heating at 110° C. with a microwave device. After thereaction was completed, water was added to the reaction solution. Themixture was extracted with chloroform/ethanol (4/1). The organic layerwas dried over sodium sulfate and concentrated in vacuo, and then theobtained residue was purified by amino silica gel column chromatography(eluate: chloroform/methanol) to give the title compound 103 (20.6 mg).

LCMS: [M+H]⁺/Rt (min): 215/0.57

Reference Example 35 (3S,4S)-4-Fluoro-1-(propan-2-yl)pyrrolidin-3-ol

Step (i):

To a solution of Compound 104 (500 mg) in chloroform (2 mL) was addedhydrogen chloride/1,4-dioxane (4 M, 6 mL) at 0° C., and the mixture waswarmed to room temperature and stirred. After the reaction wasterminated as judged by the consumption of the starting material, thereaction solution was concentrated in vacuo. The obtained residue wasdissolved in chloroform (2 mL). To the solution were added acetone (1.79mL), sodium acetate (200 mg), and sodium triacetoxyborohydride (1.03 g)at 0° C., and the mixture was warmed to room temperature and stirred.After the reaction was completed, aqueous sodium bicarbonate was addedto the reaction mixture at 0° C., and the mixture was extracted withchloroform/methanol (5/1). The organic layer was dried over anhydroussodium sulfate and concentrated in vacuo, and then the obtained residuewas purified by amino silica gel column chromatography (eluate:hexane/ethyl acetate) to give the title compound 105 (348 mg).

LCMS: [M+H]⁺/Rt (min): 148/0.17

Reference Example 36 (3R)-4,4-Difluoro-1-(propan-2-yl)pyrrolidin-3-ol

The compound of Reference example 36 shown in the table below wasprepared according to the process in the above

Reference Example 35, by using the appropriate starting compound insteadof Compound 104 at Step (i) in Reference example 35

Instrumental Reference analytical example Chemical structure data 36

LCMS: [M + H]⁺/Rt (min): 166/0.19

Reference Example 37(1R,6S)-2,2-Difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexan-1-amine

Step (i):

A mixture of Compound 49 (1.5 g), (S)-1-isopropylpyrrolidin-3-ol (0.792mg), and NMP (1 mL) was stirred heating at 150° C. After the reactionwas terminated as judged by the consumption of the starting material,the reaction solution was directly purified by silica gel columnchromatography (eluate: chloroform/methanol/triethylamine) and then byamino silica gel column chromatography (eluate: hexane/ethyl acetate) togive the title compound 106 (1.03 g).

LCMS: [M+H]⁺/Rt (min): 448/0.78

Step (ii):

The title compound 107 (43 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 106 (100 mg).

LCMS: [M+H]⁺/Rt (min): 263/0.22

Reference Examples 38 to 40

The compounds of Reference examples 38 to 40 shown in the table belowwere prepared according to the process in the above Reference example37, by using each appropriate starting compound instead of(S)-1-isopropylpyrrolidin-3-ol at Step (i) in Reference example 37.

Instrumental Reference analytical example Chemical structure data 38

LCMS: [M + H]⁺/Rt (min): 263/0.151 39

LCMS: [M + H]⁺/Rt (min): 281/0.18 40

LCMS: [M + H]⁺/Rt (min): 299/0.35

Reference Example 38:(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexan-1-amineReference Example 39:(1R,6S)-2,2-difluoro-6-{[(3S,4S)-4-fluoro-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexan-1-amineReference Example 40:(1R,6S)-6-{[(3R)-4,4-difluoro-1-(propan-2-yl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexan-1-amineReference Example 41 3-Fluoro-5-methyl-2-(piperidin-4-yl)pyridine

Step (i):

The title compound 109 (90.5 mg) was prepared in the same manner as Step(i) in Reference example 32 by using Compound 108 (72.4 mg) and1-carbobenzoxy-1,2,3,6-tetrahydro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)pyridine.

LCMS: [M+H]⁺/Rt (min): 327/1.04 (Method C)

Step (ii):

To a solution of Compound 109 (88.0 mg) in ethyl acetate (1.5 mL) wasadded palladium/carbon (88.0 mg), and the mixture was stirred underhydrogen atmosphere for 8 hours. The reaction solution was filtratedwith Celite, and the filtrate was concentrated in vacuo to give thetitle compound 110 (22.2 mg).

LCMS: [M+H]⁺/Rt (min): 195/0.35 (Method C)

Reference Example 42(1R,6S)-2,2-Difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-ol

Step (i):

To a solution of Compound 111 (300 mg) and sodium bicarbonate (634 mg)in ethanol (10 mL) was added N-benzyl-N,N-bis(2-chloroethyl)aminehydrochloride (586 mg), and the mixture was stirred heating at 120° C.with a microwave device. After the reaction was completed, water wasadded to the reaction solution, and the mixture was extracted withchloroform. The organic layer was dried over sodium sulfate andconcentrated in vacuo, and then the obtained residue was purified byamino silica gel column chromatography (eluate: hexane/ethyl acetate) togive the title compound 112 (398 mg).

LCMS: [M+H]⁺/Rt (min): 311/0.46

Step (ii):

The title compound 113 (289 mg) was prepared in the same manner as Step(ii) in Reference example 2 by using Compound 112 (389 mg).

LCMS: [M+H]⁺/Rt (min): 221/0.16

Step (iii):

To a mixture of Compound 113 (389 mg), acetone (1.73 mL), anddichloromethane (6 mL) was added sodium triacetoxyborohydride (1.5 g) at0° C., and the mixture was warmed to room temperature and the stirringwas continued for 1.5 hours. To the reaction mixture was added water at0° C., and the mixture was extracted with chloroform. The organic layerwas dried over anhydrous sodium sulfate and concentrated in vacuo, andthen the obtained residue was purified by amino silica gel columnchromatography (eluate: hexane/ethyl acetate) to give the title compound114 (255 mg).

LCMS: [M+H]⁺/Rt (min): 263/0.36

Reference Example 43 tert-Butyl[(1S,4R)-3-{[4-(propan-2-yl)piperazin-1-yl]methyl}bicyclo[2.2.1]heptan-2-yl]carbamate

Step (i):

To a mixture of Compound 115 (239 mg), 1-isopropylaziridine (128 mg),acetic acid (0.086 mL), and THF (2.5 mL) was added sodiumtriacetoxyborohydride (635 mg) at room temperature, and the mixture wasstirred at the same temperature for 3 hours. To the reaction mixture wasadded aqueous sodium bicarbonate at 0° C., and the mixture was extractedwith ethyl acetate. The organic layer was dried over anhydrous sodiumsulfate and concentrated in vacuo, and then the obtained residue waspurified by amino silica gel column chromatography (eluate: hexane/ethylacetate) to give the title compound 116 (310 mg).

LCMS: [M+H]⁺/Rt (min): 352/1.35 (Method B)

Reference Example 44rac-2-[6-(Propan-2-yl)pyridin-3-yl]cyclohex-2-en-1-amine

Step (i):

To a mixture of Compound 117 (350 mg), 6-isopropylpyridin-3-yl boronate(273 mg), cesium carbonate (1.28 g), 1,4-dioxane (5 mL), and water (1mL) was added [1,1′-bis(diphenylphosphino)ferrocene]palladium(II)dichloride dichloromethane adduct (129 mg) at room temperature, and themixture was stirred at 90° C. for 3 hours. To the reaction mixture wasadded water at 0° C., and the mixture was extracted with chloroform. Theorganic layer was dried over anhydrous sodium sulfate and concentratedin vacuo, and then the obtained residue was purified by silica gelcolumn chromatography (eluate: hexane/ethyl acetate) to give the titlecompound 118 (168 mg).

Step (ii) to Step (iv):

The title compound 121 (29.7 mg) was prepared in the same manner asSteps (i) to (iii) in Reference example 13 by using Compound 118 (68.2mg).

LCMS: [M+H]⁺/Rt (min): 217/0.39

Reference Example 45N-Methyl-N-[(1-methylcyclopropyl)methyl]piperidin-4-amine

Step (i):

To a solution of Cert-butyl 4-(methylamino)piperidine-1-carboxylate (584mg), 1-methylcyclopropane-1-carboxylic acid (300 mg), and triethylamine(0.76 mL) in DMF (4 mL) was added HATU (1.24 g), and the mixture wasstirred at room temperature. After the reaction was completed, water wasadded to the reaction mixture, and the mixture was extracted with ethylacetate. The organic layer was dried over anhydrous sodium sulfate,concentrated in vacuo, and then the obtained residue was purified bysilica gel column chromatography (eluate: hexane/ethyl acetate) to givethe title compound 123 (926 mg).

Step (ii):

To a solution of Compound 123 (806 mg) in chloroform (4.5 mL) was addedhydrochloric acid (in CPME, 5 M, 2.7 mL) at 0° C., and the reactionsolution was warmed to room temperature and stirred. After the reactionwas completed, the reaction mixture was concentrated in vacuo, and thenthe obtained residue was purified by amino silica gel columnchromatography (eluate: chloroform/methanol) to give the title compound124 (477 mg).

Step (iii):

The title compound 125 (203 mg) was prepared in the same manner as Step(ii) in Reference example 22 by using Compound 124 (413 mg).

LCMS: [M+H]⁺/Rt (min):183/0.15

Reference Examples 46-47

The compounds of Reference examples 46-47 shown in the table below wasprepared according to the process in the above Reference example 45, byusing each appropriate starting compound instead of1-methylcyclopropane-1-carboxylic acid at Step (i) in Reference example45.

Instrumental Reference analytical example Chemical structure data 46

LCMS: [M + H]⁺/Rt (min): 187/0.14 47

LCMS: [M + H]+/Rt (min): 237/0.19

Reference Example 46:N-[(1-fluorocyclopropyl)methyl]-N-methylpiperidin-4-amine ReferenceExample 47:N-methyl-N-{[1-(trifluoromethyl)cyclopropyl]methyl}piperidin-4-amineReference Example 48:(3S)-1-{[1-(trifluoromethyl)cyclopropyl]methyl}pyrrolidin-3-ol

Step (i):

The title compound 127 (196 mg) was prepared in the same manner as Step(i) in Reference example 45 by using (S)-3-pyrrolidinol (103 mg) and1-(trifluoromethyl)cyclopropane-1-carboxylic acid (200 mg).

Step (ii):

The title compound 128 (87.2 mg) was prepared in the same manner as Step(iii) in Reference example 45 by using Compound 127 (184 mg).

LCMS: [M+H]⁺/Rt (min):210/0.30

Reference Example 49(1R,3S,5S)—N-(Cyclopropylmethyl)-N-methyl-8-azabicyclo[3.2.1]oxtan-3-amine

Step (i):

The title compound 130 (178 mg) was prepared in the same manner as Step(iii) in Reference example 42 by using Compound 129 (146 mg) andcyclopropane-carbaldehyde (170 mg).

Step (ii):

The title compound 131 (106 mg) was prepared in the same manner as Step(ii) in Reference example 45 by using Compound 130 (166 mg).

LCMS: [M+H]⁺/Rt (min): 195/0.14

Reference Examples 50-52

The compounds of Reference examples 50-52 shown in the table below wereprepared according to the process in the above Reference example 49, byusing each appropriate starting compound instead of Compound 129 at Step(i) in Reference example 49.

Instrumental Reference analytical example Chemical structure data 50

LCMS: [M + H]⁺/Rt (min): 195/0.14 51

LCMS: [M + H]⁺/Rt (min): 183/0.14 52

LCMS: [M + H]⁺/Rt (min): 183/0.14

Reference Example 50:(1R,3R,5S)—N-(cyclopropylmethyl)-N-methyl-8-azabicyclo[3.2.1]octan-3-amineReference Example 51: (4S)—N-(cyclopropylmethyl)-N-methylazepan-4-amineReference Example 52: (4R)—N-(cyclopropylmethyl)-N-methylazepan-4-amineReference Example 53(1R,3S,5S)-8-(Propan-2-yl)-8-azabicyclo[3.2.1]octan-3-ol

Step (i):

The title compound was prepared in the same manner as Step (iv) inReference example 2 by using Compound 132 (3 g).

Step (ii):

The title compound 134 (1.98 g) was prepared in the same manner as Step(iii) in Reference example 42 by using Compound 133 and acetone (1.3 g).

LCMS: [M+H]⁺/Rt (min): 170/0.15

Reference Examples 54-57

The compounds of Reference examples 54-57 shown in the table below wereprepared according to the process in the above Reference example 53, byusing each appropriate starting compound instead of Compound 132 at Step(i) in Reference example 53.

Instrumental Reference analytical example Chemical structure data 54

LCMS: [M + H]⁺/Rt (min): 170/0.25 55

LCMS: [M + H]⁺/Rt (min): 170/0.15 56

LCMS: [M + H]⁺/Rt (min): 170/0.24 57

LCMS: [M + H]⁺/Rt (min): 142/0.15

Reference Example 54:(1R,5S,8R)-3-(propan-2-yl)-3-azabicyclo[3.2.1]octan-8-ol ReferenceExample 55: (1R,5S,8S)-3-(propan-2-yl)-3-azabicyclo[3.2.1]octan-8-olReference Example 56:(1R,3R,5S)-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-3-ol ReferenceExample 57: (1R,5S,6S)-3-(propan-2-yl)-3-azabicyclo[3.1.0]hexan-6-olReference Examples 58-79

The compounds of Reference examples 58-79 shown in the table below wereprepared according to the process in the above Reference example 18, byusing each appropriate starting compound instead of1-isopropylpiperazine at Step (ii) in Reference example 18.

Instrumental Reference analytical example Chemical structure data 58

LCMS: [M + H]⁺/Rt (min): 262/0.17 59

LCMS: [M + H]⁺/Rt (min): 276/0.28 60

LCMS: [M + H]⁺/Rt (min): 277/0.55 61

LCMS: [M + H]⁺/Rt (min): 276/0.20 62

LCMS: [M + H]⁺/Rt (min): 276/0.20 63

LCMS: [M + H]⁺/Rt (min): 290/0.24 64

LCMS: [M + H]⁺/Rt (min): 288/0.31 65

LCMS: [M + H]⁺/Rt (min): 288/0.32 66

LCMS: [M + H]⁺/Rt (min): 316/0.35 67

LCMS: [M + H]⁺/Rt (min): 290/0.38 68

LCMS: [M + H]⁺/Rt (min): 304/0.32 69

LCMS: [M + H]⁺/Rt (min): 316/0.36 70

LCMS: [M + H]⁺/Rt (min): 320/0.36 71

LCMS: [M + H]⁺/Rt (min): 370/0.48 72

LCMS: [M + H]⁺/Rt (min): 328/0.51 73

LCMS: [M + H]⁺/Rt (min): 328/0.39 74

LCMS: [M + H]⁺/Rt (min): 316/0.49 75

LCMS: [M + H]⁺/Rt (min): 316/0.46 76

LCMS: [M + H]⁺/Rt (min): 262/0.15 77

LCMS: [M + H]⁺/Rt (min): 274/0.15 78

LCMS: [M + H]⁺/Rt (min): 276/0.24 79

LCMS: [M + H]⁺/Rt (min): 348/0.66

Reference Example 58:(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-amineReference Example 59:(3S)-1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-methyl-N-(propan-2-yl)pyrrolidin-1-amineReference Example 60:(1R,6S)-2,2-difluoro-6-{4-[(propan-2-yl)oxy]piperidin-1-yl}cyclohexan-1-amineReference Example 61:(1R,6S)-2,2-difluoro-6-[(2S)-2-methyl-4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-amineReference Example 62:(1R,6S)-2,2-difluoro-6-[(2R)-2-methyl-4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-amineReference Example 63:(1S,2R)-3,3-difluoro-N¹-methyl-N¹-[1-(propan-2-yl)piperidin-4-yl]cyclohexan-1,2-diamineReference Example 64:(1R,6S)-2,2-difluoro-6-[4-(pyrrolidin-1-yl)piperidin-1-yl]cyclohexan-1-amineReference Example 65:(1R,6S)-2,2-difluoro-6-[5-(propan-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]cyclohexan-1-amineReference Example 66:(1R,6S)-2,2-difluoro-6-[2-(propan-2-yl)-2,8-diazaspiro[4.5]decan-8-yl]cyclohexan-1-amineReference Example 67:1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N,N-diethylpiperidin-4-amineReference Example 68:1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N,4-dimethyl-N-(propan-2-yl)piperidin-4-amineReference Example 69:1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-methyl-N-[(1-methylcyclopropyl)methyl]piperidin-4-amineReference Example 70:1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-[(1-fluorocyclopropyl)methyl]-N-methylpiperidin-4-amineReference Example 71:1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-methyl-N-{[1-(trifluoromethyl)cyclopropyl]methyl}piperidin-4-amineReference Example 72:(1R,3R,5S)-8-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-(cyclopropylmethyl)-N-methyl-8-azabicyclo[3.2.1]octan-3-amineReference Example 73:(1R,3S,5S)-8-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-(cyclopropylmethyl)-N-methyl-8-azabicyclo[3.2.1]octan-3-amineReference Example 74:(4S)-1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-(cyclopropylmethyl)-N-methylazepan-4-amineReference Example 75:(4R)-1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-(cyclopropylmethyl)-N-methylazepan-4-amineReference Example 76:1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-methyl-N-(propan-2-yl)azetidin-3-amineReference Example 77:1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-(cyclopropylmethyl)-N-methylazetidin-3-amineReference Example 78:(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)-1,4-diazepan-1-yl]cyclohexan-1-amineReference Example 79: tert-butyl{1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]piperidin-4-yl}methylcarbamateReference Example 80N-{(1R,6S)-2,2-Difluoro-6-[4-(methylamino)piperidin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

Step (i):

The title compound 136 (2.92 g) was prepared in the same manner asExample 19 by using the compound of Reference example 79 (2.61 g).

Step (ii):

To a solution of Compound 136 (2.92 g) in toluene (24 ml) was added TFA(5.56 g), and the mixture was stirred at room temperature for 3.5 hours.The reaction solution was concentrated in vacuo, the obtained residuewas dissolved in water, and aqueous sodium bicarbonate was added to thesolution. The mixture was extracted with chloroform, and the organiclayer was concentrated in vacuo to give the title compound 137 (2.38 g).

LCMS: [M+H]⁺/Rt (min):499/0.49 (Method C)

Reference Example 81(1S,2R)-3,3-Difluoro-N¹-methyl-N¹-[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]cyclohexan-1,2-diamine

Step (i):

Compound 138 (2.61 g) was prepared in the same manner as Step (ii) inReference example 18, by using Cert-butyl(3S)-3-(methylamino)pyrrolidine-1-carboxylate instead of1-isopropylpiperazine at Step (ii) in Reference example 18.

Step (ii):

The title compound 139 (2.59 g) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound 138 (2.61 g).

Step (ii):

The title compound 140 (1.97 g) was prepared in the same manner as Step(iii) in Reference example 42 by using Compound 139 (2.59 g) and acetone(3.87 mL).

Step (iv):

The title compound 141 (925 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 140 (1.97 g).

LCMS: [M+H]⁺/Rt (min): 276/0.15

Reference Examples 82-88

The compounds of Reference examples 82-88 shown in the table below wereprepared in the same manner as Reference example 81, by using theappropriate starting compound (Material A) instead of Cert-butyl(3S)-3-(methylamino)pyrrolidine-1-carboxylate at Step (i) in Referenceexample 81, and each appropriate starting compound (Material B) insteadof acetone at Step (iii) in Reference example 81.

Instrumental Reference Chemical analytical example Material A Material Bstructure data 82

LCMS: [M + H]⁺/Rt (min): 276/0.28 83

LCMS: [M + H]⁺/Rt (min): 276/0.16 84

LCMS: [M + H]⁺/Rt (min): 290/0.34 85

LCMS: [M + H]⁺/Rt (min): 274/0.30 86

LCMS: [M + H]+/Rt (min): 290/0.37 87

LCMS: [M + H]+/Rt (min): 288/0.36 88

LCMS: [M + H]+/Rt (min): 293/0.33

Reference Example 82:(3R)-1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-methyl-N-(propan-2-yl)pyrrolidin-1-amineReference Example 83:(1S,2R)-3,3-difluoro-N¹-methyl-N¹-[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]cyclohexan-1,2-diamineReference Example 84:1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-methyl-N-(propan-2-yl)piperidin-4-amineReference Example 85:(3S)-1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-cyclopropyl-N-methylpyrrolidin-1-amineReference Example 86:(3S)-1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-methyl-N-(2-methylpropyl)pyrrolidin-1-amineReference Example 87:(3S)-1-[(1S,2R)-2-amino-3,3-difluorocyclohexyl]-N-(cyclopropylmethyl)-N-methylpyrrolidin-1-amineReference Example 88:(1S,6S)-2,2-difluoro-6-{[1-(propan-2-yl)piperidin-4-yl]sulfanyl}oyclohexan-1-amineReference Example 89(1S,2R)—N¹-Benzyl-3,3-difluoro-N¹-[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]cyclohexan-1,2-diamine

Step (i):

Compound 142 (2.19 g) was prepared in the same manner as Step (ii) inReference example 18, by using Cert-butyl(3S)-3-aminopyrrolidine-1-carboxylate instead of 1-isopropylpiperazineat Step (ii) in Reference example 18.

Step (ii):

The title compound 143 (240 mg) was prepared in the same manner as Step(iii) in Reference example 42 by using Compound 142 (990 mg) andbenzaldehyde (312 mg).

Step (iii):

The title compound 144 (161 mg) was prepared in the same manner as Step(ii) and Step (iii) in Reference example 81 by using Compound 143 (235mg).

Step (iv):

The title compound 145 (87.4 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 144 (158 mg).

LCMS: [M+H]⁺/Rt (min): 352/0.42 (Method C)

Reference Example 90 Benzyl{(1S,2R)-3,3-difluoro-2-[(4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carbonyl)amino]cyclohexyl}[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]carbamate

Step (i):

To a solution of Compound 142 (680 mg) in a mixture of dioxane and water(10 mL/3.3 mL) were added benzyl chloroformate (345 mg) and sodiumacetate (116 mg) at 0° C., and the reaction solution was refluxed for 2hours. After the reaction was completed, the reaction solution wasextracted with chloroform. The organic layer was concentrated in vacuoto give the title compound 146 (530 mg).

Step (ii):

The title compound 147 (256 mg) was prepared in the same manner as Step(ii) and Step (iii) in Reference example 81 by using Compound 146 (530mg).

Step (iii):

The title compound 148 (137 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 147 (254 mg).

Step (iv):

The title compound 149 (175 mg) was prepared in the same manner asExample 19 by using Compound 148 (135 mg).

LCMS: [M+H]⁺/Rt (min): 647/0.79 (Method C)

Reference Example 91(1R,6S)-2,2-Difluoro-6-[5-(propan-2-yl)-1,2,4-oxadiazol-3-yl]cyclohexan-1-amine

Step (i):

To a solution of Compound 49 (2.01 g) in acetonitrile (12.6 ml) wereadded sodium cyanide (495 mg) and lithium perchlorate (67 mg), and thereaction solution was refluxed for 3 hours. After the reaction wascompleted, water was added to the reaction mixture, and the mixture wasextracted with ethyl acetate. The organic layer was dried over anhydroussodium sulfate, concentrated in vacuo, and then the obtained residue waspurified by silica gel column chromatography (eluate: hexane/ethylacetate) to give the title compound 150 (2.05 g).

Step (ii):

The title compound 151 (1.88 g) was prepared in the same manner as Step(i) in Reference example 8 by using Compound 150 (2.04 g).

Step (iii):

The title compound 152 (89.7 mg) was prepared in the same manner as Step(ii) and Step (iii) in Reference example 8 by using Compound 151 (200mg) and isobutyric acid (53.6 mg).

Step (iv):

The title compound 153 (41.5 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 152 (87.7 mg).

LCMS: [M+H]⁺/Rt (min): 246/0.37 (Method C)

Reference Example 92(1R,6S)-2,2-Difluoro-6-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]cyclohexan-1-amine

Step (i):

To a solution of Compound 49 (1.6 g) in a mixture of acetonitrile andwater (23 mL/2.5 mL) was added sodium azide (490 mg), and the reactionsolution was heated at 70° C. for 1.5 hours. After the reaction wascompleted, saturated aqueous sodium bicarbonate was added to thereaction mixture, and the mixture was extracted with ethyl acetate. Theorganic layer was dried over anhydrous sodium sulfate, concentrated invacuo, and then the obtained residue was purified by silica gel columnchromatography (eluate: hexane/ethyl acetate) to give the title compound154 (1.78 g).

Step (ii):

To a solution of Compound 154 (550 mg) in a mixture of methanol and THF(11.4 mL/2.3 mL/4 mL) were added sodium ascorbate (30.2 mg),tris(2-benzimidazolylmethyl)amine (46.5 mg), and 3-methylbut-1-yne (156mg). A solution of copper sulfate (18.2 mg) in water (3.8 mL) was addedto the reaction solution, and the reaction mixture was stirred at roomtemperature. After the reaction was completed, the reaction mixture wasfiltrated with Celite, and concentrated in vacuo. Then, the obtainedresidue was purified by silica gel column chromatography (eluate:hexane/ethyl acetate) to give the title compound 155 (353 mg).

Step (iii):

The title compound 156 (168 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 155 (353 mg).

LCMS: [M+H]⁺/Rt (min): 245/0.42

Reference Example 93(1R,6S)-2,2-Difluoro-6-[4-(2-methylpropyl)-1H-1,2,3-triazol-1-yl]cyclohexan-1-amine

The compound of Reference example 93 shown in the table below wasprepared according to the process in the above Reference example 92 byusing 4-methylpent-1-yne instead of 3-methylbut-1-yne at Step (ii) inReference example 92.

Instrumental Reference analytical example Chemical structure data 93

LCMS: [M + H]⁺/Rt (min): 259/0.51

Reference Example 94[(1S,2R)-2-Amino-3,3-difluorocyclohexyl][4-(propan-2-yl)piperazin-1-yl]methanone

Step (i):

To a solution of Compound 150 (555 mg) in DMSO (6 mL) was added aqueoushydrochloric acid (9 mL), and the reaction solution was heated at 120°C. After the reaction was completed, water was added to the reactionmixture, and the mixture was extracted with ethyl acetate. The organiclayer was dried over anhydrous sodium sulfate, and concentrated in vacuoto give the title compound 157 (600 mg).

Step (ii):

To a solution of Compound 157 (476 mg) in DMF (1.5 mL) were added1-isopropylpiperazine (234 mg), triethylamine (308 mg), and HATU (753mg), and the reaction solution was stirred at room temperature. Afterthe reaction was completed, water was added to the reaction mixture, andthe mixture was extracted with ethyl acetate. The organic layer wasdried over anhydrous sodium sulfate, concentrated in vacuo, and then theobtained residue was purified by amino silica gel column chromatography(eluate: chloroform/methanol) to give the title compound 158 (610 mg).

LCMS: [M+H]⁺/Rt (min): 475/0.59

Step (iii):

The title compound 159 (180 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 158 (605 mg).

LCMS: [M+H]⁺/Rt (min): 290/0.16

Reference Example 95(1R,6R)-2,2-Difluoro-6-{[4-(propan-2-yl)piperazin-1-yl]methyl}cyclohexan-1-amine

Step (i):

The title compound 160 (112 mg) was prepared in the same manner as Step(ii) in Reference example 22 by using Compound 159 (171 mg).

LCMS: [M+H]⁺/Rt (min): 276/0.24

Reference Examples 96-114

The compounds of Reference examples shown in the table below wereprepared according to the process in the above Reference example 37, byusing each appropriate starting compound instead of(S)-1-isopropylpyrrolidin-3-ol at Step (i) in Reference example 37.

Instrumental Reference analytical example Chemical structure data  96

LCMS: [M + H]⁺/Rt (min): 277/0.30  97

LCMS: [M + H]⁺/Rt (min): 278/0.57  98

LCMS: [M + H]⁺/Rt (min): 260/0.45  99

LCMS: [M + H]⁺/Rt (min): 249/0.16 100

LCMS: [M + H]⁺/Rt (min): 303/0.32 101

LCMS: [M + H]⁺/Rt (min): 303/0.33 102

LCMS: [M + H]⁺/Rt (min): 303/0.31 103

LCMS: [M + H]⁺/Rt (min): 303/0.32 104

LCMS: [M + H]⁺/Rt (min): 275/0.43 105

LCMS: [M + H]⁺/Rt (min): 277/0.38 106

LCMS: [M + H]⁺/Rt (min): 293/0.36 107

LCMS: [M + H]⁺/Rt (min): 291/0.16 (Method C) 108

LCMS: [M + H]⁺/Rt (min): 275/0.49 109

LCMS: [M + H]⁺/Rt (min): 291/0.20 (Method C) 110

LCMS: [M + H]⁺/Rt (min): 289/0.32 111

LCMS: [M + H]⁺/Rt (min): 293/0.26 112

LCMS: [M + H]⁺/Rt (min): 343/0.37 113

LCMS: [M + H]⁺/Rt (min): 295/0.37 114

LCMS: [M + H]⁺/Rt (min): 305/0.15

Reference Example 96:(1R,6S)-2,2-difluoro-6-{[1-(propan-2-yl)piperidin-4-yl]oxy}cyclohexan-1-amineReference Example 97:(1R,6S)-2,2-difluoro-6-{[3-(propan-2-yl)-1,2,4-thiadiazol-5-yl]oxy}cyclohexan-1-amineReference Example 98:(1R,6S)-2,2-difluoro-6-{[1-(propan-2-yl)-1H-pyrazol-4-yl]oxy}cyclohexan-1-amineReference Example 99:(1R,6S)-2,2-difluoro-6-{[1-(propan-2-yl)azetidin-3-yl]oxy}cyclohexan-1-amineReference Example 100:(1R,6S)-2,2-difluoro-6-{[(1R,3S,5S)-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-3-yl]oxy}cyclohexan-1-amineReference Example 101:(1R,6S)-2,2-difluoro-6-{[(1R,5S,8R)-3-(propan-2-yl)-3-azabicyclo[3.2.1]octan-8-yl]oxy}cyclohexan-1-amineReference Example 102:(1R,6S)-2,2-difluoro-6-{[(1R,5S,8S)-3-(propan-2-yl)-3-azabicyclo[3.2.1]octan-8-yl]oxy}cyclohexan-1-amineReference Example 103:(1R,6S)-2,2-difluoro-6-{[(1R,3R,5S)-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-3-yl]oxy}cyclohexan-1-amineReference Example 104:(1R,6S)-2,2-difluoro-6-{[(1R,5S,6S)-3-(propan-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl]oxy}cyclohexan-1-amineReference Example 105:(1R,6S)-2,2-difluoro-6-{[(3S)-1-(2-methylpropyl)pyrrolidin-3-yl]oxy}cyclohexan-1-amineReference Example 106:(1R,6S)-2,2-difluoro-6-{[(3R,4R)-4-methoxy-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexan-1-amineReference Example 107:(1R,6S)-2,2-difluoro-6-{[4-methyl-1-(propan-2-yl)piperidin-4-yl]oxy}cyclohexan-1-amineReference Example 108:(1R,6S)-6-{[(3S)-1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexan-1-amineReference Example 109:(1R,6S)-6-{[(3S)-1-(2,2-dimethylpropyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexan-1-amineReference Example 110:(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-methylcyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexan-1-amineReference Example 111:(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-fluorocyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexan-1-amineReference Example 112:(1R,6S)-2,2-difluoro-6-{[(3S)-1-{[1-(trifluoromethyl)cyclopropyl]methyl}pyrrolidin-3-yl]oxy}cyclohexan-1-amineReference Example 113:(1R,6S)-2,2-difluoro-6-{[(3S)-1-(2-fluoro-2-methylpropyl)pyrrolidin-3-yl]oxy}cyclohexan-1-amineReference Example 114:(1R,6S)-2,2-difluoro-6-({(3S)-1-[(3-methyloxetan-3-yl)methyl]pyrrolidin-3-yl}oxy)cyclohexan-1-amineReference Examples 115-118

The compounds of Reference examples 115-118 shown in the table belowwere prepared in the same manner as Reference example 8, by using theappropriate starting compound (Material A) instead of Compound 26 atStep (i) in Reference example 8, and each appropriate starting compound(Material B) instead of cyclopropane-carboxylic acid at Step (iii) inReference example 8.

Instrumental Reference Chemical analytical example Material A Material Bstructure data 115

LCMS: [M + H]⁺/Rt (min): 226/0.29 (Method C) 116

LCMS: [M + H]⁺/Rt (min): 226/0.29 (Method C) 117

LCMS: [M + H]⁺/Rt (min): 220/0.43 (Method C) 118

LCMS: [M + H]⁺/Rt (min): 240/0.39 (Method C)

Reference Example 115:4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidineReference Example 116:4-{5-[(1R,2R)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidineReference Example 117:4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidinemonohydrochloride Reference Example 118:4-ethyl-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}piperidineReference Example 119(1R,6S)-2,2-Difluoro-6-{[2-(propan-2-yl)pyrimidin-4-yl]oxy}cyclohexan-1-amine

Step (i):

To a solution of Compound 161 (148 mg) known in literature in THF (3 ml)were added sodium hydride (55%, 30 mg) at 0° C., and then4-chloro-2-(propan-2-yl)pyrimidine. The reaction solution was warmed toroom temperature and stirred. After the reaction was completed, waterwas added to the reaction mixture, and the mixture was extracted withchloroform. The organic layer was dried over anhydrous sodium sulfate,concentrated in vacuo, and then the obtained residue was purified bysilica gel column chromatography (eluate: hexane/ethyl acetate) to givethe title compound 162 (209 mg).

Step (ii):

To a solution of Compound 162 (113 mg) in ethyl acetate (2 mL) was addedpalladium hydroxide (17 mg) at room temperature, and the mixture wasstirred under hydrogen atmosphere. After the reaction was terminated asjudged by LC-MS, the reaction mixture was filtrated with Celite, and thefiltrate was concentrated in vacuo to give the title compound 163 (33.5mg).

LCMS: [M+H]⁺/Rt (min): 272/0.47

Reference Example 120(1R,6S)-2,2-Difluoro-N-methyl-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-amine

Step (i):

To a solution of Compound 50 (173 mg) in DMF (3 mL) were added cesiumcarbonate (253 mg) and methyl iodide (72 mg) at 0° C., and then thereaction mixture was warmed to room temperature and stirred. After thereaction was completed, water was added to the reaction mixture, and themixture was extracted with diethyl ether. The organic layer was driedover anhydrous sodium sulfate, concentrated in vacuo, and then theobtained residue was purified by amino silica gel column chromatography(eluate: hexane/ethyl acetate) to give the title compound 164 (159 mg).

Step (ii):

The title compound 165 (71 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 164 (134 mg).

LCMS: [M+H]⁺/Rt (min): 276/0.15

Reference Example 121rac-(1S,6S)-2,2-Dimethyl-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-amine

Step (i):

To a solution of Compound 166 (283 mg) in 2-propanol (8 ml) was addedaqueous ammonia (6 g), and the reaction mixture was refluxed. After thereaction was terminated as judged by the consumption of the startingmaterial, the reaction solution was concentrated in vacuo to be used inthe next step.

Step (ii):

The title compound 168 (64.3 mg) was prepared in the same manner as Step(i) in Reference example 18 by using Compound 167.

Step (iii):

The title compound 169 (102 mg) was prepared in the same manner as Step(ii) in Reference example 18 by using Compound 168 (60.8 mg).

Step (iv):

The title compound 170 (40.2 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 169 (102 mg).

LCMS: [M+H]⁺/Rt (min): 254/0.43

Reference Example 122rac-(1S,2S)-2-[4-(Propan-2-yl)piperazin-1-yl]cycloheptan-1-amine

The compounds of Reference examples shown in the table below wereprepared according to the process in the above Reference example 120, byusing 8-oxabicyclo[5.1.0]octane instead of Compound 166 at Step (i) inReference example 120.

Instrumental Reference analytical example Chemical structure data 122

LCMS: [M + H]⁺/Rt (min): 240/0.24

Reference Example 123rac-(1R,2R,6S)-2-Fluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-amine

Step (i):

A solution of Compound 171 (403 mg) and tetrabutylammonium dihydrogentrifluoride (1.78 g) in toluene (1 mL) was heated at 150° C. with amicrowave device. After the reaction was completed, water was added tothe reaction mixture, and the mixture was extracted with diethyl ether.The organic layer was dried over anhydrous sodium sulfate, concentratedin vacuo, and then the obtained residue was purified by amino silica gelcolumn chromatography (eluate: hexane/ethyl acetate) to give the titlecompound 172 (323 mg).

Step (ii):

Compound 172 (457 mg) was dissolved in THF (4.1 mL). To the solutionwere added triethylamine (1.13 mL) and methanesulfonyl chloride (0.318mL) under ice temperature, and the reaction mixture was stirred. Afterthe reaction was terminated as judged by the consumption of the startingmaterial, water was added to the reaction mixture, and the mixture wasextracted with ethyl acetate. The organic layer was dried over anhydroussodium sulfate, concentrated in vacuo, and then the obtained residue waspurified by amino silica gel column chromatography (eluate: hexane/ethylacetate) to give the title compound 173 (578 mg).

Step (iii):

To a solution of Compound 173 (571 mg) in ethanol (3.5 mL) was addedpalladium hydroxide (20%, 133 mg) at room temperature, and the mixturewas stirred under hydrogen atmosphere. After the reaction was completed,the reaction mixture was filtrated with Celite, and the filtrate wasconcentrated in vacuo. The obtained residue was purified by silica gelcolumn chromatography (eluate: hexane/ethyl acetate) to give the titlecompound 174 (400 mg).

Step (iv):

Compound 174 (176 mg) was dissolved in 1,4-dioxane (3.5 mL). To thesolution was added DBU (0.25 mL), and the reaction mixture was stirredat 85° C. After the reaction was terminated as judged by the consumptionof the starting material, the reaction mixture was subsequently reactedin the same manner as Step (i) in Reference example 121, andmethanesulfonylated in the same manner as the present Step (ii). Waterwas added to the reaction mixture, and the mixture was extracted withchloroform. The organic layer was dried over anhydrous sodium sulfateand concentrated in vacuo to give the title compound 175 (86 mg).

Step (v):

The title compound 176 (92.8 mg) was prepared according to thecyclization condition of Step (ii) in Reference example 121 followed bythe same manner as Step (ii) in Reference example 18 by using Compound175 (86 mg).

Step (vi):

The title compound 177 (35.1 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 176 (86.1 mg).

LCMS: [M+H]⁺/Rt (min): 244/0.19

Reference Example 124rac-(1R,2S,6S)-2-Fluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexan-1-amine

Step (i):

The title compound 179 (953 mg) was prepared in the same manner as Step(i) in Reference example 123 by using Compound 178 (929 mg).

Step (ii):

Compound 179 (283 mg) was dissolved in chloroform (6 mL). To thesolution were added pyridine (0.51 mL) and trifluoromethanesulfonicanhydride (0.256 mL) under ice temperature, and the reaction mixture wasstirred. After the reaction was terminated as judged by the consumptionof the starting material, aqueous sodium bicarbonate was added to thereaction mixture, and the mixture was extracted with chloroform. Theorganic layer was dried over anhydrous sodium sulfate, concentrated invacuo, and then the obtained residue was purified by silica gel columnchromatography (eluate: hexane/ethyl acetate) to give the title compound180 (424 mg).

Step (iii):

To a solution of Compound 180 (418 mg) in DMF (4 mL) was added sodiumazide (229 mg), and the reaction solution was stirred at roomtemperature. After the reaction was completed, water was added to thereaction mixture, and the mixture was extracted with diethyl ether. Theorganic layer was dried over anhydrous sodium sulfate, concentrated invacuo, and then the obtained residue was purified by silica gel columnchromatography (eluate: hexane/ethyl acetate) to give the title compound181 (102 mg).

Step (iv):

To a solution of Compound 181 (102 mg) in ethanol (2 mL) was addedpalladium hydroxide (20%, 58 mg) at room temperature, and the mixturewas stirred under hydrogen atmosphere. The reaction mixture wasfiltrated with Celite, and the filtrate was concentrated in vacuo. Theobtained residue was dissolved in ethanol (2 mL) again, and aqueoushydrogen chloride (cyclopentylmethyl solution, 5 M, 0.327 mL) andpalladium carbon (10%, 71 mg) were added thereto. The mixture wasstirred under hydrogen atmosphere. After the reaction was completed, thereaction mixture was filtrated with Celite, and the filtrate wasconcentrated in vacuo to give the title compound 182 (76.8 mg).

Step (v):

The title compound 183 (69 mg) was prepared in the same manner as Step(i) and Step (ii) in Reference example 18 by using Compound 182 (103mg).

Step (vi):

The title compound 184 (34.3 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 183 (72 mg).

LCMS: [M+H]⁺/Rt (min): 244/0.14

Reference Example 125 (1S,2R)-2-Amino-3,3-difluorocyclohexyl4-(propan-2-yl)piperazine-1-carboxylate

Step (i):

To a solution of Compound 185 known in literature in acetonitrile (3 mL)was added Boc₂O (238 mg), and the reaction solution was stirred at roomtemperature. After the reaction was completed, the reaction mixture wasconcentrated in vacuo, and the obtained residue was purified by silicagel column chromatography (eluate: hexane/ethyl acetate) to give thetitle compound 186 (216 mg).

Step (ii):

The title compound 187 (118 mg) was prepared in the same manner as Step(iii) in Reference example 2 by using Compound 186 (95.7 mg).

Step (iii):

The title compound 188 (99.7 mg) was prepared in the same manner as Step(iv) in Reference example 2 by using Compound 187 (118 mg).

LCMS: [M+H]⁺/Rt (min): 306/0.25

Reference Example 126N-{(1S,6S)-2,2-Difluoro-6-[1-(propan-2-yl)piperidine-4-sulfonyl]cyclohexyl}-4-nitrobenzene-1-sulfonamide

Step (i):

The title compound 189 (402 mg) was prepared in the same manner as Step(ii) in Reference example 18 by using Compound 49 (399 mg) andCert-butyl 4-sulfanylpiperidine-1-carboxylate (300 mg).

Step (ii):

To a solution of Compound 189 (210 mg) in chloroform (2 mL) was addedm-CPBA (242 mg), and the reaction solution was stirred at roomtemperature. After the reaction was completed, aqueous sodiumthiosulfate was added to the reaction mixture, and the mixture wasextracted with chloroform. The organic layer was dried over anhydroussodium sulfate, concentrated in vacuo, and then the obtained residue waspurified by amino silica gel column chromatography (eluate:chloroform/methanol) to give the title compound 190 (250 mg).

Step (iii):

The title compound 191 (223 mg) was prepared in the same manner as Step(i) and Step (ii) in Reference example 53 by using Compound 190 (250mg).

Step (iv):

The title compound 192 (102 mg) was prepared in the same manner as Step(iii) in Reference example 18 by using Compound 191 (223 mg).

LCMS: [M+H]⁺/Rt (min): 325/0.21

Test 1: Evaluation of Agonist Activity for Orexin Receptor Type 2

Human orexin receptor type 2 and apoaequorin were transiently expressedin CHO cells, and the agonist activity was evaluated based onintracellular calcium mobilization with ligand stimulation. The CHOcells transiently-expressed human orexin receptor type 2 and apoaequorinwere seeded on a 384-well plate by 2,000 cells/well, and then incubatedfor 16-22 hours. After the plate was returned to room temperature,Coelenterazine hcp (final concentration: 1 μM) was added to the plate,and the plate was allowed to stand at room temperature for 2 hours. Andthen, Orexin A (PEPTIDE INSTITUTE, INC., Lot. 641114) or each testcompound was added to the plate, and the luminescence of the cells wasmeasured with FDSS7000 (Hamamatsu Photonics K.K.), wherein Orexin A andeach test compound were dissolved in DMSO (final concentration: 0.1%),and diluted with a buffer (Hanks, 20 mM HEPES, 0.1% BSA). The agonistactivity of each test compound for orexin receptor type 2 was calculatedas relative percentage of luminescence for the luminescence (100%) ofOrexin A (100 pM).

Result:

The results that each compound obtained in Examples was evaluated aboutthe agonist activity for orexin receptor type 2 showed that the presentcompounds have agonist activity for orexin receptor type 2. Each agonistactivity of the example compounds is shown in the table below asrelative percentage of luminescence for the luminescence (100%) ofOrexin A (100 pM).

Example agonist activity (%) 1 137 2 58 3 67 4 62 5 103 6 43 7 75 8 2079 207 10 213 11 211 12 178 13 56 14 178 15 62 16 39 17 72 18 73 19 16720 160 21 153 22 163 23 104 24 210 25 165 26 198 27 162 28 190 29 109 30128 31 168 32 176 33 123 34 183 35 165 36 114 37 45 38 142 39 157 41 2342 141 43 146 44 148 45 150 46 136 47 163 48 156 49 151 50 154 51 149 52113 53 143 54 146 55 95 56 140 57 155 58 150 59 164 60 151 61 169 62 17463 149 64 204 65 155 66 144 67 175 68 156 69 161 70 141 71 199 72 146 73185 74 174 75 141 76 145 77 158 78 36 79 191 80 178 81 57

Test 2: Evaluation of Agonist Activity for Orexin Receptor Type 2

Human orexin receptor type 2 and apoaequorin were transiently expressedin CHO cells, and the agonist activity was evaluated based onintracellular calcium mobilization with ligand stimulation. The CHOcells transiently-expressed human orexin receptor type 2 and apoaequorinwere seeded on a 384-well plate by 2,000 cells/well, and then incubatedfor 16-22 hours. After the plate was returned to room temperature,Coelenterazine hcp (final concentration: 1 μM) was added to the plate,and the plate was allowed to stand at room temperature for 2 hours. Andthen, Orexin A (PEPTIDE INSTITUTE, INC., Lot. 671009) or each testcompound was added to the plate, and the luminescence of the cells wasmeasured with FDSS7000 (Hamamatsu Photonics K.K.), wherein Orexin A andeach test compound were dissolved in DMSO (final concentration: 0.1%),and diluted with a buffer (Hanks, 20 mM HEPES, 0.1% BSA). The agonistactivity of each test compound for orexin receptor type 2 was calculatedas relative percentage of luminescence for the luminescence (100%) ofOrexin A (100 pM).

Result:

The results that each compound obtained in Examples was evaluated aboutthe agonist activity for orexin receptor type 2 showed that the presentcompounds have agonist activity for orexin receptor type 2. Each agonistactivity of the example compounds is shown in the table below asrelative percentage of luminescence for the luminescence (100%) ofOrexin A (100 pM).

Example agonist activity (%) 82 69 83 371 84 372 85 360 86 367 87 226 88201 89 0 90 112 91 243 92 16 93 365 94 382 95 447 96 493 97 486 98 27199 499 100 340 101 326 102 374 103 369 104 289 105 359 106 220 107 363108 292 109 359 110 380 111 382 112 376 113 374 114 438 115 403 116 488117 465 118 524 119 378 120 387 121 379 122 369 123 366 124 391 125 402126 394 127 367 128 402 129 435 130 450 131 461 132 166 133 506 134 456135 396 136 346 137 376 138 385 139 351 140 249 141 405 142 407 143 444144 399 145 403 146 23 147 373 148 391 149 419 150 437 151 368 152 470153 350 154 493 155 167 156 323 157 392 158 389 159 392 160 410 161 374

INDUSTRIAL APPLICABILITY

The compounds of the present invention exhibit a potent agonist activityfor orexin receptor, thereby they are useful as a medicament fortreating or preventing narcolepsy, idiopathic hypersomnia, hypersomnia,sleep apnea syndrome, narcolepsy syndrome involving narcolepsy-likesymptom, hypersomnia associated with Parkinson's disease, hypersomniaassociated with dementia with Lewy body, etc.

1. A compound of formula (1):

or a pharmaceutically acceptable salt thereof wherein R¹ isoptionally-substituted C₆₋₁₀ aromatic carbocyclyl group,optionally-substituted 5- to 10-membered aromatic heterocyclyl group,optionally-substituted C₃₋₆ saturated carbocyclyl group,optionally-substituted 4- to 10-membered saturated heterocyclyl group,or cyano; L¹ and L² are each independently single bond, methylene (whichmay be optionally substituted with the same or different one or moreC₁₋₄ alky), —NR⁸—, —C(═O)—, —OC(═O)—, —SO—, —SO₂—, —S—, or oxygen atom;R² is hydrogen atom, hydroxy group, halogen atom, cyano, oroptionally-substituted C₁₋₄ alkyl; or when L¹ is single bond, R¹ and R²may be combined together as a Spiro ring to form optionally-substitutedC₃₋₆ saturated carbocyclic ring or optionally-substituted 4- to10-membered saturated heteroring; R³ and R⁴ are each independentlyhydrogen atom, halogen atom, cyano, —(C═O)NR⁵R⁶, carboxy group,—(C═O)O—R⁷, optionally-substituted C₁₋₄ alkyl, or optionally-substitutedC₁₋₄ alkoxy, wherein R³ and R⁴ may bind to the same carbon atom ifchemically possible; or when R³ and R⁴ bind to different ring carbonatoms, R³ and R⁴ may be taken together via C₁₋₆ alkylene to form a fusedring or a bridged ring; R⁵ to R⁷ are each independently hydrogen atom,halogen atom, or optionally-substituted C₁₋₄ alkyl; R⁸ is eachindependently hydrogen atom or optionally-substituted C₁₋₄ alkyl; n isan integer of 1, 2, 3, or 4; Ring G is optionally-substituted C₆₋₁₀aromatic carbocyclyl group, optionally-substituted 5- to 10-memberedaromatic heterocyclyl group, optionally-substituted C₃₋₆ saturatedcarbocyclyl group, or optionally-substituted 4- to 10-membered saturatedheterocyclyl group; A¹ is oxygen atom or sulfur atom; A² is oxygen atomor —NR⁸—, A³ is —CH—, nitrogen atom, or carbon atom; and the bondaccompanied with broken line is each independently single bond or doublebond.
 2. The compound of claim 1 or a pharmaceutically acceptable saltthereof, wherein in R²-R⁸, the optional substituent of“optionally-substituted C₁₋₄ alkyl” is the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkoxy, C₆₋₁₀ aromatic carbocyclyl group, and C₃₋₇cycloalkyl; and the optional substituent of “optionally-substituted C₁₋₄alkoxy” is the same or different one or more substituents selected fromthe group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl, andC₃₋₇ cycloalkyl; in R¹, the optional substituent of“optionally-substituted C₆₋₁₀ aromatic carbocyclyl group”,“optionally-substituted 5- to 10-membered aromatic heterocyclyl group”,“optionally-substituted C₃₋₆ saturated carbocyclyl group”, and“optionally-substituted 4- to 10-membered saturated heterocyclyl group”is each independently at least one substituent selected from the groupconsisting of hydrogen atom, halogen atom, hydroxy group, C₆₋₁₀ aromaticcarbocyclyl group (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇cycloalkyl), C₁₋₄ alkyl (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkoxy, and C₃₋₇cycloalkyl), C₃₋₇ cycloalkyl (which may be optionally substituted withthe same or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, C₁₋₄ alkoxy, andC₃₋₇ cycloalkyl), C₁₋₆ alkylamino (the alkyl group of which may beoptionally substituted with halogen atom, hydroxy group, or C₃₋₇cycloalkyl), C₃₋₇ cycloalkoxy (which may be optionally substituted withthe same or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, C₁₋₄ alkoxy, andC₃₋₇ cycloalkyl), cyano, C₁₋₄ alkoxy (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyloptionally-substituted with the same or different one or more halogenatoms, and C₃₋₇ cycloalkyl), and 5- to 10-membered aromatic heterocyclylgroup (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl); andin Ring G, the optional substituent of “optionally-substituted C₆₋₁₀aromatic carbocyclyl group”, “optionally-substituted 5- to 10-memberedaromatic heterocyclyl group”, “optionally-substituted C₃₋₆ saturatedcarbocyclyl group”, and “optionally-substituted 4- to 10-memberedsaturated heterocyclyl group” is each independently at least onesubstituent selected from the group consisting of halogen atom, C₁₋₆alkyl (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₆₋₁₀ aromaticcarbocyclyl group (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇cycloalkyl), C₁₋₄ alkoxy (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and C₃₋₇cycloalkyl), C₁₋₆ alkylamino (the alkyl group of which may be optionallysubstituted with halogen atom, hydroxy group, or C₃₋₇ cycloalkyl), C₃₋₇cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇cycloalkyl), and C₃₋₇ cycloalkoxy (which may be optionally substitutedwith the same or different one or more substituents selected from thegroup consisting of halogen atom, hydroxy group, C₁₋₄ alkyl, C₁₋₄alkoxy, and C₃₋₇ cycloalkyl); or when there are plural optionalsubstituents, two of them may be taken together via C₁₋₆ alkylene toform a chemically-possible bicyclic structure selected from a fusedring, a Spiro ring, and bridged ring.
 3. The compound of claim 1 or apharmaceutically acceptable salt thereof, wherein in R²-R⁷, the optionalsubstituent of “optionally-substituted C₁₋₄ alkyl” is the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkoxy; and the optional substituent of“optionally-substituted C₁₋₄ alkoxy” is the same or different one ormore substituents selected from the group consisting of halogen atom andC₁₋₄ alkyl; in R¹, the optional substituent of “optionally-substitutedC₆₋₁₀ aromatic carbocyclyl group”, “optionally-substituted 5- to10-membered aromatic heterocyclyl group”, “optionally-substituted C₃₋₆saturated carbocyclyl group”, and “optionally-substituted 4- to10-membered saturated heterocyclyl group” is each independently at leastone substituent selected from the group consisting of hydrogen atom,halogen atom, hydroxy group, C₆₋₁₀ aromatic carbocyclyl group (which maybe optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₁₋₄ alkyl (whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), C₃₋₇ cycloalkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl), cyano, C₁₋₄ alkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl optionally-substituted with the same ordifferent one or more halogen atoms, and C₃₋₇ cycloalkyl), and 5- to10-membered aromatic heterocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,C₁₋₄ alkoxy, and C₃₋₇ cycloalkyl); and in Ring G, the optionalsubstituent of “optionally-substituted C₆₋₁₀ aromatic carbocyclylgroup”, “optionally-substituted 5- to 10-membered aromatic heterocyclylgroup”, “optionally-substituted C₃₋₆ saturated carbocyclyl group”, and“optionally-substituted 4- to 10-membered saturated heterocyclyl group”is each independently at least one substituent selected from the groupconsisting of halogen atom, C₁₋₆ alkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkoxy), C₆₋₁₀aromatic carbocyclyl group (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₁₋₄ alkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom andC₁₋₄ alkyl), C₃₋₇ cycloalkyl (which may be optionally substituted withthe same or different one or more substituents selected from the groupconsisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₁₋₆alkylamino (the alkyl group of which may be optionally substituted withhalogen atom, hydroxy group, or C₃₋₇ cycloalkyl), and C₃₋₇ cycloalkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,C₁₋₄ alkyl, and C₁₋₄ alkoxy); or when there are plural optionalsubstituents, two of them may be taken together via C₁₋₆ alkylene toform a chemically-possible bicyclic structure selected from a fusedring, a spiro ring, and bridged ring.
 4. The compound of claim 1 or apharmaceutically acceptable salt thereof, wherein R¹ is selected fromthe following formulae (1a-1) to (1a-4):

wherein X¹-X⁷ are each independently nitrogen atom or CR^(a6); Q¹ and Q²are oxygen atom, —NR^(a7)—, or sulfur atom; R^(a1)-R^(a7) are eachindependently (if there are plural CR^(a6), each R^(a6) is alsoindependently), hydrogen atom, halogen atom, C₆₋₁₀ aromatic carbocyclylgroup (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₁₋₄ alkyl (which maybe optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₇ cycloalkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), cyano, C₁₋₄ alkoxy (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₇ cycloalkoxy (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or 5- to 10-membered aromaticheterocyclyl group; wherein R^(a4) and R^(a5) may bind to the samecarbon atom if chemically possible; and when X¹ and X³ are both CR^(a6),the two R^(a6) may be taken together with the carbon atoms to which theyare each attached to form 6-membered carbon ring that is fused with the5-membered ring comprising X¹, X², and X³; and q¹ is an integer of 1 or2.
 5. The compound of claim 1 or a pharmaceutically acceptable saltthereof, wherein Ring G is selected from the following (1b-1) to(1b-14):

wherein W¹, W³, W⁵, W⁶, W⁷, W¹¹, W¹², W¹³, W¹⁵, W¹⁶, W¹⁷, W¹⁹, and W²⁵are each independently nitrogen atom or CR^(b4), W², W⁴, W⁸, W⁹, W¹⁰,W¹⁴, W¹⁸, W²⁰, W²¹, W²², W²³, and W²⁴ are NR^(b5), oxygen atom, orCR^(b6)R^(b7); R^(b1)-R^(b7) are each independently (if there are pluralCR^(b4), each R^(b4) is also independently), hydrogen atom,—N(R^(b8))R^(b9), C₁₋₆ alkyl (which may be optionally substituted withthe same or different one or more substituents selected from the groupconsisting of halogen atom, C₃₋₇ cycloalkyl which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkyl (said C₁₋₄alkyl may be substituted with halogen atom), and C₁₋₄ alkoxy), C₆₋₁₀aromatic carbocyclyl group (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy), 5- to10-membered aromatic heterocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),C₁₋₄ alkoxy (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkyl), C₃₋₇ cycloalkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),or C₃₋₇ cycloalkoxy (which may be optionally substituted with the sameor different one or more substituents selected from the group consistingof halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy); wherein R^(b1) and R^(b2)may bind to the same carbon atom if chemically possible; or R^(b1) andR^(b2) may be taken together via C₁₋₆ alkylene to form achemically-possible bicyclic structure selected from a fused ring, aSpiro ring, and bridged ring; and R^(b8) and R^(b9) are eachindependently hydrogen atom, C₁₋₆ alkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkoxy, C₃₋₇ cycloalkylwhich may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom andC₁₋₄ alkyl (said C₁₋₄ alkyl may be substituted with halogen atom), and5- to 10-membered aromatic heterocyclyl group), C₁₋₄ alkoxy (which maybe optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom and C₁₋₄alkyl), 5- to 10-membered aromatic heterocyclyl group (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy), or C₃₋₇ cycloalkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,and C₁₋₄ alkoxy); or R^(b8) and R^(b9) may be taken together with thenitrogen atom to which they are attached to form 3- to 7-memberednitrogen-containing saturated heterocycle.
 6. The compound of claim 1 offormula (2):

or a pharmaceutically acceptable salt thereof, wherein R¹ is selectedfrom the following formulae (1a-1) to (1a-4):

wherein X¹-X⁷ are each independently nitrogen atom or CR^(a6); Q¹ and Q²are oxygen atom, —NR^(a7)—, or sulfur atom; R^(a1)-R^(a7) are eachindependently (if there are plural CR^(a6), each R^(a6) is alsoindependently), hydrogen atom, halogen atom, C₆₋₁₀ aromatic carbocyclylgroup (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₁₋₄ alkyl (which maybe optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₆ cycloalkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), cyano, C₁₋₄ alkoxy (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₇ cycloalkoxy (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or 5- to 10-membered aromaticheterocyclyl group; wherein R^(a4) and R^(a5) may bind to the samecarbon atom if chemically possible; and when X¹ and X³ are both CR^(a6),the two R^(a6) may be taken together with the carbon atoms to which theyare each attached to form 6-membered carbon ring that is fused with the5-membered ring comprising X¹, X², and X³; and q¹ is an integer of 1 or2; L¹ and L² are each independently single bond, —CH₂—, or oxygen atom;R² is hydrogen atom, hydroxy group, halogen atom, cyano, oroptionally-substituted C₁₋₄ alkyl; R³ and R⁴ are each independentlyhydrogen atom, halogen atom, C₁₋₄ alkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkoxy,and C₃₋₇ cycloalkyl), or C₁₋₄ alkoxy (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,and C₃₋₇ cycloalkyl); wherein R³ and R⁴ may bind to the same carbon atomif chemically possible; and when R³ and R⁴ bind to different carbonatoms on the ring, R³ and R⁴ may be taken together via C₁₋₆ alkylene toform a fused ring or bridged ring; Ring G is selected from the following(1b-1) to (1b-4):

wherein W³, W⁵, W⁶, and W⁷ are each independently nitrogen atom orCR^(b4); W², W⁴, and W⁸ are NR^(b5), oxygen atom or CR^(b6)R^(b7);R^(b1)-R^(b7) are each independently (if there are plural CR^(b4), eachR^(b4) is also independently), hydrogen atom, C₁₋₆ alkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom and C₁₋₄alkoxy), C₆₋₁₀ aromatic carbocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),C₁₋₄ alkoxy (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkyl), C₃₋₇ cycloalkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),or C₃₋₇ cycloalkoxy (which may be optionally substituted with the sameor different one or more substituents selected from the group consistingof halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy); wherein R^(b1) and R^(b2)may bind to the same carbon atom if chemically possible; or R^(b1) andR^(b2) may be taken together via C₁₋₆ alkylene to form achemically-possible bicyclic structure selected from a fused ring, aSpiro ring, and bridged ring; A¹ is oxygen atom or sulfur atom; A² isoxygen atom or —NH—; and A³ is —CH—, nitrogen atom, or carbon atom. 7.The compound of claim 6 or a pharmaceutically acceptable salt thereof,wherein R¹ is selected from the following formulae (1a-1), (1a-2), and(1a-3-1)

wherein X¹-X⁶ are each independently nitrogen atom or CR^(a6); Q¹ and Q²are oxygen atom, —NR^(a7)—, or sulfur atom; and R^(a1)-R^(a3), R^(a6),and R^(a7) are each independently (if there are plural CR^(a6), eachR^(a6) is also independently), hydrogen atom, halogen atom, C₆₋₁₀aromatic carbocyclyl group (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy),C₁₋₄ alkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₇cycloalkyl (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), cyano, C₁₋₄alkoxy (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₃₋₇ cycloalkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom,hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or 5- to 10-memberedaromatic heterocyclyl group; wherein when X¹ and X³ are both CR^(a6),the two R^(a6) may be taken together with the carbon atoms to which theyare each attached to form 6-membered carbon ring that is fused with the5-membered ring comprising X¹, X², and X³.
 8. The compound of claim 6 ora pharmaceutically acceptable salt thereof, wherein Ring G is selectedfrom the following (1b-1), (1b-2), and (1b-4):

wherein W¹, W³, W⁵, W⁶, and W⁷ are each independently nitrogen atom orCR^(b4); W² and W⁴ are NR^(b5) or CR^(b6)R^(b7); and R^(b1), R^(b2), andR^(b4)-R^(b7) are each independently (if there are plural CR^(b4), eachR^(b4) is also independently), hydrogen atom, C₁₋₆ alkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom and C₁₋₄alkoxy), C₆₋₁₀ aromatic carbocyclyl group (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),C₁₋₄ alkoxy (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkyl), C₃₋₇ cycloalkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy),or C₃₋₇ cycloalkoxy (which may be optionally substituted with the sameor different one or more substituents selected from the group consistingof halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy); or R^(b1) and R^(b2) maybind to the same carbon atom if chemically possible; or R^(b1) andR^(b2) may be taken together via C₁₋₆ alkylene to form a bridgedbicyclic structure.
 9. The compound of claim 6 or a pharmaceuticallyacceptable salt thereof, wherein Ring G is selected from the following(1b-1) and (1b-2):

wherein W¹ and W³ are nitrogen atom or CR^(b4); W² and W⁴ are NR^(b5) orCR^(b6)R^(b7); and R^(b1), R^(b2), and R^(b4)-R^(b7) are eachindependently hydrogen atom, C₁₋₆ alkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkoxy), C₆₋₁₀aromatic carbocyclyl group (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy), C₁₋₄ alkoxy(which may be optionally substituted with the same or different one ormore substituents selected from the group consisting of halogen atom andC₁₋₄ alkyl), C₃₋₇ cycloalkyl (which may be optionally substituted withthe same or different one or more substituents selected from the groupconsisting of halogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy), or C₃₋₇cycloalkoxy (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom, C₁₋₄ alkyl, and C₁₋₄ alkoxy); wherein R^(b1) and R^(b2)may bind to the same carbon atom if chemically possible; or R^(b1) andR^(b2) may be taken together via C₁₋₆ alkylene to form a bridgedbicyclic structure.
 10. The compound of claim 1 of formula (3):

or a pharmaceutically acceptable salt thereof, wherein R¹ is thefollowing formula (1a-1), (1a-2), or (1a-3-1):

wherein X¹-X⁶ are each independently nitrogen atom or CR^(a6); Q¹ and Q²are oxygen atom or sulfur atom; R^(a1)-R^(a3) and R^(a6) are eachindependently (if there are plural CR^(a6), each R^(a6) is alsoindependently), hydrogen atom, halogen atom, C₁₋₄ alkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, hydroxygroup, and C₁₋₄ alkoxy), C₃₋₇ cycloalkyl (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,and C₁₋₄ alkoxy), cyano, or C₁₋₄ alkoxy (which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom, hydroxy group, C₁₋₄ alkyl,and C₁₋₄ alkoxy); wherein when X¹ and X³ are both CR^(a6), the twoR^(a6) may be taken together with the carbon atoms to which they areeach attached to form 6-membered carbon ring that is fused with the5-membered ring comprising X¹, X², and X³; L¹ and L² are eachindependently single bond or oxygen atom; R² is hydrogen atom, halogenatom, or C₁₋₄ alkyl which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and hydroxy group; R³ and R⁴ are each independently halogenatom; Ring G is the following (1b-1), (1b-2-1), (1b-2-2), or (1b-2-3):

wherein R^(b5) is hydrogen atom, or C₁₋₆ alkyl which may be optionallysubstituted with the same or different one or more substituents selectedfrom the group consisting of halogen atom and C₁₋₄ alkoxy; and A¹ isoxygen atom or sulfur atom.
 11. The compound of claim 4 or apharmaceutically acceptable salt thereof, wherein R¹ is formula (1a-2),and R^(a1) is hydrogen atom, halogen atom, C₁₋₄ alkyl (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom and C₁₋₄alkoxy), C₃₋₇ cycloalkyl (which may be optionally substituted with thesame or different one or more substituents selected from the groupconsisting of halogen atom, hydroxy group, C₁₋₄ alkyl, and C₁₋₄ alkoxy),or C₁₋₄ alkoxy (which may be optionally substituted with the same ordifferent one or more substituents selected from the group consisting ofhalogen atom and C₁₋₄ alkyl).
 12. The compound of claim 10 or apharmaceutically acceptable salt thereof, wherein R¹ is formula (1a-2),and X⁴ and X⁵ are both nitrogen atom.
 13. The compound of claim 10 or apharmaceutically acceptable salt thereof, wherein Ring G is formula(1b-1-1), and R^(b5) is C₁₋₄ alkyl which may be optionally substitutedwith the same or different one or more halogen atoms.
 14. The compoundof claim 10 or a pharmaceutically acceptable salt thereof, wherein RingG is formula (1b-2-1), and R^(b5) is hydrogen atom, or C₁₋₄ alkyl whichmay be optionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom and C₁₋₄alkoxy.
 15. The compound of any one of claim 1 of formula (4):

or a pharmaceutically acceptable salt thereof, wherein R¹ is thefollowing (1a-2-1):

wherein Q² is oxygen atom or sulfur atom; R^(a2) is C₃₋₇ cycloalkylgroup (which may be optionally substituted with the same or differentone or more substituents selected from the group consisting of halogenatom, C₁₋₄ alkyl, and C₁₋₄ alkoxy) or cycloalkoxy group (which may beoptionally substituted with the same or different one or moresubstituents selected from the group consisting of halogen atom, C₁₋₄alkyl, and C₁₋₄ alkoxy); R² is C₁₋₄ alkyl; Ring G is the following(1b-1-1) or (1b-2-1):

wherein R^(b5) is C₁₋₄ alkyl which may be optionally substituted withthe same or different one or more substituents selected from the groupconsisting of halogen atom and C₁₋₄ alkoxy; and L² is single bond oroxygen atom.
 16. The compound of claim 15 or a pharmaceuticallyacceptable salt thereof, wherein R^(a2) is C₃₋₇ cycloalkyl group whichmay be optionally substituted with the same or different one or moresubstituents selected from halogen atoms, and R² is methyl group. 17.The compound of claim 15 or a pharmaceutically acceptable salt thereof,wherein R^(a2) is cyclopropyl group which may be optionally substitutedwith the same or different one or more substituents selected fromhalogen atoms, and R² is methyl group.
 18. The compound of claim 15 or apharmaceutically acceptable salt thereof, wherein Ring G is formula(1b-2-1), and R^(b5) is isopropyl group.
 19. The compound of claim 15 ora pharmaceutically acceptable salt thereof, wherein Ring G is formula(1b-1-1), and R^(b5) is isobutyl group.
 20. The compound of claim 15 ora pharmaceutically acceptable salt thereof, wherein Ring G is formula(1b-1-1), R^(b5) is isopropyl group, and L² is oxygen atom.
 21. Thecompound of claim 15 or a pharmaceutically acceptable salt thereof,wherein Q² is oxygen atom.
 22. The compound of claim 1 or apharmaceutically acceptable salt thereof, which is selected from thefollowing compound names or structures:4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamide

4-(5-cyclopropyl-1,2-oxazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[3-(propan-2-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-{5-[(1S,2R)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamide

N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methyl-4-{5-[(1S,2R)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamide

rac-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carbothioamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carbothioamide


23. The compound of claim 1 or a pharmaceutically acceptable saltthereof, which is selected from the following compound names orstructures:4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methyl-4-(4-methylphenyl)piperidine-1-carboxamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{[(3R)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methyl-4-{5-[(1R,2S)-2-methylcyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S,4S)-4-fluoro-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-6-{[(3R)-4,4-difluoro-1-(propan-2-yl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-methylpiperidine-1-carboxamide.


24. The compound of claim 1 or a pharmaceutically acceptable saltthereof, which is selected from the following compound names orstructures:N-{(1S,6R)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1R,2R)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{methyl[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{(3S)-3-[methyl(propan-2-yl)amino]pyrrolidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)-N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{(3S)-3-[methyl(propan-2-yl)amino]pyrrolidin-1-yl}cyclohexyl]-4-methylpiperidine-1-carboxamide

N-{(1R,6S)-2,2-difluoro-6-[(2S)-2-methyl-4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-{(1R,6S)-2,2-difluoro-6-[(2R)-2-methyl-4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{(3R)-3-[methyl(propan-2-yl)amino]pyrrolidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{4-[methyl(propan-2-yl)amino]piperidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-6-{(3S)-3-[cyclopropyl(methyl)amino]pyrrolidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{(3S)-3-[methyl(2-methylpropyl)amino]pyrrolidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-(4-{methyl[(1-methylcyclopropyl)methyl]amino}piperidin-1-yl)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-(4-{[(1-fluorocyclopropyl)methyl](methyl)amino}piperidin-1-yl)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-6-{(3S)-3-[(cyclopropylmethyl)(methyl)amino]pyrrolidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-6-{(3S)-3-[(cyclopropylmethyl)(methyl)amino]pyrrolidin-1-yl}-2,2-difluorocyclohexyl]-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide

rac-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-{(1R,2R,6S)-2-fluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

N-{(1R,6S)-2,2-difluoro-6-[4-(propan-2-yl)-1,4-diazepan-1-yl]cyclohexyl}-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-{(1R,2S,6S)-2-fluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-N-{(1S,2R,6R)-2-fluoro-6-[4-(propan-2-yl)piperazin-1-yl]cyclohexyl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{4-[methyl(2-methylpropyl)amino]piperidin-1-yl}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-6-{4-[(cyclopropylmethyl)(methyl)amino]piperidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-6-{4-[cyclobutyl(methyl)amino]piperidin-1-yl}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]amino}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide


25. The compound of claim 1 or a pharmaceutically acceptable saltthereof, which is selected from the following compound names orstructures:N-[(1R,6S)-2,2-difluoro-6-{[1-(propan-2-yl)piperidin-4-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[1-(propan-2yl)piperidin-4-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

4-(5-cyclobutyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(propan-2-yl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-ethyl-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}piperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(2-methylpropyl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(2-methylpropyl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-6-{[(3S)-1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-6-{[(3S)-1-(2,2-dimethylpropyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-6-{[(3S)-1-(2,2-dimethylpropyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-methylcyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-6-{[(3S)-1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy}-2,2-difluorocyclohexyl]-4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-methylpiperidine-1-carboxamide

4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-methylcyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-({(3S)-1-[(1-fluorocyclopropyl)methyl]pyrrolidin-3-yl}oxy)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-(4-{methyl[(1-methylcyclopropyl)methyl]amino}piperidin-1-yl)cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide

N-[(1R,6S)-2,2-difluoro-6-{[(3S)-1-(2-fluoro-2-methylpropyl)pyrrolidin-3-yl]oxy}cyclohexyl]-4-{5-[(1S,2S)-2-fluorocyclopropyl]-1,2,4-oxadiazol-3-yl}-4-methylpiperidine-1-carboxamide.

26-28. (canceled)
 29. A method for treating narcolepsy, idiopathichypersomnia, hypersomnia, sleep apnea syndrome, narcolepsy syndromeinvolving narcolepsy-like symptom, hypersomnia associated withParkinson's disease, or hypersomnia associated with dementia with Lewybody, comprising administering a therapeutically effective amount of thecompound of claim 1 or a pharmaceutically acceptable salt thereof to apatient in need thereof.
 30. (canceled)